

PB84-199546

Draft Criteria Document for
Dichloroethylenes
(1,1-Dichloroethylene) (Cis-1,2-
Dichloroethylene) (Trans-1,2-Dichloroethylene)

Life Systems, Inc., Cleveland, OH

Prepared for
Environmental Protection Agency, Washington, DC

Feb 84



U.S. Department of Commerce
National Technical Information Service

NTIS

DRAFT

DRAFT CRITERIA DOCUMENT
FOR DICHLOROETHYLENES*

(1,1-Dichloroethylene)
(cis-1,2-Dichloroethylene)
(trans-1,2-Dichloroethylene)

FEBRUARY 1984

Prepared by

Life Systems, Inc.
Contract No. EPA-68-02-3659

for

HEALTH EFFECTS BRANCH
CRITERIA AND STANDARDS DIVISION
OFFICE OF DRINKING WATER
U.S. ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

*This draft criteria document contains information on three dichlorinated ethylenes. At this time, an RMCL for 1,1-dichloroethylene is being proposed. The cis- and trans-1,2-dichloroethylenes will be examined for possible inclusion in Phase II of the revised regulations.

REPRODUCED BY
NATIONAL TECHNICAL
INFORMATION SERVICE
U.S. DEPARTMENT OF COMMERCE
SPRINGFIELD, VA. 22161

		PB84 199546	
1. TITLE AND SUBTITLE Draft Criteria Document for Dichloroethylenes		2. REPORT DATE January 1984	
3. AUTHOR(S) Klaassen		4. PERFORMING ORGANIZATION NUMBER 45021005	
5. PERFORMING ORGANIZATION NAME AND ADDRESS Life Systems, Inc, 24755 Highpoint Road Cleveland, OH 44122		6. PERFORMING ORGANIZATION REPORT NO.	
12. SPONSORING AGENCY NAME AND ADDRESS Environmental Protection Agency Office of Drinking Water (WH-550) 401 M Street SW Washington, D.C. 20460		10. PROGRAM ELEMENT NO. A63C2B	
		11. CONTRACT/GRANT NO. EPA-68-02-3659	
		13. TYPE OF REPORT AND PERIOD COVERED Technical	
		14. SPONSORING AGENCY CODE	
15. SUPPLEMENTARY NOTES			
16. ABSTRACT This document summarizes the health effects of Dichloroethylenes. Topics include: General Information and Properties; Human Exposure; Pharmacokinetics; Health Effects in Animals and Humans; Mechanisms of Toxicity; Risk Assessment and Quantification of Toxicological Effects.			
17. KEY WORDS AND DOCUMENT ANALYSIS			
a. DESCRIPTORS		b. IDENTIFIERS-OPEN ENDED TERMS	c. COSATI Field/Group
Dichloroethylenes Volatile Synthetic organic chemicals Drinking Water Criteria Documents			
18. DISTRIBUTION STATEMENT Open distribution		19. SECURITY CLASS. (This Report) non-sensitive	21. NO. OF PAGES 156
		20. SECURITY CLASS. (This page)	22. PRICE

I. SUMMARY

1,1-Dichloroethylene is used industrially as a chemical intermediate and in the manufacture of polyvinylidene chloride copolymers (PVDCs). The impermeability of PVDCs make them useful as barrier coatings in the packaging industry where they are widely used in food wrappings. PVDCs also are used in the manufacture of nonflammable synthetic fibers and are extensively used as interior coatings for tanks, pipes, etc. 1,2-DCEs are not widely used industrially, although they have had limited use as solvents.

The DCEs, like other chlorinated hydrocarbons, cause depression of the central nervous system (CNS). Therefore, exposure to high concentrations of DCEs can cause narcosis and presumably could ultimately cause death due to respiratory depression.

The toxic effects of cis- and trans-1,2-DCE are not well documented. However, 1,1-DCE has been shown to cause liver and kidney injury in animal studies and similar injuries would be expected in prolonged human exposures to high concentrations.

Neither 1,1-DCE nor cis- or trans-1,2-DCE have been shown to be mutagenic without microsomal activation. However, with microsomal activation, 1,1-DCE was found to be mutagenic in bacterial systems, but no mutagenicity was observed with V79 Chinese hamster cells or in dominant lethal studies in mice and rats.

There are no data indicating the carcinogenic potential of cis- or trans- 1,2-DCE. 1,1-DCE was shown to produce kidney adenocarcinomas in male Swiss mice and mammary adenocarcinomas in Swiss mice and Sprague-Dawley rats, although there was no unequi-

I-1-a
TABLE OF CONTENTS

	Page
I. Summary.....	I-1-2
II. General Information and Properties.....	II-1-7
III. Sources of Human Exposure..... (To be developed by STB)	III-1-
IV. Toxicokinetics.....	IV-1-33
V. Health Effects in Animals.....	V-1-54
VI. Health Effects in Humans.....	VI-1-3
VII. Mechanism(s) of Toxicity.....	VII-1-12
VIII. Quantification of Toxicological Effects..	VIII-1-25
IX. References.....	IX-1-10

vocal evidence of carcinogenic potential in several other studies using different strains of mice, rats and hamsters. EPA's Carcinogen Assessment Group found 1,1-dichloroethylene to have limited evidence for carcinogenicity using the IARC classification scheme for animal evidence. In addition, there is no evidence to date for any increased cancer risk in 1,1-DCE-exposed human populations.

II. GENERAL INFORMATION AND PROPERTIES

A. Physical and Chemical Properties

Dichloroethylenes consist of three isomers: 1,1-dichloroethylene, cis-1,2-dichloroethylene and trans-1,2-dichloroethylene. All isomers of dichloroethylene are clear, colorless liquids with the molecular formula $C_2H_2Cl_2$ and a molecular weight of 96.95 (Windholz et al., 1976; Hardie, 1964).

1,1-Dichloroethylene. The isomer 1,1-dichloroethylene (also referred to as vinylidene chloride, 1,1-dichloroethene, DCE and VDC) dissolves in organic solvents and is soluble in water to 400 mg/l at 20°C (Irish, 1963). Other estimates of 1,1-DCE's solubility in water range from 0.01 wt% (10 mg/l) to 0.64 wt% (640 mg/l) at temperatures varying from 4-25°C (Weiner, 1951; Hardie, 1964; Ley et al., 1967; Wessling and Edwards, 1971; Jaeger and Stringer, 1972). More recently, DeLassus and Schmidt (1981) determined that the solubility of 1,1-DCE was nearly constant at 0.25 wt% (250 mg/l) over the range of 15-90°C. For air concentrations, one (1) ppm is equivalent to 3.97 mg/m³, and one (1) mg/l is equivalent to 252 ppm, when measured at 25°C and 760 mm Hg (Irish, 1963). It is extremely volatile, having a vapor pressure of 591 Torr (mm Hg) at 20°C and a boiling point of 31.5°C. It has a melting point of -122.1°C and a mild, sweet odor similar to that of chloroform. The liquid is heavier than air and will, therefore, settle in low places in a still atmosphere. It is also flammable, with 7.3-16.0% explosive limits in air at 28°C. The monomer polymerizes to a plastic at temperatures above

0°C, especially in the presence of oxygen or other catalysts. It also forms explosive peroxides in contact with air. Therefore, it is stored and shipped either with an inhibitor (e.g., 200 ppm of monomethyl ether of hydroquinone) or is refrigerated under an inert gas in the absence of light and air (Warren and Ricci, 1978; Windholz et al., 1976; Hardie, 1964). The presence of the inhibitor could influence the results of toxicity studies (although its concentration is rather low). The octanol/water partition coefficient for 1,1-dichloroethylene was reported as 5.37 ($\log P = 0.73$) by Radding et al. (1977), indicating that it should not accumulate significantly in aquatic animals (U.S. EPA, 1980).

None of three listings of azeotropes (the first of which is extensive) indicates that 1,1-dichloroethylene forms azeotropes with water (Horsely, 1947; Lange and Forker, 1961; Perry and Chilton, 1973), although it does form an azeotrope with methanol. Azeotropes occur infrequently between compounds with boiling points differing by more than about 30°C (Perry and Chilton, 1973). Therefore, formation of an azeotrope between 1,1-dichloroethylene (31.5°C boiling point) and water (100°C boiling point) is unlikely to occur, eliminating this as a concern during possible evaporative purification of water from the chemical.

1,2-Dichloroethylene. This isomer is also referred to as acetylene dichloride, 1,2-dichloroethene, sym-dichloroethylene and dioform. The marketed product is generally a mixture of cis- and trans- isomers. Both the cis- and trans- isomers are soluble in water (solubilities of 3,500 mg/l and 6,300 mg/l at 25°C, respectively), but readily soluble in most organic solvents. 1,2-Dichloro-

ethylene is volatile, though less so than 1,1-dichloroethylene. The cis- isomer has a vapor pressure of 180 Torr (mm Hg) at 20°C and boils at 60°C. The trans- isomer has a vapor pressure of 265 Torr (mm Hg) at 20°C and a boiling point of 47°C. The vapor densities are identical to that of 1,1-dichloroethylene, which is over three times that of air (Windholz et al., 1976; Irish, 1963; Hardie, 1964; Lange and Forker, 1961). 1,2-Dichloroethylene is gradually decomposed by air, light and moisture, forming hydrogen chloride (HCl). The trans- form is noticeably subject to air oxidation (Windholz et al., 1976).

1,2-Dichloroethylenes form azeotropes with water. This factor must be evaluated if evaporative purification of water from these isomers is considered. Horsely (1947) lists a binary azeotrope for cis-1,2-dichloroethylene with water (3.35% water by weight, boiling at 55.3°C) and a ternary azeotrope of this substance with water and ethanol (2.85% water, 90.5% cis-1,2-dichloroethylene and 6.65% ethanol by weight, boiling at 53.8°C). Azeotropes with ethanol and methanol alone also are formed.

Horsely (1947) similarly lists a binary azeotrope for trans-1,2-dichloroethylene with water (1.9% water by weight, boiling at 45.3°C) and a ternary azeotrope with water and ethanol (1.1% water, 94.5% trans-1,2-dichloroethylene and 4.4% ethanol by weight). The trans- isomer, like the cis- isomer, also forms an azeotrope with ethanol alone.

B. Manufacturing and Uses

1,1-Dichloroethylene. Mid-decade annual production of 1,1-dichloroethylene approximated 120,000 metric tons (Arthur D. Little, Inc., 1976). It is used primarily in the production of polyvinylidene chloride polymers and copolymers (PVDC's), but also as a chemical intermediate in the synthesis of methylchloroform. Other monomers used with 1,1-dichloroethylene in copolymer production are vinyl chloride, acrylonitrile, and alkyl acrylates. The impermeability of PVDC's make them useful primarily as barrier coatings on paper products and plastic films. Polymers containing 1,1-dichloroethylene are widely used in the food packaging industry. [FDA regulations require that for polyvinylidene chloride (PVDC) copolymer coatings on polyolefin, nylon and polycarbonate films contacting food, chloroform soluble extractives may not exceed 0.5 mg/in², as extracted under conditions specific to the application (CFR, 1981). No such regulations were found for pure PVDC]. They are likewise used as binders for nonwoven fabrics, paint and concrete. 1,1-Dichloroethylene polymers have been used extensively as interior coatings for ship tanks, railroad cars, and fuel storage tanks and for coating of steel pipes and structures (Wessling and Edwards, 1970; Hardie, 1964). The literature provides no quantitative information as to the concentration of the monomer, although this would be expected to be quite low following processing of the basic resin (e.g., coating, film, formation, storage).

1,2-Dichloroethylene. 1,2-Dichloroethylene is used as a solvent for such substances as rubber, fats, phenol and camphor and for retarding fermentation. It is also used as a low temperature

extraction solvent for heat sensitive substances and has been employed as a coolant in refrigeration plants (Windholz et al., 1976; Hardie, 1964). No production figures have been found, although in the previous decade Irish (1963) indicated that neither isomer had developed wide industrial usage.

C. Extent and Significance of Problem

1,1-Dichloroethylene. Annual emissions of 1,1-dichloroethylene were estimated in 1975 to be 1.3 million lb/year, primarily from monomer production process vents and spills and from polymer production and processing. This chemical is expected to be short-lived in water because of its poor solubility and rapid volatilization to the atmosphere (Hushon and Kornreich, 1976). Its tendency to form peroxides spontaneously in the presence of air or oxygen (Barr and Watts, 1972; Wessling and Edwards, 1970) would be expected to limit its persistence in the atmosphere.

However, Pearson and McConnell (1975) indicate that degradation of such compounds dissolved in water is much slower than in the atmosphere. They estimate a tropospheric half-life of eight weeks. 1,1-Dichloroethylene in air decomposed to carbon monoxide (CO), carbon dioxide (CO₂) and hydrogen chloride (HCl) when irradiated at wavelengths of light simulating atmosphere exposure (Pearson and McConnell, 1975). Therefore, those compounds may be the primary degradation products of 1,1-dichloroethylene in the natural atmosphere as well. The results of a sampling/analysis-method study of the air around or near industrial/waste disposal areas of the U.S. has been reported (Pellizzari, 1978). In general, the concentrations of 1,1-dichloroethylene in the air were low

(typically $<1 \text{ ug/m}^3$). Concentrations in drinking water, detected in water supplies of four out of ten cities in the U.S., were also low (e.g., 0.1 ug/l) as shown in Table II-1 (U.S. EPA, 1975).

1,2-Dichloroethylene. In view of their slow decomposition by air, light and moisture (Windholz et al., 1976), the 1,2-dichloroethylenes would be expected to be removed slowly from the environment. The tropospheric half-lives of the isomers are likely to be the same order of magnitude as estimated by Pearson and McConnell (1975) for 1,1-dichloroethylene (eight weeks). 1,2-Dichloroethylene has been detected in a limited number of U.S. drinking water supplies, as shown in Table II-1 (U.S. EPA, 1975).

Table II-1

Summary of Dichloroethylene Concentrations in
Finished Drinking Waters at Ten Areas
of the United States^a

Area	Concentration, ug/l		
	1,1- Dichloroethylene	cis 1,2- Dichloroethylene	trans 1,2- Dichloroethylene
Miami, FL	D ^b , 0.1	D ^b , 16.0	D ^b 1.0
Seattle, WA	ND ^c	ND	ND
Ottumwa, IA	ND	ND	ND
Philadelphia, PA	D ^b , 0.1	D ^b , 0.1	ND
Cincinnati, OH	D ^b	D ^b , 0.1	ND
Tucson, AR	ND	ND	ND
New York, NY	ND	ND	ND
Lawrence, MA	D ^b	ND	ND
Grand Forks, ND	ND	ND	ND
Terrebonne, Parish, LA	ND	ND	ND

^aFrom U.S. EPA, 1975, Table I-3

^bDetected by 500 ml volatile organic analysis but not quantified

^cNot detected

III. HUMAN EXPOSURE

Humans may be exposed to 1,1-dichloroethylene in drinking water, food, and air. Detailed information concerning the occurrence of and exposure to 1,1-dichloroethylene in the environment is presented in another document entitled "Occurrence of 1,1-Dichloroethylene in Drinking Water, Food, and Air" (Letkiewicz et al. 1983). This section summarizes the pertinent information presented in that document in order to assess the relative source contribution from drinking water, food, and air.

This analysis is limited to drinking water, food, and air, since these media are considered to be general sources common to all individuals. Some individuals may be exposed to 1,1-dichloroethylene from sources other than the three considered here, notably in occupational settings and from the use of consumer products containing 1,1-dichloroethylene. Even in limiting the analysis to these three sources, it must be recognized that individual exposure will vary widely based on many personal choices and several factors over which there is little control. Where one lives, works, and travels, what one eats, and physiologic characteristics related to age, sex, and health status can all profoundly affect daily exposure and intake. Individuals living in the same neighborhood or even in the same household can experience vastly different exposure patterns.

Unfortunately, data and methods to estimate exposure of identifiable population subgroups from all sources simultaneously have not yet been developed. To the extent possible, estimates are provided of the number of individuals exposed to each medium at various 1,1-dichloroethylene concentrations. The 70-kg male is used for estimating intake.

a. Water

Cumulative estimates of the U.S. populations exposed to various 1,1-dichloroethylene levels in drinking water from public drinking water systems are presented in Table IV-I. The values in the table were obtained using Federal Reporting Data Systems data on populations served by primary water supply systems (FRDS 1983) and the estimated number of these water systems that contain a given level of 1,1-dichloroethylene. An estimated 4,789,000 individuals (2.2% of the population of 214,419,000 using public water supplies) are

Table IV-I. Total Estimated Cumulative Population (in Thousands)
Exposed to 1,1-Dichloroethylene in Drinking Water
Exceeding the Indicated Concentration

System type	Number of people served in U.S. (thousands)	Cumulative population (thousands) exposed to concentrations (ug/l) of:		
		≥ 0.2	> 5	> 10
Groundwater	73,473	2,347	52	0
Surface water	140,946	2,442	0	0
Total	214,419	4,789	52	0
(% of total)	(100%)	(2.2%)	(<0.1%)	(0.0%)

exposed to levels of 1,1-dichloroethylene in drinking water at or above 0.2 ug/l, while 52,000 individuals (< 0.1%) are exposed to levels above 5 ug/l. It is estimated that no individuals are exposed to levels greater than 10 ug/l. Of the approximately 4.7 million people exposed to levels ranging from 0.2 to 5 ug/l, 2.4 million (52%) obtain water from surface water supplies. All exposure to 1,1-dichloroethylene in drinking water at levels above 5 ug/l is expected to be from groundwater sources.

No data were obtained on regional variations in the concentration of 1,1-dichloroethylene in drinking water. The highest concentrations are expected to occur near sites of production and use of 1,1-dichloroethylene.

Daily intake levels of 1,1-dichloroethylene from drinking water were estimated using various exposure levels and the assumptions presented in Table IV-II. The data in the table suggest that the majority of the persons using public drinking water supplies would be exposed to intake levels below 0.0057 ug/kg/day.

Table IV-II. Estimated Drinking Water Intake of 1,1-Dichloroethylene

Exposure level (ug/l)	Persons using supplies exposed to indicated levels		Intake (ug/kg/day)
	Population	% of Total population	
≥0.2	4,789,000	2.2%	≥0.0057
>5.0	52,000	< 0.1%	>0.14
>10	0	0.0%	>0.29

Assumptions: 70-kg man, 2 liters of water/day.

An indication of the overall exposure of the total population to 1,1-dichloroethylene can be obtained through the calculation of population-concentration values. These values are a summation of the individual levels of 1,1-dichloroethylene to which each member of the population is exposed. An explanation of the derivation of these values is presented in Appendix C. Population-concentration estimates for 1,1-dichloroethylene in drinking water are 1.2×10^6 ug/l x persons (best case), 1.3×10^7 ug/l x persons (mean best case), 5.3×10^7 ug/l x persons (mean worst case), and 6.4×10^7 ug/l x persons (worst case).

Assuming a consumption rate of 2 liters of water/day, population-exposure values of 2.4×10^6 ug/day x persons (best case), 2.6×10^7 ug/day x persons (mean best case), 1.1×10^8 ug/day x persons (mean worst case), and 1.3×10^8 ug/day x persons (worst case) were derived.

b. Diet

No data were obtained on levels of 1,1-dichloroethylene in foods. Therefore, the intake of 1,1-dichloroethylene from the diet could not be estimated.

c. Air

Exposure to 1,1-dichloroethylene in the atmosphere varies from one location to another. The highest level of 1,1-dichloroethylene reported in the atmosphere was $27,000$ ng/m³ (Going and Spigarelli 1977 cited in Brodzinsky and Singh 1982). Normal levels, however, are lower. Brodzinsky and Singh (1982)

calculated median air levels of 1,1-dichloroethylene for urban/ suburban areas and source dominated areas of 20 ng/m^3 (0.020 ug/m^3) and $14,000 \text{ ng/m}^3$ (14 ug/m^3), respectively. Two data points for 1,1-dichloroethylene in rural/ remote areas showed 0.0 ng/m^3 .

The monitoring data available are not sufficient to determine regional variations in exposure levels for 1,1-dichloroethylene. However, urban and industrial areas appear to contain higher levels, as expected.

The daily respiratory intake of 1,1-dichloroethylene from air was estimated using the assumptions presented in Table IV-III and the median and maximum levels for 1,1-dichloroethylene reported above. The estimates in Table IV-III indicate that the daily 1,1-dichloroethylene intake from air for adults in source dominated areas is approximately 4.6 ug/kg/day . The intake calculated using the maximum level reported is 8.9 ug/kg/day . The values presented do not account for variances in individual exposure or uncertainties in the assumptions used to estimate exposure.

Table IV-III. Estimated Respiratory Intake of 1,1-Dichloroethylene

Exposure (ug/m^3)	Intake (ug/kg/day)
Rural/remote (0.0)	0.0
Urban/suburban (0.020)	0.0066
Source dominated (14)	4.6
Maximum (27)	8.9

Assumptions: 70-kg man, 23 m^3 of air inhaled/day (ICRP 1975).

SUMMARY

Table IV-IV presents a general view of the total amount of 1,1-dichloroethylene received by an adult male from air and drinking water. Four separate exposure levels in air and four exposure levels in drinking water are shown in the table. Since no data were obtained on levels of 1,1-dichloroethylene in foods in the United States, the contribution of 1,1-dichloroethylene in the diet to total 1,1-dichloroethylene exposure could not be assessed.

Table IV-IV. Estimated Intake of 1,1-Dichloroethylene
from the Environment by Adult Males in ug/kg/day
(% from Drinking Water)

Concentration in drinking water (ug/l)	Concentration in air			
	Rural/remote (0.0 ug/m ³)	Urban/suburban (0.020 ug/m ³)	Source dominated (14 ug/m ³)	Maximum (27 ug/m ³)
0	0.0 (--)	0.0066 (0%)	4.6 (0%)	8.9 (0%)
0.2 ^a	0.0057 (100%)	0.012 (48%)	4.6 (0.1%)	8.9 (0.06%)
5.0 ^b	0.14 (100%)	0.15 (93%)	4.7 (3.0%)	9.0 (1.6%)
10 ^c	0.29 (100%)	0.30 (97%)	4.9 (5.9%)	9.2 (3.2%)

Intake from each source (see Sections 5.1-5.3):

Water: 0.2 ug/l: 0.0057 ug/kg/day
5.0 ug/l: 0.14 ug/kg/day
10 ug/l: 0.29 ug/kg/day

Air: 0.0 ug/m³: 0.0 ug/kg/day
0.020 ug/m³: 0.0066 ug/kg/day
14 ug/m³: 4.6 ug/kg/day
27 ug/m³: 8.9 ug/kg/day

Food: Not included

^a4,789,000 individuals using public drinking water systems are estimated to be exposed to levels $\geq$ 0.2 ug/l (2.2% of population using public water supplies).

^b52,000 individuals using public drinking water systems are estimated to be exposed to levels $>$ 5.0 ug/l ($<$ 0.1% of population using public water supplies).

^cNo individuals using public drinking water systems are estimated to be exposed to levels $>$ 10 ug/l.

The data presented have been selected from an infinite number of possible combinations of exposure from each of the two sources. The actual exposures encountered would represent some finite subset of this infinite series of combinations. Whether exposure occurs at any specific combination of levels is not known; nor is it possible to determine the number of persons that would be exposed to 1,1-dichloroethylene at any of the combined exposure levels. The data presented represent possible exposures based on the occurrence data and the estimated intakes.

The relative source contribution data are based on estimated intake and do not account for a possible differential absorption rate for 1,1-dichloroethylene by route of exposure. The relative dose received may vary from the relative intake. In addition, the relative effects of the chemical on the body may vary by different routes of exposure.

Brodzinsky and Singh (1982) calculated a median urban/suburban air level of 1,1-dichloroethylene of 0.020 ug/m^3 based on air monitoring data. Assuming an air level of 0.020 ug/m^3 , drinking water would be the predominant source of 1,1-dichloroethylene exposure in the adult male at drinking water levels above 0.2 ug/l . An accurate assessment of the number of individuals for which drinking water is the predominant source of exposure cannot be determined from the data since specific locations containing high concentrations of 1,1-dichloroethylene in drinking water and low concentrations of 1,1-dichloroethylene in ambient air and food are unknown.

REFERENCES

Brodzinsky R, Singh HB. 1982. Volatile organic chemicals in the atmosphere: An assessment of available data. Prepared by SRI International, Menlo Park, CA, for Environmental Sciences Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC. Contract No. 68-02-3452.

FRDS. 1983. Federal Reporting Data System. Facilities and population served by primary water supply source (FRDS07), April 19, 1983. U.S. Environmental Protection Agency, Washington, DC.

Going JE, Spigarelli JL. 1977. Environmental monitoring near industrial sites: Vinylidene chloride. Prepared by Midwest Research Institute, Kansas City, MO, for U.S. Environmental Protection Agency. EPA-560/6-77-026. Cited in Brodzinsky and Singh 1982.

ICRP. 1975. International Commission on Radiological Protection. Report of the task group on reference man. ICRP Publication 23. New York: Pergamon Press.

Letkiewicz F, Johnston P, Macaluso C, Elder R, Yu W, Bason C. 1983. Occurrence of 1,1-dichloroethylene in drinking water, food and air. Prepared by JRB Associates, McLean, VA, for Office of Drinking Water, U.S. Environmental Protection Agency, Washington, DC. EPA Contract No. 68-01-6388.

IV. TOXICOKINETICS

A. Absorption

Dichloroethylenes are neutral, low molecular weight, lipid soluble materials which should be absorbed readily following any route of administration.

Pharmacokinetic studies based on urinary and biliary excretion data have shown that administration of a single oral dose of 1,1-dichloroethylene in the dose range 0.5-50 mg/kg results in rapid and complete absorption (McKenna et al., 1978b; Reichert et al., 1979; Jones and Hathway, 1978a). Rapid absorption and distribution of 1,1-DCE after intravenous or intraperitoneal administration also have been demonstrated (Jones and Hathway, 1978a).

It is well established that the absorption of gases from the lung is highly dependent on the blood gas partition coefficient. As shown in Table IV-1, all three dichloroethylenes probably have a blood:gas partition coefficient in the range of 5-10, indicating that the materials equilibrate like a soluble vapor. These chemicals in inspired air have been shown to come to a steady-state with the whole animal within 1-2 hours (Table IV-1). The rate constant for reaching equilibrium has been determined to be 2.2 hr^{-1} (Andersen et al., 1979b). The blood:gas solubility of these compounds combined with the observation that they have a relatively short equilibration time suggests that they do not concentrate in poorly perfused tissues. Using relatively new pharmacokinetic procedures, a mixed partition coefficient (S), which is defined as the concentration of the chemical in the richly perfused tissues divided by its concentration in the gas phase, has been determined for these

Table IV-1

Correlation of Physical and Chemical Characteristics
to Inhalation Absorption and Distribution of Dichloroethylenes

	Blood:gas Partition Coefficient	Whole Body Equilibration Time, hr	Mixed Partition Coefficients	Equilibration Constant K_{eq}	Boiling Point, °C
cis-1,2-DCE	9.2 ^a	2 ^b	-	20 ^b	60
trans-1,2-DCE	5.8 ^a	1.5 ^b	10.9 ^c	11.5 ^b	47
1,1-DCE	-	1 ^{b,c}	4.0 ^c	7.8 ^b	31.5

^a Sato and Nakajima, 1979. Data determined in experiments using human blood.

^b Filser and Bolt, 1979. Data determined in experiments using rats.

^c Andersen et al., 1980a. Data determined in experiments using rats.

chemicals (Andersen et al., 1980a). As can be seen from Table IV-1, rats exposed to trans-1,2-DCE have been shown by this method to absorb more chemical at equilibrium than rats exposed to 1,1-DCE. A similar pharmacokinetic analysis of the distribution of these chemicals has been performed (Filser and Bolt, 1979). They determined the equilibration constant (K_{eq}), which is defined as the clearance of a chemical from the chamber into the animal relative to clearance from the animal into the chamber, for all three chemicals. The data for K_{eq} in Table IV-1 show that, at equilibrium, the amount of chemical present in animals exposed to the dichloroethylenes would be cis-1,2-DCE > trans-1,2-DCE > 1,1-DCE. This study found an empirical relationship between K_{eq} and the volatility of the toxicant for a wide variety of halogenated ethylenes. Using the boiling point as a measure of volatility, it was shown that compounds with low boiling points have lower concentrations in tissue than those of higher boiling points. Thus, 1,1-DCE which has the lowest boiling point, would have the lowest concentration in tissue and cis-1,2-DCE, which has the highest boiling point, would have the highest concentration in tissues (Table IV-1).

B. Tissue Distribution

The distribution of 1,1-DCE to various organs of rats following inhalation exposure for 2 hours at an initial concentration of 2000 ppm has been studied using [^{14}C]1,1-DCE (Jaeger et al., 1977a). Many studies with 1,1-DCE have been performed using both fed and fasted animals because 1,1-DCE is known to be more hepatotoxic in fasted animals (Jaeger et al., 1974). The concentration of total radioactivity 30 minutes after cessation of exposure was

highest in the blood followed by kidney, liver, spleen, heart and brain in both the fed and fasted rats. The distribution of trichloroacetic acid insoluble labeled material, hereafter referred to as covalently bound material, followed a similar pattern with the following exceptions. Whereas the kidney contained very little covalently bound ^{14}C , approximately one-third of the ^{14}C in the liver was covalently bound (Jaeger et al., 1977a).

Similar studies have been conducted on rats 72 hours after inhalation exposure to either 10 or 200 ppm [^{14}C]1,1-DCE for 6 hours (McKenna et al., 1977, 1978a). The data on the distribution of ^{14}C in different tissues are in Table IV-2. At either exposure level, the highest concentration of ^{14}C was found in the liver and kidney. When tissue concentration data were normalized to account for differences in end-exposure body burdens, the greatest percentage of the body burden per gram of tissue was found in the kidney, liver and lung and were consistently higher in fasted rats at both exposure levels. Only a small amount of the ^{14}C was found in the fat. Table IV-3 compares the extent of covalent binding of ^{14}C and the total metabolism of 1,1-DCE. A comparison of fed and fasted rats at the different exposure concentrations shows that the concentration of covalently bound ^{14}C in the liver increases in 1,1-DCE metabolism. Although fasted rats metabolize less 1,1-DCE than fed rats, the concentration of covalently bound ^{14}C activity in the liver was greater in fasted than fed rats following exposure to 200 ppm. The increase in covalent binding in the livers of fasted rats was more apparent after normalization of the data to account for differences in metabolism of 1,1-DCE (B/A

IV-5

Table IV-2

Relative Amounts of ^{14}C in Tissues 72 Hr After Exposure
to 10 or 200 ppm [^{14}C]1,1-DCE for 6 Hr.

Microgram Equivalents of [^{14}C]1,1-DCE per gram of Tissue				
Tissue	10 ppm		200 ppm	
	Fed Rats	Fasted Rats	Fed Rats	Fasted Rats
Liver	0.56 (0.075)	0.57 (0.097) ^a	15.75 (0.147)	19.57 (0.204) ^a
Kidney	1.68 (0.228)	1.85 (0.314) ^a	3.15 (0.079)	19.90 (0.208) ^a
Lung	0.19 (0.026)	0.21 (0.036) ^a	5.19 (0.044)	7.12 (0.074) ^a
Fat	0.07	0.06	0.74	1.25
Muscle	0.06	0.04	0.91	1.19
Skin	0.19	0.15	3.78	5.98
Carcass	0.08	0.06	1.68	2.18
Plasma	0.15	0.16	3.15	5.20 ^a

() Represent tissue burdens normalized for differences in end-exposure body burden of ^{14}C activity. Microgram equivalents of [^{14}C]1,1-DCE per gram of tissue/total milligram equivalents recovered per rat.

^a Significantly different from fed rats of the same exposure group, $p < 0.05$, Student's t test.

Based on McKenna et al., 1978a.

Table IV-3

Metabolism of [^{14}C]1,1-DCE and Covalent Binding of ^{14}C to Rat Hepatic Tissue After Inhalation Exposure to 10 or 200 ppm of [^{14}C]1,1-DCE.

Concentration and Pretreatment	Body Burden (mg of [¹⁴ C]1,1-DCE/kg)	(A)	(B)	B/A
		Metabolized [¹⁴ C]1,1-DCE (mgEq/kg)	Microgram Equivalents of [¹⁴ C]1,1-DCE bound per gram of liver protein	
10 ppm				
Fed	2.89	2.84	2.49	0.88
Fasted	2.30	2.26	2.47	1.10
200 ppm				
Fed	44.53	42.73	64.18	1.49
Fasted	35.93 ^a	32.92 ^a	79.46	2.42 ^a

^a Significantly different than fed rats exposed to the same concentration of 1,1-DCE, $p < 0.05$, Students test.

Based on McKenna *et al.*, 1978a.

ratio, Table IV-3).

Distribution of 1,1-DCE to the organs of rats following intragastric administration of 25 mg/kg bw of [^{14}C]1,1-DCE also has been studied (Jones and Hathway, 1978a). Sequential autoradiograms of longitudinal sagittal sections through whole animals showed large ^{14}C concentrations in the kidneys and liver after 30 minutes and a more general distribution of ^{14}C throughout the soft organs of the body at 1 hour. The kidneys and liver retained ^{14}C for the longest time after dosing.

Distribution studies also have been conducted with rats 72 hours after administration of a single oral dose of 1 or 50 mg/kg [^{14}C]1,1-DCE (McKenna et al., 1978b). The distribution of ^{14}C to different tissues (Table IV-4) was shown to be independent of dose and not to be influenced by fasting the animals. The greatest percentage of the ^{14}C dosage per gram of tissue 72 hours after administration was found in the liver. Table IV-5 compares the extent of covalent binding of ^{14}C to hepatic tissue macromolecules with the amount of [^{14}C]1,1-DCE metabolized. No statistically significant differences for covalent binding on a per gram protein basis were observed between fed and fasted animals at either dose level. Normalization of the data to account for differences in metabolism (B/A, Table IV-5) showed an increase in the amount of ^{14}C covalently bound to liver macromolecules in fasted rats at the 50 mg/kg level.

Subcellular distribution of [^{14}C] 30 minutes following inhalation of 2,000 ppm of [^{14}C]1,1-DCE for 2 hours was determined in the microsomal, mitochondrial and cytosolic compartments of the liver (Jaeger et al., 1977a). More ^{14}C was found in liver

Table IV-4

Relative Amounts of ^{14}C in Tissues After a Single Oral
Dose of 1 or 50 mg/kg of [^{14}C]1,1-DCE^a

Tissue	1 mg/kg		50 mg/kg	
	Fed	Fasted	Fed	Fasted
Liver	0.063	0.101	0.089	0.073
Kidney	0.030	0.028	0.018	0.033
Lung	0.013	0.001	0.003	0.019
Fat	0.014	0.108	ND	ND
Muscle	0.007	0.005	ND	ND
Skin	0.018	0.014	0.009	0.015
Carcass	0.008	0.008	0.006	0.007
Whole Blood	0.013	0.011	0.013	0.016

^a Expressed as percentage of dose per gram of tissue

ND = Not detectable above background

Based on McKenna et al., 1978b

Table IV-5

Metabolism of [^{14}C]1,1-DCE and Covalent Binding of
 ^{14}C to Rat Hepatic Tissue After a Single Oral Dose of
 ^{14}C]1,1-DCE

Dose and Pretreatment	(A)	(B)	B/A
	Metabolized [^{14}C]1,1-DCE (mgEq/kg)	Covalently bound 1,1-DCE (ug Eq of [^{14}C]1,1-DCE/ gram liver protein)	
1 mg/kg			
Fed	0.956	0.854	0.89
Fasted	0.924	0.861	0.93
50 mg/kg			
Fed	39.08	37.67	0.96
Fasted	31.86	44.45	1.40 ^a

^a Significant fed vs fasted difference, $p < 0.05$, Student's test.

Based in McKenna et al., 1978b


fractions from fasted rats than from fed rats. There was no marked subcellular localization of ^{14}C , since its concentration was about the same in mitochondria, cytoplasm and microsomes. The ^{14}C found in microsomes and mitochondria was largely covalently bound (TCA-insoluble). In contrast, the cytosol contained substantial amounts of TCA-soluble ^{14}C , suggesting the presence of metabolites. Significant amounts of the ^{14}C in microsomes and mitochondria was CHCl_3 -soluble, suggesting that there is considerable binding of ^{14}C to lipids. The turnover rate of TCA-insoluble radioactivity derived from 1,1-DCE has a half-life of 2-3 hours.

Distribution data on 1,2-DCE isomers are not available.

C. Biotransformation

The comparative metabolism of chloroethylenes has been studied extensively. Metabolic end products of chlorinated ethylenes are predominantly alcohols and carboxylic acids. Liebman and Ortiz (1977) have postulated the various metabolic pathways for 1,1-DCE, cis-1,2-DCE, and trans-1,2-DCE as shown in Figure IV-1. Perfusion of either cis-1,2-DCE or trans-1,2-DCE in an isolated rat liver produced detectable amounts of dichloroethanol and dichloroacetic acid (Bonse et al., 1975), possibly indicating the initial formation of dichloroacetaldehyde. The metabolism of the cis-isomer relative to the quantity taken up by the liver was much greater than the trans-isomer. Chloroacetic acid has been identified as a product in the metabolism of 1,1-DCE in perfused rat liver, but dichloroacetaldehyde has not been unequivocally identified as a metabolite of 1,1-DCE. Inhibition of epoxide

Figure IV-1
Proposed Metabolic Pathways for 1,1-DCE and cis-and trans-1,2-DCE



Based on Liebman and Ortiz, 1977.


hydrase in in vitro studies using rat liver S-9 resulted in a stimulation of chloroacetic acid formation from 1,1-DCE, leading to the conclusion that the glycol intermediate is relatively unimportant in the conversion of 1,1-DCE to chloroacetic acid (Leibman and Ortiz, 1977). Additionally, studies using competitive epoxide substrates have shown that epoxide hydrating pathways are of minimal significance in the metabolism of reactive intermediates of 1,1-DCE (Andersen et al., 1980b). The essential feature of the metabolic pathway for dichloroethylenes is that all of these compounds appear to be metabolized through epoxide intermediates which are reactive and may form covalent bonds with tissue macromolecules (Henschler 1977, Henschler and Bonse, 1977).

A generalized scheme proposed for 1,1-DCE metabolism (McKenna et al., 1977; Anderson and Jenkins, 1977a) which relates metabolic processes, detoxification reactions and toxic effects is shown in Figure IV-2.

In live animals, it has been established that 1,1-DCE metabolites are conjugated with glutathione, presumably a detoxification process (McKenna et al., 1977, 1978a, 1978b; Jones and Hathway, 1978a; Reichert et al., 1978, 1979). The major urinary metabolites have been determined in several studies (Figure IV-3). McKenna et al. (1978a, 1978b) have isolated four main metabolites in rat urine, two of which they have identified: thiodiglycolic acid and the mercapturic acid N-acetyl-S-(2-hydroxyethyl) cysteine which was present in the highest amount. Both of these materials presumably would be formed as a result of conjugation of the metabolite, chloroacetic acid, with glutathione. Jones and Hathway

Figure IV-2

Proposed Scheme of 1,1-DCE Metabolism




Based on McKenna et al., 1977; Andersen and Jenkins, 1977a.

Figure IV-3

Metabolic Pathways of 1,1-DCE.

Identified Metabolites Underlined



Based on: (a) Reichert et al., 1979; (b) McKenna et al., 1978a; (c) Jones and Hathway, 1978a.

(1978a) have found two major metabolites in rat urine: besides thiodiglycolic acid they postulate a cyclic product, an N-acetyl-S-cysteiny-acetyl derivative, as the major metabolite. In addition, they have shown chloroacetic acid, dithioglycolic acid and thioglycolic acid in lesser concentrations. The formation of the N-acetyl-S-cysteiny-acetyl derivative was unexpected, since this material was not produced in the metabolism of chloroacetic acid administered in rats. This suggests that the N-acetyl-S-cysteiny-acetyl derivative was formed from an earlier metabolite than chloroacetic acid, perhaps 1,1-dichloroethylene oxide, which was conjugated with glutathione. Reichert et al. (1979) identified three metabolites in rat urine: thiodiglycolic acid, the major metabolite, N-acetyl-S-(2-carboxymethyl) cysteine and methylthioacetylamin ethanol. In addition, three unidentified materials were present in lesser concentrations. The identification of methylthioacetylamin ethanol suggests that, in addition to glutathione conjugation, a totally different reaction mechanism must exist which leads to the formation of ethanolamine derivatives. The ethanolamine is postulated to originate from membrane lipids which react with 1,1-DCE epoxide and/or its metabolites. The various pathways are shown in Figure IV-3.

In the intact animal, several studies have shown that a large portion of systemically absorbed 1,1-DCE is metabolically converted in rats. Table IV-6 summarizes the data on disposition and metabolism. The fifth column indicates the percent of the dose excreted into the air as CO₂ and is a reflection of the amount metabolized. Thus, as the dosage is increased a larger

Table IV-6

Disposition and Metabolism of [^{14}C]1,1-Dichloroethylene in Rats

Dose mg/kg	Route	Time After Dose	% of Original Dose of [^{14}C] Activity				Residual in Body	Referen
			Pulmonary 1,1-DCE	Excretion CO_2	Renal Excretion	Biliary Excretion		
0.5	oral	72	1.26	13.64	43.55	15.74	5.57	Reicher et al. 1979
5	oral	72	9.70	11.35	53.88	14.54	2.83	
50	oral	72	16.47	6.13	42.11	7.65	2.77	
0.5	oral	72	0.9	23	52		2-4	Reicher & Werne 1978
50	oral	72	20	6	36			
0.5	oral	0-24	0.6	3.9	71.3	5.1		Jones & Hathway 1978a
		24-48	0.06	0.5	5.3	2.7		
		48-72	0.08	0.5	3.6	0.6		
		Total	0.07	4.8	80.2	8.3		
0.5	iv	0-24	80.0	3.5	14.4	0.3		Jones & Hathway 1978a
		24-48	0	0	0.7	0.1		
		48-72	0	0	0	0		
		Total	80.0	3.5	15.0	0.4		
0.5	ip	0-24	11.4	2.6	65.8	14.2		Jones & Hathway 1978a
		24-48	0.2	0.5	2.0	1.6		
		48-72	0.1	0.5	1.2	0.4		
		Total	11.7	3.6	69.0	16.2		
350	oral	0-24	62.4	0.3	17.6	0.4		Jones & Hathway 1978a
		24-48	4.8	0.4	10.0	0.5		
		48-72	0.1	0.3	1.9	0.4		
		Total	67.3	1.0	29.5	1.3		
350	ip	0-24	90.5	0.7	7.1	0.5		Jones & Hathway 1978a
		24-48	0.6	0.5	0.3	0.1		
		48-72	0	0.1	0.3	0.1		
		Total	91.1	1.3	7.7	0.7		
1	oral ^a	72	2.89	10.85	62.68	16.25	3.18	McKenn et al. 1978b
1	oral ^b	72	1.36	7.82	66.42	11.18	3.46	
50	oral ^a	72	18.75	4.16	46.62	4.14	2.39	



Table IV-6 (Continued)

Dose mg/kg	Route	Time After Dose	% of Original Dose of [^{14} C] Activity				Residual in Body	Reference
			Pulmonary 1,1-DCE	Excretion CO ₂	Renal Excretion	Biliary Excretion		
50	oral ^b	72	29.23	3.19	34.88	4.28	3.08	
2.89 ^c	inhal ^a	72	1.63	8.74	74.72	9.73	4.75	McKenna et al., 1977, 1978a
2.30 ^d	inhal ^b	72	1.60	8.27	78.19	6.75	5.28	
44.53 ^c	inhal ^a	72	4.17	8.22	74.66	6.39	6.18	
35.39 ^d	inhal ^b	72	8.36	7.24	70.41	2.72	10.52	
e	inhal ^a	24			36.7			Jaeger et al., 1977a
e	inhal ^b	24			36.5			

a Fed rats

b Fasted rats

c Total body burden after 6 hr exposure to 10 ppm

d Total body burden after 6 hr exposure to 200 ppm

e Exposure for 2 hours to gas with initial concentration of 2000 ppm

absolute amount of metabolite is formed, but a lesser percentage of the administered dose is metabolized. This was observed after various routes of administration such as oral, intraperitoneal and inhalation. These data show that the metabolism of 1,1-DCE is readily saturable. As the dose is increased and metabolism reaches saturation, more parent compound is excreted into the air (Table IV-6). Additionally, fasting the animals for several hours prior to dosing also influenced the metabolism. Fasted rats had lower body burdens at the end of the experiments and metabolized less of their body burden than normally fed rats.

Studies comparing the relative ability of mice and rats to metabolize 1,1-DCE have been conducted. Disposition of ^{14}C from [^{14}C]1,1-DCE in mice and rats (McKenna *et al.*, 1977) is shown in Table IV-7. These data show that the mouse develops a higher body burden of 1,1-DCE or metabolites than the rat at identical exposure levels (10 ppm). The disposition of 1,1-DCE appears quite similar in the two species. However, as a result of the overall greater rate of metabolism, covalently bound 1,1-DCE metabolites are higher in the mouse than in the rat as shown in Table IV-8. The substantial difference in biotransformation may be responsible for the different sensitivity of the two species to the carcinogenic effects of 1,1-DCE (Hathway, 1977) since mice, which metabolize more 1, 1-DCE than rats, are more sensitive than rats.

In a study where mice and rats were administered an oral dose (50 mg/kg) of 1,1-DCE, mice were found to metabolize a greater proportion (Jones and Hathway, 1978b). Although 1,1-DCE was metabolized in much the same way in both species (Table IV-9), mice formed

Table IV-7

Disposition of [^{14}C] Following Inhalation of 10 ppm
1,1-DCE Over a 48 Hour Period

	<u>Mice</u>	<u>Rats</u>
Expired 1,1-DCE %	0.65 $\pm$ 0.07	1.63 $\pm$ 0.14
Expired $^{14}\text{CO}_2$ %	4.64 $\pm$ 0.17	8.74 $\pm$ 3.72
Body Burden %		
Urine	80.83 $\pm$ 1.68	74.72 $\pm$ 2.30
Feces	6.58 $\pm$ 0.81	9.73 $\pm$ 0.10
Carcass	5.46 $\pm$ 0.41	4.75 $\pm$ 0.78
Cage Wash	1.83 $\pm$ 0.84	0.44 $\pm$ 0.28
Body Burden mg. eq.		
1,1-DCE/kg	5.30 $\pm$ 0.75	2.89 $\pm$ 0.24
Total Metabolized		
mg. eq. 1,1-DCE/kg	5.27 $\pm$ 0.74	2.84 $\pm$ 0.26

Based on McKenna et al., 1977b.

Table IV-8

Covalently Bound ^{14}C in Rat and Mouse Following
Exposure to 10 ppm [^{14}C]-1,1-DCE

^{14}C -1,1-DCE, ug eq/mg Protein		
	Liver	Kidney
Mice	22.29 $\pm$ 3.77	79.55 $\pm$ 19.11
Rats	5.28 $\pm$ 0.14	13.14 $\pm$ 1.15

Based on McKenna et al., 1977b

Table IV-9

Relative Proportion of [^{14}C] Excretory Products After
Oral Administration of 50 mg/kg of [^{14}C]1,1-DCE to Rodents

[^{14}C] Excretory Products	^{14}C Expressed as % of Dose	
	Mice	Rats
Unchanged DCE pulmonary	6	2.8
CO_2 excretion	3	3.5
Chloroacetic acid	0	1
Thiodiglycolic acid	3	22
Thioglycolic acid	5	3
Dithioglycolic acid	23	5
Thioglycolyloxalic acid	3	2
N-acetyl-S-cysteinyl acetyl derivative	50	28
N-acetyl-S-(2-carboxymethyl) cysteine	4	0
Urea	3	3.5

Based on Jones and Hathway, 1978b.

considerably more of the N-acetyl-S-cysteiny-acetyl derivative, and excreted a small amount of N-acetyl-S-(2-carboxymethyl)-cysteine, which was not found in rats. It was suggested that the efficiency of DCE metabolism follows the activity of the cytochrome P-450 systems in the livers of these animals and that "real exposure," expressed in the amount metabolized, is higher for orally dosed mice than rats.

Studies of the effects of various inducers and inhibitors of microsomal enzymes on the rate of metabolism of 1,1-DCE have been conducted using isolated perfused livers (Reichert and Henschler, 1978; Reichert et al., 1978) and whole animals (Andersen et al., 1979b). The results of these studies are summarized in Table IV-10. These studies show contradictory results for the effects of phenobarbital and SKF 525-A, but these may be due to the difference in experimental technique, i.e., whole animal compared to isolated perfused liver.

Exposure of rats to trans-1,2-DCE or cis-1,2-DCE was shown to cause exhalation of acetone (Filser et al., 1978). However, this acetone is probably not a metabolite, but rather reflects a DCE-induced alteration in lipid and fatty acid metabolism.

Using isolated rat liver microsomes, both cis- and trans-1,2-DCE have shown competitive and reversible interaction with the mixed function oxygenase system. This interaction produced decreased drug metabolism (Freundt and Macholz, 1978).

Table IV-10

Effects of Inducers and Inhibitors of Microsomal Enzymes
on Rate of Metabolism of 1,1-DCE

Chemical	Experimental Method	Metabolism	Investigator
CCl ₄	whole animal	decrease	a
Pyrazole	whole animal	decrease	a
Aminotriazole	whole animal	decrease	a
2,3-Epoxypropan-1-ol	whole animal	none	a
Phenobarbital	whole animal	none	a
Phenobarbital	isolated perfused liver	increase	b
SKF 525-A	whole animal	none	a
SKF 525-A	isolated perfused liver	decrease	b
DDT	isolated perfused liver	increase	b
Decreased glutathione	isolated perfused liver	decrease	b

^a Anderson et al., 1979b.

^b Reichert and Henschler, 1978.
Reichert et al., 1978.

D. Excretion

Considerable work on the excretion of 1,1-DCE and its metabolites has been done using [^{14}C]1,1-DCE (Jaeger et al., 1977a; McKenna et al., 1977, 1978a, 1978b; Jones and Hathway, 1978a; Reichert and Werner, 1978; Reichert et al., 1979). These data are summarized in Table IV-6. The data show that both unmetabolized 1,1-DCE and CO_2 formed by metabolism of 1,1-DCE are excreted via the lung, whereas the other metabolites are eliminated via renal and biliary excretion. However, the pattern of excretion depends upon the concentration of 1,1-DCE in the blood, which is affected by the amount of chemical administered and to a certain extent by the route of administration. At low dose levels where the concentration of 1,1-DCE in the blood is low and metabolism is effective, most of the ^{14}C is eliminated as metabolites via renal and biliary excretion. It has been shown that a portion of the material excreted in the urine was actually of biliary origin and entered the urine by means of enterohepatic circulation (Jones and Hathway, 1978a). At higher dose levels where the concentration of 1,1-DCE in blood is much higher, metabolism approaches saturation and becomes less effective in removing the xenobiotic from the blood as it passes through the liver. As a result, increasing amounts of unmetabolized 1,1-DCE are eliminated through the lung. This is reflected in a change in the relative amounts of ^{14}C excreted as 1,1-DCE and CO_2 via the lung. Another example of the effect of metabolism on the course of elimination is seen by comparing the excretion following a low dose (0.5 mg/kg) of 1,1-DCE administered intravenously with results following oral or intraperitoneal admin-

istration. Whereas oral administration presents blood containing all of the 1,1-DCE to the liver for metabolism prior to passing through the lung, intravenous administration allows systemic distribution of 1,1-DCE and each pass brings approximately 25% of the blood to the liver. Therefore, the excretion by the lung is much more important following intravenous administration; a large part of the ^{14}C is eliminated as unmetabolized 1,1-DCE via the lung, rather than being eliminated as metabolites via the renal and biliary routes.

For 1,1-DCE the rate of elimination is relatively rapid, since most of the total absorbed dose is eliminated in the first 24-72 hours after administration (Jaeger, et al., 1977; McKenna, et al., 1977, 1978a; Jones and Hathway, 1978a).

Disappearance of covalently bound metabolites of 1,1-DCE, measured as TCA-insoluble fractions, also appears to be fairly rapid with a reported half-life of 2-3 hours (Jaeger et al., 1977a).


No data concerning the excretion of cis- and trans-1,2-DCE are available presently.

E. Pharmacokinetics

Several studies have shown that the pharmacokinetic behavior of the halogenated ethylenes is dose-dependent. This phenomenon is attributed to saturability of the metabolic capacity of the organism at higher doses (Jones and Hathway, 1978a; McKenna et al., 1978a, 1978b; Reichert and Henschler, 1978; Reichert and Werner, 1978, Andersen et al., 1979a, 1979b, 1980a; Filser and Bolt, 1979). A hypothetical two compartment pharmacokinetic model (Figure IV-4) has been employed to explain the results of inhalation

Figure IV-4

Two Compartment Pharmacokinetic Model for DCEs Between a
Closed Atmosphere and Animal and Metabolism



Based on Filser and Bolt, 1979.

studies of halogenated ethylenes (Filser and Bolt, 1979). In their closed system, saturation of the biotransformation processes was observed at high levels of exposure. When rats were exposed to atmospheric concentrations which exceeded the "point of saturation (SP)," metabolism followed zero-order kinetics, i.e., the rate of metabolism was independent of the concentration (Filser and Bolt, 1979). Concentrations below this saturation point result in normal first-order kinetics, i.e., the rate of metabolism was dependent upon the concentration.

The metabolic first-order clearance of the three dichloroethylenes is shown in Table IV-11. Cis-1,2-DCE has the highest rate of clearance, trans-1,2-DCE the lowest and 1,1-DCE intermediate. The concentration of the dichloroethylenes in the air at which there is a transition from first-order to zero-order metabolism also is shown in Table IV-11. The concentration necessary to saturate the metabolism was much higher for 1,1-DCE than for the 1,2-DCEs. Although the in vivo metabolism of DCEs does not follow simple Michaelis-Menten kinetics, a zero order kinetic rate constant, $V_{\max}$, for metabolism under saturation conditions could be determined (Table IV-11). This rate constant measures the maximum rate of metabolism of a particular chemical. The $V_{\max}$ for 1,1-DCE is much higher than for the 1,2-DCEs. The $V_{\max}$ values are quite different for the isomeric DCEs even when a correction is made for the differing tissue concentrations of these materials. This suggests that the maximum velocity of metabolism depends on the chemical structure. For the dichloroethylenes, the relative rate of metabolism was determined to be 1,1-DCE > cis-1,2-DCE > trans-1,2-DCE.

Table IV-11

First-Order and Zero-Order Metabolic Elimination of DCEs from a Closed Exposure System: Saturation Points (Sp) and Metabolic Rates Expressed as $V_{\max}$ and Clearance, Based on 1 kg Body Weight

Chemical	First Order Clearance hr·kg $\frac{\text{liter}}{\text{body weight}}$	Saturation Point, SP (ppm in air)	Zero Order $V_{\max}$ hr·kg $\frac{\text{umole}}{\text{body weight}}$
1,1-DCE	17	150	100
trans-1,2-DCE	11	(15)	7
cis-1,2-DCE	30	20	25


() Not observed experimentally, but obtained by extrapolation, i.e., from intersection of observed zero-order and first-order declines.

Filser and Bolt, 1979.

A hypothetical three compartment, steady-state, pharmacokinetic model (Figure IV-5) also has been used to explain kinetic data obtained in inhalation studies using gas uptake measurements (Andersen *et al.*, 1980a, 1979a, 1979b). According to this model, tissues richly perfused with blood rapidly equilibrate with atmospheric vapors of the DCEs. Following the initial blood:gas equilibration, the blood concentration of DCEs is decreased by metabolism in the richly perfused tissues, storage in the poorly perfused tissues and excretion. Excretion of the unmetabolized volatile toxicants occurs primarily via the lungs into the expired breath. For both 1,1-DCE and trans-1,2-DCE, there were significant contributions to the overall gas uptake rate from both a first order process, k_{23} , representing storage in the poorly perfused tissues, and a saturable process, k_m , representing metabolism. At very high concentrations, the relative contribution of the first order process (storage in poorly perfused tissue) to the overall gas uptake rate increased. At lower concentrations, the first order process became less important and the saturable process (metabolism) became the main route of gas uptake by the animal. Table IV-12 contains the kinetic data determined for the saturable process. The concentration dependence of the saturable phase was adequately described by Michaelis-Menten kinetics. The V_{max} , the maximum rate of metabolism, was determined to be 15.9 mg/kg·hr (164 umoles/kg·hr) for 1,1-DCE and 3.4 mg/kg·hr (35 umoles/kg·hr) for trans-1,2-DCE. Therefore, the relative rate of metabolism was 1,1-DCE > trans-1,2-DCE. The atmospheric concentration, K_m , that causes metabolism *in vivo* in rats to occur at one-half

Figure IV-5

Three Compartment Pharmacokinetic Model for Describing
Uptake of DCEs by Rats



Based on Andersen et al., 1980a.

Table IV-12

Inhalation Kinetic Constants for the Metabolism of
DCEs Determined Using Gas Uptake Measurements

Chemical	$v_{\max}^a$		K_m^b	
	(mg/kg·hr)	(umoles/kg·hr)	(ppm)	(umoles/liter plasma)
1,1-DCE	15.9	164	336	55.1
trans-1,2-DCE	3.4	35	411	183

^a $v_{\max}$ is the maximum rate of metabolism.

^b K_m is the atmospheric concentration that causes metabolism in vivo to proceed at half maximal velocity.

Based on Andersen et al., 1980a.

the maximum metabolic rate also was determined. The K_m was found to be 336 ppm (55.1 umoles/liter plasma) for 1,1-DCE and 411 ppm (183 umoles/liter plasma) for trans-1,2-DCE.

Based on the analysis of pharmacokinetic data from the gas uptake studies, it has been suggested that the rate limiting step in metabolism of DCEs at low concentration is blood flow to the liver (Andersen et al., 1980a). The rate at which an inhaled chemical is presented to the liver is determined by pulmonary absorption. Since the weight-adjusted breathing volume decreases as body weight increases, the rate of uptake and therefore the rate of presentation of DCEs to the liver would be expected to be reduced to a similar degree. For a rat, the resting breathing volume is estimated to be 32 liters/kg·hr. For a moderately active 70 kg man, the 8 hr work shift breathing volume is usually taken to be 10^3 m, i.e., 18 liters/kg·hr. Therefore, at lower exposure concentrations, less DCE would be presented to the liver in man relative to the rat. It has therefore been suggested that at low atmospheric concentrations, DCE metabolism would be slower in man than rats. This would shift the K_m (ppm in atmosphere) to even higher concentrations for man (Andersen et al., 1980a), if V_{max} were similar in each species.

Assuming that metabolism of 1,1-DCE is probably limited by hepatic perfusion and pulmonary ventilation at low inhaled concentrations, the relative amounts of metabolites formed by different species can be calculated. The human, on a per unit weight basis, would biotransform considerably less 1,1-DCE to toxic metabolites than does the rat or mouse. The data for 1,1-DCE metabo-

lism in mice and rats in Table IV-7 can be extrapolated by reference to physiological parameters to yield an estimate of the amount of metabolism likely to occur in a human exposed to 10 ppm of 1,1-DCE for six hours. Ventilation is given by an equation of the form (Guyton, 1947):

$$V_t = 0.126 \text{ l/hr (body weight)}^{0.75}$$

For the mouse, rat and human (30 g, 250 g and 70 kg, respectively), V is 53.0, 31.7 and 7.75 l/hr respectively, for the animals at rest. In a six hour exposure to 10 ppm (0.0397 mg/l) each species will inhale 12.82, 7.55 and 1.65 mg/kg, respectively. The data in Table IV-7 for the total metabolized 1,1-DCE show that the percent retained is 41% for the mouse and 38% for the rat. If the same percent retained (about 40%) holds, a human will metabolize only about 0.74 mg/kg. If these assumptions are correct, the human would be less at risk than the rat by a factor of 31.7/7.7, or about 4.1.

V. HEALTH EFFECTS IN ANIMALS

A. Acute and Chronic Effects

Data on the acute oral toxicity of the DCEs, as measured by the LD₅₀, have been reported in several studies (Jenkins et al., 1972; Andersen and Jenkins, 1977b; Andersen et al., 1979a; Freundt et al., 1977; Jones and Hathway, 1978b; NIOSH, 1978, Ponomarkov and Tomatis, 1980). Data from these sources are summarized in Table V-1. These data show a wide range of values for the LD₅₀.

1,1-Dichloroethylene. The lethality of 1,1-DCE in fasted rats was found to depend upon the size (age) of the animals: large rats (395 g) had an oral LD₅₀ (observed for 14 days following dosage) of > 1500 mg/kg, whereas smaller rats had LD₅₀ of < 50 mg/kg (Andersen and Jenkins, 1977b). The LD₅₀ value for the larger rats agreed with a previous study (Jenkins et al., 1972). The dose mortality curves for the fasted rats showed an extended plateau and even a maximum that reached 100% and then decreased at higher doses for young animals (73 g). Because of this unusual dose-response, the authors concluded that it was impossible to unambiguously determine LD₅₀ values for 1,1-DCE in younger rats (Andersen and Jenkins, 1977b). It was also determined in this study that the amount of 1,1-DCE retained by immature fasted male rats increased linearly up to a total dose of 100 mg/kg and then leveled off due to the greater percentage of the dose being excreted by the lungs at higher doses (Andersen and Jenkins, 1977b).

The acute inhalation toxicity of 1,1-DCE also has been determined (Jaeger et al., 1974). A large difference in 24-hr LC₅₀ values was found between fed (15,000 ppm) and fasted (600 ppm)

Table V-1

Acute Toxic Effects of DCEs

Compound	Route	Species	Dose	Effect	Reference
1,1-DCE	oral	rat	200 mg/kg	LD ₅₀	NIOSH (1978)
1,1-DCE	oral	rat	>1500 mg/kg	LD ₅₀	Jenkins, <u>et al.</u> (1972)
		rat ^a	84 mg/kg	LD ₅₀	Jenkins, <u>et al.</u> (1972)
1,1-DCE	oral	rat (395 g) (fasted)	>1500 mg/kg	LD ₅₀	Andersen and Jenkins (1977b)
1,1-DCE	oral	rat (138 g) (fasted)	<50 mg/kg	LD ₅₀	Andersen and Jenkins (1977b)
1,1-DCE	oral	rat (Male)	1800 mg/kg		Pononmarkov and Tomatis (1980)
		rat (Female)	1500 mg/kg		
1,1-DCE	oral	mouse (male)	217 mg/kg	LD ₅₀	Jones and Hathway (1978b)
		mouse (female)	194 mg/kg		Jones and Hathway (1978b)
1,1-DCE	oral	dog	5750 mg/kg	LD ₅₀	NIOSH (1978)
	iv	dog	225 mg/kg	LD ₅₀	NIOSH (1978)
1,1-DCE	inhal	rat (fed)	15,000 ppm/4 hr	LC ₅₀	Jaeger <u>et al.</u> (1974)
	inhal	rat (fasted)	600 ppm/4 hr	LC ₅₀	Jaeger <u>et al.</u> (1974)
	inhal	rat (fasted)	200 ppm/4.1 hr 400 ppm/3.6 hr 500 ppm/13.0 hr 1000 ppm/2.4 hr 2000 ppm/1.4 hr	LC ₅₀	Andersen <u>et al.</u> (1979a)
1,1-DCE	inhal	rat (fed)	6350 ppm/4 hr	LC ₅₀	Siegel <u>et al.</u> (1971)

Table V-1 (Continued)

Compound	Route	Species	Dose	Effect	Reference
1,2-DCE	oral	rat	770 mg/kg	LD ₅₀	NIOSH (1978)
	ip	mouse	2000 mg/kg	LD ₅₀	NIOSH (1978)
trans, 1-2-DCE	oral	rat (180-200 g)	1.0 ml/kg (1300 mg/kg)	LD ₅₀	Freundt <u>et al.</u> (1977)
	ip	rat (180-200 g)	6.0 ml/kg (7800 mg/kg)	LD ₅₀	Freundt <u>et al.</u> (1977)
	ip	mouse	3.2 ml/kg (4160 mg/kg)	LD ₅₀	Freundt <u>et al.</u> (1977)

^a Adrenalectomized

rats exposed for four hours. In another study of the inhalation toxicity of 1,1-DCE in mature male rats, the percent mortality that occurred in a 7 day period following a 4 hr exposure increased from 0 to 50% in the concentration range from 100 to 200 ppm but did not increase much over 50% as the concentration was increased from 200 to 2000 ppm, i.e., mortality was virtually independent of concentration (Andersen et al., 1979a). At high concentrations, the mortality was related to the duration of exposure rather than to the ambient concentration.

Based on the above data for the acute oral and inhalational toxicity, it has been suggested that the acute toxicity of 1,1-DCE is the result of a toxic metabolite and not due to the parent compound. Further, this metabolite is formed by a saturable process (Andersen et al., 1979a, 1980b). Under inhalation exposure conditions above the point of saturation of metabolism, i.e., ambient concentrations above the 200 ppm, unmetabolized 1,1-DCE is readily excreted via the lung. Using data from pharmacokinetic studies on the metabolic rate, the acute inhalation toxicity in rats was shown to be a function of the amount of metabolite formed and not of the concentration of 1,1-DCE (Andersen et al., 1979b). Short term exposures produced mortality after formation of 25-30 mg of metabolite/kg. At concentrations between 200-1000 ppm, a direct correspondence was found between the duration of an exposure required to kill rats (LT₅₀) and the time calculated to produce a constant amount of metabolite (Andersen et al., 1979b).

A comparative study of the lethality of 1,1-DCE in different species showed that inhalation of 60 ppm of 1,1-DCE for 2 days caused higher mortality in mice (8/10) than in rats (0/10) (Short *et al.*, 1977a). This study also showed that there were similar values for the LC₅₀ for one-day exposures (22-23 hrs/day) to 1,1-DCE in male (98 ppm) and female (105 ppm) mice. After repeated exposures, male mice were more sensitive to the lethal effects of 40 ppm of 1,1-DCE since the mortality for males after day 3 (3/10) and day 5 (7/10) of exposure was higher than for females (0/10). Similarly, it has been shown that species, strain and sex greatly influence the toxic effects of 1,1-DCE, presumably due to the formation of differing amounts of toxic metabolites (Maltoni, 1977).

The effects of exposure to 1,1-DCE over a greater number of days also have been studied. Repeated exposure (20 days) of rats to 500 ppm of 1,1-DCE for 6 hr/day has been reported to cause nasal irritation, decreased body weight gain and liver cell degeneration, whereas only slight nasal irritation was noted for the same exposures to 200 ppm (Gage, 1970).

It also has been reported that liver and kidney damage occurred in animals exposed by inhalation for 8 hr/day, 5 day/week for several months at concentrations of 50 and 100 ppm of 1,1-DCE in air (Irish, 1963).

Continuous 90 day inhalation exposures to 0, 5, 15, 25 or 47 ppm (0, 20, 61, 101 and 189 mg/m³) of 1,1-DCE or repeated daily exposures of 8 hr/day, five days per week for six weeks to 100 ppm (395 mg/m³) were studied using rats, guinea pigs, dogs, rab-

bits and monkeys (Prendergast, et al., 1967). Repeated exposures (30 exposures) to 100 ppm produced no mortality or visible toxic signs in any species. Hematologic and growth data did not reveal any evidence of a toxic response and histopathologic findings were negative in all species. In contrast to repeated intermittent exposures, continual exposure to 1,1-DCE caused increased mortality at concentrations as low as 5 ppm for guinea pigs and 25 ppm for monkeys. Growth depression was found in all species at the 47 ppm exposure level. Significant increases in serum glutamic-pyruvic transaminase and liver alkaline phosphatase were found in rats and guinea pigs exposed continually to the 47 ppm level, but these changes could not be demonstrated at the 5 ppm level. No determinations of enzyme levels were performed at the 15 and 25 ppm levels. Histopathological study of organs revealed definite morphological changes in liver and kidneys of rats and guinea pigs at the 47 ppm exposure level, but none at 25 ppm or lower.

A study of the inhalation exposure to 60 ppm of 1,1-DCE for 22 hr/day for 7 days showed evidence for liver toxicity in both mice and rats as measured by increased levels of serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) (Short et al., 1977a,b).

A few deaths (three) and a few hepatic hemangiosarcomas (three) were noted in an inhalation study in which 72 mice were exposed to 55 ppm of 1,1-DCE for 6 hr/day, 5 days/week for 12 months (Lee, et al., 1978). Inflammatory, degenerative and mitotic changes were observed in most of the livers. Several mice (six) had bronchioalveolar adenomas, but there were no mammary gland tumors. Expo-

sure of rats to the same inhalation regimen resulted in slightly depressed body weights. Hemangiosarcomas occurred in the mesenteric lymph nodes or subcutaneous tissue in two of 72 exposed rats.

Dow Chemical Company has reported that daily oral administration of 1,1-DCE to dogs for 97 successive days at dosages of 6.25, 12.5 or 25 mg/kg bw caused no adverse effects (Norris, 1977; Quast, et al., 1983). The animals (4/sex/group) were given the compound as a 50% solution in peanut oil in a gelatin capsule. Each day, a control group of 4 animals/sex was given a capsule containing an amount of peanut oil equivalent to that given the dogs at the 25 mg/kg/ dose level. The dogs were housed 4/pen.

The dogs were observed daily for toxicity, with food consumption/pen measured twice weekly, calculating average daily consumption/animal. Hematological parameters measured on Days -48, +33 and +84 were: packed cell volume, RBC count, hemoglobin concentration, total and differential white cell counts. Urinalyses to measure specific gravity, sugar, protein, ketones, occult blood, bilirubin and a microscopic examination of sediment were conducted on Days 833 and at necropsy. Clinical chemistry, done after overnight fasting on Days -7, +85 and +97, included blood urea nitrogen, serum GPT, alkaline phosphatase, serum GOT. Non-protein free SH content of liver^a and kidney was determined at necropsy, along with weights of the brain, liver, kidney, heart and testes. Ophthalmological exams were conducted on all animals at the start and end of the study. At necropsy,

both eyes of each dog in the control and high dose groups were examined grossly and microscopically.

No exposure-related changes were observed in appearance, demeanor, body weights or food consumption. The mean white cell counts of dogs receiving 6.25 or 25 mg/kg/day were significantly lower than control values on Day 84 ($P < 0.05$). However, these values were not significantly different from their own pre-exposure white cell counts. In addition, they were within the range of normal values observed in that laboratory. Therefore, the investigators considered the differences to be unrelated to the ingestion of 1,1-DCE.

Female dogs receiving 6.25 mg/kg 1,1-DCE exhibited a significant decrease in BUN levels at Day -7 and a significant increase in SGOT at Day 85 ($P < 0.05$). Males in that dose group showed elevated SGOT and SGPT at sacrifice ($P < 0.005$). These comparisons were made with the concomitant controls. However, the investigators stated that the values were within the range of normal values observed historically in that laboratory. No alterations in the clinical chemistry parameters were noted at the 12.5 or 25 mg/kg/day doses except for one high dose male that had an elevated SGPT on Day 85 but not on Day 97. No changes were seen in the SH content of the liver or kidneys.

No compound-related changes were reported in any of the parameters measured on urinalysis, in organ weight or organ:body weight ratios or on gross or microscopic examination of tissues. One male receiving 12.5 mg/kg/day had grossly enlarged kidneys, but no accompanying histopathology. The investigators determined that

this finding was not compound-related.

Results were reported from a 90-day toxicity study in rats given nominal concentrations of 50, 100 or 200 ppm of 1,1-DCE in water or exposed for 6 hr/day, 5 days/week at initial levels of 0, 10 or 40 ppm 1,1-DCE in air (Rampy, et al., 1977). After 5 weeks, the doses were increased to 25 or 75 ppm. There was also a separate study done at 0, 25 or 75 ppm.

Ten rats/sex/group were used, with 2 rats/sex/group sacrificed at Days 1,3,10 and 30 for the determination of non-protein sulfhydryl groups in the liver and kidney. The mean daily dosage levels in mg/kg based upon the amount of water consumed were 0, 7.5, 12.6 or 25.6 mg/kg for the females and 0, 5.9, 10 or 19 mg/kg for the males. Body weight was recorded once a week for the first month and monthly thereafter. Hematological and clinical chemistry measurements and urinalyses were conducted at 30 and 90 days. The parameters measured were the same as described in Quast, et al. (1983).

Except for a decreased kidney:body weight ratio in males at the low dose, there were no statistically significant differences in organ weights or organ:body weight ratios at the termination of the study. The only histopathology noted was an increased cytoplasmic vacuolization of hepatocytes in livers of both sexes exposed to the highest dose. The investigators considered this to be a minimal change which would be reversible if the animals were removed from exposure to the chemical.

In the inhalation studies, there were no significant differences in organ weights at 30 or 90 days. Increased

vacuolization in the liver was seen at both the 25 and 75 ppm exposure levels at 30 days and beyond. It was not seen in rats exposed to 10 or 40 ppm for only 30 days.

A two year chronic toxicity/oncogenicity study was conducted in rats given nominal concentrations of 0, 50, 100 or 200 ppm of 1,1-DCE in drinking water (Rampy, et al., 1977; Quast, et al., 1983). In the interim report, the primary finding from this study was increased vacuolization of hepatocytes in the livers in the of animals in the high dose group (Rampy et al., 1977). Based on gross tumor count, tumor incidence was not greater than controls.

The time-weighted average mg/kg/day doses were 0, 7, 10 or 20 for the males and 0, 9, 14 or 20 for the females. Groups of 48 animals/sex/dose were used, except for controls (80/sex). The animals were observed at least twice a week for overt toxicity, changes in appearance or behavior and tumor formation. Biweekly food consumption and daily water consumption were measured for the first three months; these determinations were made at periodic intervals thereafter. Body weights were recorded once a week for 14 weeks and monthly thereafter. Hematologic determinations and urinalyses were conducted on at least 5 rats/sex/group at 6, 12, 18 and 23 months. Clinical chemistry measurements were made on 5 rats/sex/group at 6, 12 and 18 months and on 10 rats/sex/group or all survivors if fewer than 10 remained at terminal necropsy. The parameters measured are the same as those described above for Dow's subchronic rat study.

At terminal necropsy, following overnight fasting, the brain

heart, liver, kidney and testes were weighed. Gross and microscopic examination was done on complete sets of tissues (37) on all control and high dose animals. Only selected tissues from target organs and grossly recognizable neoplastic changes were examined microscopically from animals at the other two dose levels.

No consistent, dose-related changes were observed in any parameter measured. The only pathological finding considered by the investigators to be treatment-related was in the liver of animals of both sexes in the high dose group. These microscopic changes, when present, were usually characterized by a minimal amount of mid-zonal hepatocellular fatty change. The degree of increase in this pathology was statistically significant in the males. A trend toward this increase was seen in males at the intermediate dose. No exposure-related changes were seen in males at the low dose. Minimal hepatocellular swelling and fatty changes were detected in female rats at all dose levels. No significant treatment-related hepatocellular necrosis was evident in either sex at any dose.

Cis- and trans-1,2-dichloroethylene. The LD₅₀ values for 1,2-DCE (isomer mixture) and trans-1,2-DCE are shown in Table V-1 (Freundt, et al., 1977). No similar data are available for the cis- isomer.

The effects of short and long term inhalation exposure to trans-1,2-DCE have been investigated (Freundt, et al., 1977). Adult female rats were exposed to 0, 200, 600 or 1000 ppm trans-1,2-DCE for 8 hr/day, 5 days/week for 16 weeks. The lowest dose produced histological evidence of slight to severe

fatty degeneration of liver lobules and Kupffer cells. In addition, marked pulmonary hyperemia and alveolar septal distension were noted. Fibrous swelling of cardiac muscle also was observed. Exposure to 1,000 ppm of trans-1,2-DCE for 8 hours caused a fall in blood serum albumin, urea nitrogen, alkaline phosphatase activity and number of erythrocytes while 200 ppm for 8 hours was sufficient to lower leukocyte count. All of the exposure conditions investigated failed to produce narcosis.

B. Specific Toxic Effects

1. Liver

The most common toxic effect of 1,1-DCE is liver damage, which has been documented in rats, mice and guinea pigs. The morphological changes appear in fasted rats as early as 2 hr after the start of inhalation exposure to 200 ppm of 1,1-DCE (Reynolds, et al., 1975). The parenchymal cell injury is characterized by the retraction of cell borders with the formation of pericellular "lacunae" which may contain cytoplasmic projections, red blood cells and fibrin. Nuclear changes include loss of perinuclear chromatin and clumping and coalescence of perinuclear chromatin. Mitochondria in the cytoplasm appear swollen, with ruptured outer membranes. The rough and smooth endoplasmic reticulum appears relatively normal. The zone of injured midzonal parenchymal cells becomes confluent, forming a prominent midzonal stripe of necrosis which leads to hemorrhagic centrilobular necrosis. In contrast to damage caused by 1,1-DCE, the morphological change in liver caused by exposure to other halogenated ethylenes characteristically is damage to the endoplasmic reticulum. This

suggests a basic difference in the mechanisms of toxicity of 1,1-DCE (Reynolds et al., 1975).

Hepatotoxicity of 1,1-DCE has been shown to have a complex dose dependent response, having a threshold level, a concentration range of rapid increase, and an extended plateau where increasing doses caused little increase in hepatotoxicity. The threshold was lower for male rats (50 mg/kg) than for female rats (100 mg/kg) (Andersen and Jenkins, 1977b).

Continual exposure of rats or guinea pigs to 47 ppm of 1,1-DCE for 90 days caused significant increases in serum glutamic-pyruvic transaminase and liver alkaline phosphatase activities, but these changes could not be demonstrated at the 5 ppm level. Although no determinations of enzyme levels were performed at the 15 and 25 ppm levels, histopathological study of organs revealed definite morphological changes in liver and kidneys of rats and guinea pigs at the 47 ppm exposure level, but not at 25 ppm or lower (Prennergast et al., 1967). Oral administration of a single dose of 500 mg/kg of 1,1-DCE decreased liver glucose-6-phosphatase, but increased liver alkaline phosphatase (5-fold increase), liver tyrosine transaminase (11-fold increase), plasma alkaline phosphatase and plasma alanine transaminase (Jenkins et al., 1972). Exposure of rats to 60 ppm of 1,1-DCE for 22 hr/day for 7 days caused increased levels of both serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase (Short et al., 1977a).

Fasted rats were found to be more sensitive to both lethal and hepatotoxic effects of 1,1-DCE. An increase in serum alanine alpha-ketoglutarate transaminase (AKT) level was observed at 24

hours after a 4 hr exposure to 150 ppm in fasted rats, whereas a similar increase was observed in fed rats only at 2000 ppm or higher. Elevated serum AKT preceded hepatic necrosis and death. This fed-fasted difference in serum AKT elevation also was observed in isolated perfused rat liver (Jaeger et al., 1974). The increased susceptibility to liver injury has been attributed to decreased hepatic glutathione concentration which occurs after fasting (Jaeger et al., 1974, 1975a), after administration of some chemicals, e.g., diethyl maleate (Jaeger et al., 1974) or as a result of normal diurnal variation (Jaeger et al., 1973a). Additional evidence concerning the importance of glutathione concentration is the observation that thyroidectomy, which causes an increase in glutathione level, protects against hepatic injury and mortality from 1,1-DCE (Szabo et al., 1977). Conversely, pretreatment of animals with thyroxine was found to cause depletion of glutathione and increased hepatotoxicity (Jaeger et al., 1977b).

With regard to the difference in hepatotoxicity between fed and fasted rats, an in vitro study has shown that the activity of the enzymes of the mixed function oxidase system is greatly enhanced in fasted rats, without a significant increase in the microsomal protein and cytochrome P-450 content. The in vitro rate of metabolism of 1,1-DCE using microsomes obtained from fasted rats was double the rate of microsomes from fed rats, suggesting that formation of increased amounts of metabolite may be responsible for the increased hepatotoxicity of 1,1-DCE in fasted rats (Nakajima and Sato, 1979).

The glutathione level of the liver was shown to be decreased greatly following a 4 hour exposure of rats to 200 or 2000 ppm of 1,1-DCE and to rebound to higher than normal levels 24 hours after the end of the exposure (Jaeger et al., 1973a; Reynolds et al., 1975). However, the glutathione level in the mitochondria was shown to remain depressed for 24 hours following exposure. Decreased uptake of O_2 by mitochondria isolated from rats exposed to 1,1-DCE paralleled the decrease in glutathione in the mitochondria. Additionally, the serum levels of sorbitol dehydrogenase, an enzyme of cytoplasmic origin, and carbamyl transferase, an enzyme of mitochondrial origin were elevated concurrently. Both glutathione depletion and reduced O_2 uptake were shown to occur before serum enzyme levels increased. An increase in total liver citric acid level also was found. Based on these observations, it has been suggested that 1,1-DCE may be oxidized by the mixed function oxidases to monochloroacetic acid which is further metabolized to a material, possibly monochlorocitric acid, that inhibits mitochondrial performance. This mitochondrial injury may be the basis for the hepatotoxicity (Jaeger, 1977). Histochemical work has shown that exposure to 1,1-DCE caused a dramatic alteration in the pattern and a reduced intensity of the mitochondrial membrane markers, monoamine oxidase and succinate dehydrogenase. These results were interpreted as suggesting the mitochondrial membrane as a major foci of injury (Chieco et al., 1979).

The role of lipid peroxidation in hepatotoxicity by 1,1-DCE has been investigated. Whereas one study concluded that lipid peroxidation was not the mechanism of hepatic injury by 1,1-DCE

(Jaeger et al., 1973b), another study showed that depletion of glutathione in the liver by 1,1-DCE caused an increase in spontaneous lipid peroxidation (Younes and Siegers, 1980).

The relationship of metabolism of DCEs to their toxicity is not well understood. The effects of inducers and inhibitors of microsomal enzymes and xenobiotic substrates which would compete for biotransformation with DCEs have been investigated. Table V-2 summarizes the results obtained as measured by lethality, hepatotoxicity and metabolic rates. The data demonstrate that conflicting results were obtained in different studies with inducers and inhibitors of microsomal enzymes. It has been shown that the response of rats to a particular material depends upon the age or body weight (Andersen et al., 1978). Whether or not this accounts for the different response between studies is uncertain. It has been suggested that the pretreatments may interact with different sequential steps of a multi-step metabolic pathway or with different metabolic pathways (Andersen et al., 1978). An alternative proposal has been made that different mechanisms may be responsible for lethality and hepatotoxicity (Reynolds and Moslen, 1977). However, one can conclude that the microsomal enzyme inducers did not potentiate markedly the hepatotoxic effects of 1,1-DCE as they do for many other halogenated hydrocarbons. This lack of effect might be because the metabolism of 1,1-DCE is blood flow limited (Andersen et al., 1980a).

The classical microsomal enzyme inhibitor, SKF 525-A, does not alter the hepatotoxic effects of 1,1-DCE but does increase the lethality at least in larger rats. Also, it has been reported

Table V-2

Result of Various Pretreatments on 1,1-DCE Effects in Rats

<u>Pretreatment</u>	<u>Lethality</u>	<u>Hepatotoxicity</u>	<u>Metabolism</u>	<u>Reference</u>
<u>Microsomal Inducers</u>				
Phenobarbital	increase	decrease		Reynolds et al., 1975, 1977
Phenobarbital		no change		Carlson and Fuller, 1972
Phenobarbital		decrease		Jenkins et al., 1972
Phenobarbital	decrease ^a increase ^b		no change	Andersen et al., 1978, 1979b
Phenobarbital			10% increase	Reichert and Henschler, 1978
3-Methylcholanthrene		no change		Reynolds et al., 1975, 1977
3-Methylcholanthrene	increase	no change		Carlson and Fuller, 1972
Aroclor 1254		decrease		Reynolds et al., 1975, 1977
Hexachlorobenzene		no change		Reynolds et al., 1975, 1977
DDT			35% increase	Reichert and Henschler, 1978
Spirocholactone		no change		Reynolds et al., 1975, 1977
Pregnenolone-16-carbonitrile		no change		Reynolds et al., 1975, 1977
<u>Microsomal Inhibitors</u>				
SKF 525-A	no change ^a increase ^b increase		no change	Andersen et al., 1978, 1979b
SKF 525-A		no change	decrease	Carlson and Fuller, 1972
SKF 525-A				Reichert and Henschler, 1978
SKF 525-A				Jaeger et al., 1975b
Pyrazole	no change	no change	84% decrease	Andersen et al., 1978, 1979b
3-Aminotriazole	decrease ^c		65% decrease	Andersen et al., 1978, 1979b
CCl ₄	decrease		92% decrease	Andersen et al., 1978, 1979b
Diethyl Dithiocarbamate	decrease	decrease		Short et al., 1977a, 1977b
Diethyl Dithiocarbamate		decrease	decrease	Siegers et al., 1979
Disulfiram	decrease	decrease		Short et al., 1977a, 1977b
Thiram	decrease	decrease		Short et al., 1977a, 1977b

a Small rats

b Large rats

c Rats of various sizes

continued-

Table V-2. Result of Various Pretreatments on 1,1-DCE Effects in Rats (Continued)

<u>Pretreatment</u>	<u>Lethality</u>	<u>Hepatotoxicity</u>	<u>Metabolism</u>	<u>Reference</u>
<u>Competitive Substrates</u>				
2,3-Epoxypropan-1-ol	increase		no change	Andersen et al., 1977a, 1979b
Epichlorohydrin	increase			Andersen et al., 1980b
Styrene oxide	increase		decrease	Andersen et al., 1980b
Butadiene monoxide	increase		decrease	Andersen et al., 1980b
<u>Competitive Substrates</u>				
Cyclohexene oxide	increase		decrease	Andersen et al., 1980b
Diethyl maleate	increase		decrease	Andersen et al., 1980b
Cysteine	decrease	decrease		Jaeger et al., 1975b
Cysteine	decrease			Short et al., 1977b
Methionine	decrease			Short et al., 1977b
N-Acetyl cysteine	no change			Short et al., 1977b
Vitamin C	no change			Short et al., 1977b
Vitamin E	no change			Short et al., 1977b
Vinyl Chloride ^d	no change	decrease	no change	Jaeger et al., 1975a
<u>Free Radical Scavenger</u>				
(+) Cyanindol-3		decrease	no change	Siegers et al., 1979

^d Administered simultaneously, not as a pretreatment

that pretreatment of rats with disulfiram or diethyl dithiocarbamate reduces lethality, hepatotoxicity and the amount of covalently bound ^{14}C in livers of mice exposed to [^{14}C]1,1-DCE (Short et al., 1977a,b; Siegers et al., 1979). Disulfiram is known to reduce hepatic cytochrome P-450 levels. However, it is also readily split into diethyl dithiocarbamate which has sulfhydryl groups that can react with toxic metabolites (Bartsch et al., 1979). This may be the mechanism by which it decreases hepatotoxicity. Similarly, cysteine and methionine have been shown to reduce the lethality and hepatotoxicity (Jaeger et al., 1975b; Short et al., 1977b). Pretreatment with epoxides, which would interfere with subsequent metabolism of a toxic epoxide intermediate, has been shown to increase hepatotoxicity (Andersen et al., 1980b). Simultaneous administration of vinyl chloride causes a decrease in hepatotoxicity, presumably by competing with 1,1-DCE for reaction with the mixed function oxidases (MFOs) (Jaeger et al., 1975a). Pretreatment with antioxidants such as Vitamin C or Vitamin E had no effect on lethality (Short et al., 1977b).

The hepatotoxicity of 1,2-DCE, as determined by changes in hepatic enzymes, was studied and cis-1,2-DCE was found to be slightly more hepatotoxic than trans-1,2-DCE but both had less effect on the liver than 1,1-DCE (Jenkins et al., 1972). It has been reported that repeated inhalation exposures of rats to 200 ppm of trans-1,2-DCE for 8 hr/day, 5 days/week for 16 weeks produced fatty degeneration of the liver lobules and Kupffer cells (Freundt et al., 1977).

2. Kidney

Although renal lesions have been demonstrated histologically in studies at doses of 1,1-DCE similar to those causing hepatotoxicity, there has been limited research on this topic (Prendergast et al., 1967; Short et al., 1977a,b). The nephrotoxic effects of a single oral dose of 200, 400 or 600 mg/kg of 1,1-DCE has been examined in rats. Increases in plasma urea nitrogen and plasma creatinine levels as well as increased kidney weight were found in males but not in females. However, both sexes showed similar histopathologic changes: vacuolization, tubular dilatation and necrosis (Jenkins and Andersen, 1978). The degree of covalent binding of 1,1-DCE metabolites has been shown to be higher in kidney than in liver in both rats and mice (McKenna et al., 1977; Short et al., 1977a) and more water-soluble ^{14}C radioactivity has been found in fasted than fed rats (Jaeger et al., 1977a). Inhalation exposure of mice and rats to 60 ppm for 23 hr/day for up to 5 days produced renal lesions in mice but not in rats (Short et al., 1977b). The primary renal lesion observed after continuous exposure to 47 ppm for 90 days was nuclear hypertrophy of the tubular epithelium (Prendergast et al., 1967).

3. CNS

Like other members of the chlorinated ethylene series, the DCEs possess general anesthetic or narcotic properties. However, there are virtually no data characterizing either short-term or long-term effects of DCEs on the CNS. It has been reported that the primary effect of acute inhalation of 1,1-DCE is CNS depression (Irish, 1963).

Inhalation exposures to trans-1,2-DCE, either 200 ppm for 8 hr/day, 5 days/week for 16 weeks or to 3000 ppm for one 8 hour exposure, failed to produce pre-narcotic signs or narcosis (Freundt et al., 1977). The cis-isomer did not anesthetize rats in 4 hrs at 8000 ppm, but at 16,000 ppm they were anesthetized in 8 minutes and killed in 4 hours (Irish, 1963).

4. Heart

Inhalation of 1,1-DCE by rats at high concentrations (25,600 ppm) for 10 minutes has been found to sensitize the myocardium to both epinephrine-induced and non-epinephrine-induced arrhythmias. The cardiac sensitizing effects of 1,1-DCE were increased by phenobarbital pretreatment, suggesting that a metabolite of 1,1-DCE may be responsible for the cardiotoxicity (Siletnik and Carlson, 1974). However, the metabolites are not known to sensitize the heart.

Inhalation of trans-1,2-DCE by rats at high concentrations (3,000 ppm) for 8 hr was reported to produce fibrous swelling of the cardiac muscle and hyperemia which persisted for 14 hr after exposure (Freundt et al., 1977).

5. Pancreas

As reported for a number of other chlorinated hydrocarbon solvents, 1,1-DCE increases bile duct pancreatic fluid flow in fasted rats. The composition of the fluid did not differ significantly from that in control animals (Hamada and Peterson, 1977). The significance of this finding remains to be established.

6. Immune System

Trans-1,2-DCE was screened for potential immunological

effects in CD-1 mice (Munson, et al., 1982). Four-week old males were exposed for 14 consecutive days to the compound by gavage in a volume of 0.01 ml/g body weight at doses equal to $0.01 \times LD_{50}$ (~ 22 mg/kg) and $0.1 \times LD_{50}$ (~ 220 mg/kg). The LD_{50} for male mice was determined in range-finding studies to be 2221 (range=1987-2469) mg/kg. No changes in body weight or organ weight (liver, kidney, thymus, brain and lung) were observed over the test period.

The humoral immune response was assessed by measuring the number of IgM antibody-forming cells (AFC) to sheep RBCs. On the AFC/spleen basis, trans-1,2-DCE showed a trend towards producing immunosuppression ($P < 0.1$).

Cell-mediated immune response was measured by quantifying the extravasation of human serum albumin during the delayed hypersensitivity response to sheep RBCs. Trans-1,2-dichloroethylene showed no effect at either dose.

C. Teratogenicity

The teratogenic potential of inhaled 1,1-DCE has been evaluated in rats and rabbits (Murray et al., 1979). Inhalation exposure for both species was for 7 hr/day at 20 (rats only), 80 or 160 ppm. Administration of 1,1-DCE to rats was on days 6 to 15 of gestation and on days 6 to 18 for rabbits. In rats, inhalation of 80 and 160 ppm of DCE produced significant maternal effects including decreased weight gain, decreased food consumption, increased water consumption and increased liver weight (160 ppm only). In the offspring, there was a significantly increased incidence of skeletal alterations at 80 and 160 ppm; these alter-

ations included delayed ossification of various bones and wavy ribs. In rabbits, 160 ppm caused a significant increase in resorptions in the dams and a significant change in several minor skeletal variations in the offspring. In both rats and rabbits exposed to 1,1-DCE by inhalation, Murray et al., (1979) noted that concentrations which caused little evidence of maternal toxicity (20 ppm in rats and 80 ppm in rabbits) caused no adverse effect on embryonal or fetal development.

The teratogenic potential of ingested 1,1-DCE also has been evaluated in rats (Murray et al., 1979). Drinking water containing 200 ppm 1,1-DCE, corresponding to an approximate dose of 40 mg/kg/day, was administered on days 6 to 15 of gestation. The authors described this concentration as near the upper solubility limit of the compound in water. Data on maternal body weight gain, food and water consumption, and maternal liver weight showed no evidence for maternal toxicity. There was no significant effect on the average number of implantations, live fetuses or resorptions, and no alteration of the fetal sex ratio or body weight occurred. The only significant effect noted was an increase in mean fetal crown rump length. The authors concluded that 1,1-DCE was not teratogenic at this exposure level.

A study of the teratogenic potential of inhaled 1,1-DCE in rats and mice has been reported in an abstract (Short et al., 1976). Rats or mice were exposed for 23 hr/day from days 6 to 16 of gestation. The authors reported that no gross soft tissue or skeletal malformations attributable to exposure to 1,1-DCE were observed in rats exposed to up to 460 ppm or in mice exposed to 15 ppm.

D. Mutagenicity

1,1-DCE has been shown to be mutagenic in Salmonella typhimurium strains TA 1530, TA 100 (Bartsch et al., 1975; Simmon et al., 1977; Simmon and Tardiff, 1978) and TA 1530 (Jones and Hathway, 1978c) and in E. coli K12 (Greim et al., 1975). In both bacterial systems, mutagenic activity required microsomal activation. Microsomal fractions derived from liver, kidney and lung of mice and rats were used to determine their relative ability to convert 1,1-DCE into mutagenic metabolites (Bartsch et al., 1975). Data comparing the relative activity of these various tissues are in Table V-3. Mouse liver, kidney and lung fractions were all effective, with liver showing the greatest activity. A much lower mutagenic response was observed in rats than in mice with liver and kidney fractions and there was only minimal activity with the lung fraction in either species. Human liver also was found to convert 1,1-DCE into mutagenic metabolites, its activity being similar to rat liver and considerably less than mouse liver (Bartsch, 1976).

Pretreatment of rats with modifiers of microsomal enzymes affected the bacterial mutagenicity of 1,1-DCE in the presence of S-9 from liver from these animals (Table V-4). In general, microsomal enzyme inducers increased and inhibitors of microsomal P-450 decreased the mutagenicity of 1,1-DCE. Microsomal fractions derived from kidney and lung from animals pretreated with phenobarbital also increased the mutagenicity of 1,1-DCE (Bartsch et al., 1975).

Both cis- and trans-1,2-DCE were non-mutagenic when assayed with E. coli K12 at similar concentrations used for 1,1-DCE

Table V-3

Effect of Different Tissues on the In Vitro
Bacterial Mutagenicity of 1,1-DCE

<u>Species</u>	<u>Organ</u>	<u>Relative Activity</u>
Mouse	Liver	100
	Kidney	20
	Lung	6
Rat	Liver	30
	Kidney	5
	Lung	3
Human ^a	Liver	20 ^b

a Biopsy samples

b Tissue samples were from 4 patients;
relative activity for the individual
patients was 11, 16, 17, 38.

Based on Bartsch, 1976; Bartsch et al., 1976; Bartsch
et al., 1979.

Table V-4

Effect of Drug Treatment of Rats on Liver S-9
Mediated Bacterial Mutagenicity of 1,1-DCE

<u>Drug Treatment</u>	<u>Relative Activity</u>
None	100
Phenobarbital	200
Pregnenolone-16- -carbonitrile	60
3-Methylcholanthrene	150
Aminoacetonitrile	40
Dibenamine	70
Disulfiram	10
Disulfiram (added <u>in vitro</u>)	10

Based on Bartsch et al., 1979.

(Greim et al., 1975). It has been proposed that the mutagenic and presumably carcinogenic activities of chloroethylenes are related to the symmetry of the chlorine substitution of the epoxide intermediates formed by oxidation of the parent olefins. Compounds with unsymmetrical chlorine substitution would result in less stable, more reactive intermediates than symmetrically substituted materials (Henschler et al., 1976; Henschler, 1977; Henschler and Bonse, 1977). These data support this hypothesis, at least with respect to mutagenesis in E. coli K12 systems. However, generalization of this hypothesis to carcinogenesis in intact animals is not yet possible.

1,1-DCE was tested for its ability to induce both point mutation and mitotic gene conversion in the yeast Saccharomyces cerevisiae D7, in a suspension test with and without metabolic activation, and in the intrasanguineous host-mediated assay in mice (Bronzetti, et al., 1981). The chemical was tested at levels of 0, 10, 20, 30, 40 or 50 mm/plate, with a 2-hour exposure period. Without metabolic activation, 1,1-DCE was toxic at all levels, but not genetically active. When mouse liver 10,000g activation system was added, concentration-dependent increases in both mutant and revertant frequencies were seen at concentrations above 20 mM.

When 1,1-DCE was administered to mice by gavage at 400 mg/kg in the intrasanguineous host-mediated assay, the induction of gene conversion at the trp 5 locus was detected in liver and kidney; no significant increase was seen in the lungs. The same dose also induced ilv-92 reversion in the kidney and liver, but not the lung.

After multiple treatments with 1,1-DCE by gavage, with a total dose = 2500 mg/kg, increased frequency of trp 5 conversions

and ilv-92 reversions were seen in the liver and kidney, but not the lungs.

Both 1,1-DCE and cis-1,2-DCE were found to be mutagenic in the host-mediated assay using Salmonella tester strains in mice, whereas trans-1,2-DCE was found to be non-mutagenic (Cerna and Kypenova, 1977). Of the three isomeric DCEs, only cis-1,2-DCE produced chromosomal aberrations in cytogenetic analysis of bone marrow cells following repeated intraperitoneal injections (Cerna and Kypenova, 1977).

1,1-DCE was found to be non-mutagenic in V79 Chinese hamster cells in the presence of 15,000 g liver supernatant from phenobarbital-pretreated rats and mice (Drevon and Kuroki, 1979).

The finding of increased mutation rates in bacterial systems has not been confirmed in mammalian systems. CD-1 male mice exposed to 10, 30, or 50 ppm of 1,1-DCE for 6 hr/day for 5 days failed to produce dominant lethal mutations (Anderson, 1977). In this study there was a pre-implantation loss as reflected by an increase in the number of females that did not become pregnant after mating with exposed males (at the 50 ppm level only). However, there was no pre-implantation loss in those females that did become pregnant. In addition, post-implantation loss is more indicative of dominant lethality than is a pre-implantation loss. Similarly, adult CD male rats exposed to 55 ppm 1,1-DCE for 6 hr/day, 5 days/week for 11 weeks failed to produce dominant lethal mutations (Short, et al., 1977c).

E. Carcinogenicity

The carcinogenicity of 1,1-dichloroethylene has been evaluated in gavage studies with rats and mice sponsored by the National Toxicology Program (NTP, 1982). The following discussion is, in large part, taken directly from the NTP Bioassay report.

A single-dose range-finding study was conducted to determine the doses for the 14-day repeated dose study. 1,1-DCE was diluted in corn oil and administered by gavage to groups of five males and five females/species in doses of 0, 10, 50, 100, 500 or 1000 mg/kg. The animals were observed for 14 days and necropsied on Day 15.

One female rat receiving 500 mg/kg died. One male rat that received 10 mg/kg died after 7 days and two that received 1000 mg/kg died within 48 hours.

All male mice receiving 500 or 1000 mg/kg died. Among the female mice, 1/5 receiving 50 mg/kg, 3/5 receiving 500 mg/kg and 5/5 receiving 1000 mg/kg died.

Fourteen-day repeated dose studies were conducted to determine the doses to be used in the 90-day subchronic studies. Groups of five males and five females/species were administered 1,1-DCE in corn oil by gavage, daily for 14 days. On Day 16, all survivors were sacrificed and necropsied. Doses administered, survival and mean body weights of the dosed and control groups are shown in Tables V-5 and V-6.

Four of five male rats receiving 1000 mg/kg, 3/5 female rats receiving 500 mg/kg and 3/5 females receiving 1000 mg/kg died within 48 hours. All were hyporeactive. Weight gain of male rats receiving 500 mg/kg was depressed 28%; the only surviving male

rats receiving 1000 mg/kg lost weight. A dose-related decrease in mean body weight gain was observed in female rats. Weight gain was depressed 62% and 129% in females receiving 500 or 1000 mg/kg, respectively.

All mice receiving 500 mg/kg died. Before death, they exhibited hyporeactivity, a staggering gait and rapid breathing. Hemorrhagic necrosis of the liver was seen at necropsy. No compound-related histopathology was observed in the mice.

90-Day subchronic studies were performed to determine the doses to be used in the chronic studies. Groups of 10 rats and 10 mice of each sex were administered 1,1-DCE in corn oil by gavage 5 times/week at 0, 5, 15, 40, 100 or 250 mg/kg for 13 weeks. Vehicle control groups consisting of 10 males and 10 females of each species received corn oil alone. After 90 days, survivors were sacrificed and necropsied.

Representative tissues from rats and mice receiving 250 mg/kg, from mice receiving 100 mg/kg and from control animals were examined microscopically. Livers from all other dose groups also were examined. The doses administered, survival and the mean body weights at Week 13 are shown in Tables V-7 and V-8.

Three female rats receiving 250 mg/kg died during the first week. No other rats died. Weight gain was depressed 20% for male rats receiving 250 mg/kg compared with controls.

TABLE V-5

DOSAGE, SURVIVAL AND MEAN BODY WEIGHTS OF RATS
ADMINISTERED 1,1-DCE BY GAVAGE FOR 14 DAYS

(NTP, 1982)

Dose (mg/kg)	Survival(a)	Mean Body Weights (grams)			Weight Change Relative to Controls (%) (c)
		Initial	Final	Change (b)	
<u>Male</u>					
0	5/5	116.8 ± 6.57	163.4 ± 6.79	46.6 ± 7.77	---
10	5/5	110.6 ± 4.83	165.4 ± 9.24	54.8 ± 4.72	+ 17.6
50	5/5	112.0 ± 1.79	158.2 ± 4.39	46.2 ± 3.25	- 0.9
100	5/5	109.0 ± 4.68	151.8 ± 9.58	42.6 ± 9.11	- 8.6
500	5/5	114.0 ± 5.08	147.4 ± 2.25	33.4 ± 5.36	- 28.3
1000	5/5	118.0 ± 0.00	114.0 ± 0.00	-4.0 ± 0.00	-108.6
<u>Female</u>					
0	5/5	94.6 ± 4.46	120.6 ± 8.62	26.0 ± 5.06	----
10	5/5	97.2 ± 3.47	126.2 ± 1.56	29.0 ± 2.39	+ 11.5
50	5/5	97.0 ± 3.16	121.6 ± 1.56	24.6 ± 4.02	- 5.4
100	5/5	97.4 ± 2.48	120.4 ± 3.14	23.0 ± 1.79	- 11.5
500	5/5	102.0 ± 6.00	112.0 ± 11.00	10.0 ± 5.00	- 61.5
1000	5/5	100.5 ± 0.50	93.0 ± 7.00	-7.5 ± 6.50	- 128.8

(a) Number surviving/number at start. All calculations are based on numbers surviving to end of study

(b) Mean weight change of the survivors of the group $\pm$ standard error of the mean.

(c) Weight change of dosed survivors relative to survivors of the controls=

$$\frac{\text{Weight change (Dosed group)} - \text{Weight change (Control group)} \times 100}{\text{Weight change (Control group)}}$$

TABLE V-6

DOSAGE, SURVIVAL AND MEAN BODY WEIGHTS OF MICE
ADMINISTERED 1,1-DCE BY GAVAGE FOR 14 DAYS

(NTP, 1982)

Dose (mg/kg)	Survival(a)	Mean Body Weights (grams)			Weight Change Relative to Controls (%) (c)
		Initial	Final	Change (b)	
<u>Male</u>					
0	5/5	22.2 $\pm$ 0.37	24.8 $\pm$ 0.37	2.6 $\pm$ 0.40	—
5	5/5	22.0 $\pm$ 0.32	23.4 $\pm$ 0.40	1.4 $\pm$ 0.40	- 46.2
10	5/5	23.0 $\pm$ 0.84	25.8 $\pm$ 0.86	2.8 $\pm$ 0.66	+ 7.7
50	5/5	22.2 $\pm$ 0.80	24.8 $\pm$ 0.97	2.6 $\pm$ 0.51	0.0
100	5/5	22.8 $\pm$ 0.37	24.0 $\pm$ 0.32	1.2 $\pm$ 0.20	- 53.8
500	0/5	(d)	(d)	(<u>d</u>)	
<u>Female</u>					
0	5/5	20.2 $\pm$ 0.20	21.6 $\pm$ 0.40	1.4 $\pm$ 0.40	----
5	5/5	20.6 $\pm$ 0.40	21.2 $\pm$ 0.20	0.6 $\pm$ 0.40	- 57.1
10	5/5	20.4 $\pm$ 0.40	21.0 $\pm$ 0.63	0.6 $\pm$ 0.60	- 57.1
50	5/5	20.4 $\pm$ 0.24	21.0 $\pm$ 0.32	0.6 $\pm$ 0.24	- 57.1
100	5/5	21.0 $\pm$ 0.32	22.2 $\pm$ 0.49	1.2 $\pm$ 0.73	- 14.3
500	0/5	(<u>d</u>)	(<u>d</u>)	(<u>d</u>)	

(a) Number surviving/number at start. All calculations are based on numbers surviving to of study

(b) Mean weight change of the survivors of the group $\pm$ standard error of the mean.

(c) Weight change of dosed survivors relative to survivors of the controls=

$$\frac{\text{Weight change (Dosed group)} - \text{Weight change (Control group)} \times 100}{\text{Weight change (Control group)}}$$

(d) No data are presented due to 100% mortality in this group

TABLE V-7

DOSAGE, SURVIVAL AND MEAN BODY WEIGHTS OF RATS
ADMINISTERED 1,1-DCE BY GAVAGE FOR 13 WEEKS

(NTP, 1982)

Dose (mg/kg)	Survival(a)	Mean Body Weights (grams)			Weight Change Relative to Controls (%) (b)
		Initial	Final	Change	
<u>Male</u>					
0	10/10	118	316	+198	----
5	10/10	115	307	+192	- 3
15	10/10	115	306	+191	- 4
40	10/10	119	302	+183	- 8
100	10/10	117	299	+182	- 8
250	10/10	117	276	+159	-20
<u>Female</u>					
0	10/10	95	200	+105	----
5	10/10	93	193	+100	- 5
15	10/10	93	198	+105	0
40	10/10	97	194	+ 97	- 8
100	10/10	95	194	+ 99	- 6
250	7/10	97	190	+ 93	-11

(a) Number surviving/number at start. All calculations are based on numbers surviving to end of study

(b) Weight change of dosed survivors relative to survivors of the controls=

$$\frac{\text{Weight change (Dosed group)} - \text{Weight change (Control group)} \times 100}{\text{Weight change (Control group)}}$$

TABLE V-8

DOSAGE, SURVIVAL AND MEAN BODY WEIGHTS OF MICE
ADMINISTERED 1,1-DCE BY GAVAGE FOR 13 WEEKS

(NTP, 1982)

Dose (mg/kg)	Survival(a)	Mean Body Weights (grams)			Weight Change Relative to Controls (%) (b)
		Initial	Final	Change	
<u>Male</u>					
0	10/10	21	35	+14	----
5	10/10	21	35	+14	0
15	10/10	21	34	+13	- 7
40	9/10	21	33	+12	-14
100	8/10	21	30	+ 9	-36
250	0/10	21	—	—	—
<u>Female</u>					
0	10/10	18	24	+ 6	----
5	9/10	19	23	+ 4	-33
15	9/10	18	23	+ 5	-17
40	10/10	18	23	+ 5	-17
100	7/10	18	23	+ 5	-17
250	1/10	20	26	+ 6	0

(a) Number surviving/number at start. All calculations are based on numbers surviving to end of study

(b) Weight change of dosed survivors relative to survivors of the controls=

$$\frac{\text{Weight change (Dosed group)} - \text{Weight change (Control group)}}{\text{Weight change (Control group)}} \times 100$$

Severe centrilobular necrosis of the liver was observed in the 3 female rats that died.(Table V-9). Minimal to moderate hepatocytomegaly was seen in the rest of the rats that received 250 mg/kg. Lesser degrees (minimal to mild) of hepatocytomegaly were seen in 6/10 male rats and 3/10 female rats that received 100 mg/kg. Various combinations of portal and subcapsular fibrosis, bile duct hyperplasia, pigmented macrophages and hepatocellular atrophy were seen in all male rats (mild to severe in 9/10 and minimal in the other) and in 7/10 female rats (mild to moderate in 6/10 and minimal in 1/10) receiving 250 mg/kg. The rats receiving 100 mg/kg were affected to a much lesser degree, both in numbers and in severity. Foci of cytoplasmic changes, primarily clear cell foci, were seen in 3/10 males and 3/10 females receiving 250 mg/kg. Fatty metamorphosis or cytoplasmic vacuolization or both, usually in minimal or mild degrees of severity, occurred in the animals of most groups but had no distinct dose relationship.

Original examination of the lesions in the rat livers placed more emphasis on the changes seen in the animals at the lower doses whereas a review interpreted these changes to be less important. Thus, the doses of 1 and 5 mg/kg, which were selected for the chronic study and were originally based upon hepatotoxic effects, were probably too low.

Table V-9

Incidence of Liver Lesions in Rats and Mice Administered 1,1-DCE by Gavage for 13 Weeks

(NTP, 1982)

[illegible]

All male mice receiving 250 mg/kg died within 24 hours; 9/10 females receiving 250 mg/kg died within 48 hours. Deaths occurred in 1/10 females receiving 5 mg/kg; 1/10 females receiving 15 mg/kg; 1/10 males receiving 40 mg/kg; and 2/10 males and 3/10 females receiving 100 mg/kg. A dose-related decrease in body weight gain was observed for male mice.

Centrilobular necrosis, hemorrhage and congestion of the liver were observed in males and females that died in the 250 mg/kg group (Table V-9). Cellular atypia of the liver (less severe than that seen in the rats) was observed in 7/10 males and 6/10 females receiving 100 mg/kg but not in animals receiving 250 mg/kg. At 40, 15 and 5 mg/kg, severity of hepatic lesions was dose-related. The incidence of hepatic lesions in males was dose-related and higher than in the females. The most frequently encountered change in mice exposed at 40 mg/kg or less was slight, sometimes moderate, fatty metamorphosis. Patchy foci of one or a few smaller cells with sparse cytoplasm were encountered much less frequently in mice than in rats.

Hepatic effects were considered to be minimal at 5 mg/kg and doses selected for the mice for the chronic study were 2 and 10 mg/kg.

In the chronic study, rats and mice were grouped 50 sex/group with controls receiving corn oil alone. Rats were dosed at 1 or 5 mg/kg, mice at 2 or 10 mg/kg. Doses were administered 5 times per week by gavage for 104 weeks.

The animals were examined twice daily for morbidity and mortality and weighed every two weeks. At necropsy, gross and microscopic examinations were performed on major tissues, major

organs and all gross lesions from sacrificed animals and those found dead.

Mean body weights of dosed and control rats of either sex were comparable throughout the study. No compound-related clinical signs were observed.

While no significant differences in probability of survival were observed in any group, 12 control and 10 low-dose males died as a result of a 5-hour temperature excursion during Week 82 of the study and 1 low-dose male was accidentally killed during Week 42. These animals were censored in the survival analysis but were examined histologically.

In male rats, 20/50 (40%) of the vehicle controls, 24/50 (48%) of the low dose and 37/50 (74%) of the high dose group survived to the end of the study. In the females, 27/50 (54%) of the vehicle controls, 28/50 (56%) of the low dose and 29/50 (58%) of the high dose group lived to the end of the study.

The number of accidental deaths may have influenced the incidence of late appearing tumors in the control and low dose males. The tumors found were common to aging rats, occurring at comparable rates in control and treated animals. None were considered to be treatment-related.

Several non-neoplastic lesions of possible significance were observed. The incidence of chronic inflammation of the kidney in both male and female rats was higher in the high dose groups than in the controls (males: controls=26/50, 52%; low dose=24/48, 50%; high dose= 43/48, 90%; females: controls= 3/49, 6%; low dose= 6/49, 12%; high dose= 9/44, 20%). Although

the occurrence of chronic nephritis appears to be dose-related, this lesion is common in aging rats.

All of the increased tumor incidences that were statistically significant by the Fisher exact test or by the Cochran-Armitage linear trend test were not significant when life table analyses were used. This difference occurs when life table analyses adjust for intercurrent mortality and thus they minimize the impact of animals dying before the onset of late-appearing tumors. This adjustment was particularly critical for the analyses of tumor incidence in male rats because of the accidental deaths among the male rats.

Among the mice, the mean body weights of dosed male mice were lower than those in the control group. Mean body weights of high dose and control females were comparable. Mean body weights of low dose mice of either sex were lower than those of high dose or vehicle control mice. No compound-related clinical signs were observed.

No significant differences in survival were observed between any groups of male mice. A significant reduction in the survival of female mice was observed in the low dose group when compared with the high dose group.

In male mice, 33/50 (66%) of the vehicle controls, 35/50 (70%) of the low dose and 36/50 (72%) of the high dose group survived to the end of the study. In female mice, 40/50 (80%) of the vehicle controls, 32/50 (64%) of the low dose and 42/50 (84%) of the high dose group lived to the end of the study.

Non-neoplastic lesions included necrosis of the liver (focal, multifocal and diffuse) was observed more frequently

in dosed mice than in controls (males: controls= 1/46, 2%; low dose= 3/46, 7% and high dose= 7/49, 14%; females: controls= 0/47, 0%; low dose= 4/49, 8% and high dose= 1/49, 2%). The incidence of lung inflammation was slightly below that normally seen in 2-year old B6C3F1 mice.

Neoplastic lesions observed in dosed mice were considered to be unrelated to the administration of 1,1-DCE. The only observed significant ($P < 0.05$) increase in tumor incidence occurred in low dose female mice: lymphoma (2/48, 9/49, 6/50) and lymphoma or leukemia (7/48, 15/49, 7/50). These increases were not considered to be related to the administration of 1,1-DCE because similar effects were not found in the high dose female mice or for male mice or rats of either sex.

It was concluded by NTP that, under the conditions of this bioassay, 1,1-DCE administered by gavage was not carcinogenic for F344/N rats or B6C3F1 mice of either sex. NTP went on to say, however, that since the use of a maximum tolerated dose in this study has not been clearly demonstrated and since previously reported studies have shown that carcinogenicity is associated with inhalation exposure to 1,1-DCE, this study should not be taken as proof that the chemical is not a carcinogen.

Studies of the potential carcinogenicity of 1,1-DCE have been conducted with mice, rats and hamsters using either oral administration or inhalation exposure. Preliminary results after a total of 98 weeks' observation have been reported (Maltoni, 1977; Maltoni et al., 1977). In the inhalation study, Swiss mice were exposed to 10 or 25 ppm of 1,1-DCE for 4 hours/day, 4 or 5 days/week for 52

weeks and then observed for the remainder of the study. Data from this study are in Tables V-10 and V-11. Exposure to 10 ppm of 1,1-DCE caused no statistically significant increase in the incidence of any tumor in Swiss mice. At 25 ppm, 17 of the mice exposed to 1,1-DCE had developed kidney adenocarcinomas compared to none in the control group (Table V-10). The majority of the tumors were observed in male mice. In contrast, no kidney adenocarcinomas were observed in Sprague-Dawley rats under the same exposure regimen at exposures up to 200 ppm. Data from this study also showed a significant increase in mammary adenocarcinoma in Swiss mice inhaling 25 ppm (Table V-11) and in Sprague-Dawley rats inhaling 100 or 150 ppm of 1,1-DCE (Table V-12) (Maltoni et al., 1977). At 10, 25 or 50 ppm of 1,1-DCE, there was no increase in tumor incidence in Sprague-Dawley rats. Oral administration of 20 mg/kg of 1,1-DCE 4 to 5 days/week for 52 weeks to female Sprague-Dawley rats resulted in a 42% incidence of mammary tumors, whereas control animals had a 34% incidence. This is not a statistically significant difference. Hamsters exposed by inhalation to 25 ppm of 1,1-DCE did not exhibit an increased tumor incidence (Maltoni, 1977; Maltoni et al., 1977). Additionally, it has been reported indirectly that other studies by Maltoni found no statistically significant increased incidence of any tumor in BALB/C, C56BL, or C₃H mice (Fishbein, 1979).

In another inhalation study (Lee et al., 1978), CD-1 mice and CD rats were exposed to 55 ppm of 1,1-DCE for 6 hr/day, 5 days/week for 7 to 12 months. Hepatic hemangiosarcomas were observed in the mice exposed to 1,1-DCE: 2/35 for males and 1/35 for females in the treated group compared to 0/26 for males and 0/36 for females

Table V-10

Kidney Adenocarcinomas in Swiss Mice Exposed to 1,1-DCE
via Inhalation ^a

<u>1,1-DCE, ppm</u>	<u>Sex</u>	<u>Total Animals at Risk^b</u>	<u>No. Animals With Adenocarcinoma</u>	<u>%</u>
0	Male ^c	54	0	0
0	Female ^c	49	0	0
0	Male ^d	46	0	0
0	Female ^d	52	0	0
10	Male ^d	22	0	0
10	Female ^d	20	0	0
25	Male ^c	78	16	20.5
25	Female ^c	65	1	1.5

^a 4 hr/day, 4-5 days/week for 12 months

^b Defined here as the number of animals that had died since the appearance of the first tumor; or (survivors at the time of the first tumor) - (survivors at the time these preliminary data were reported).

^c Animals were 9 weeks of age at start of exposure.

^d Animals were 16 weeks of age at start of exposure.

Based on Maltoni et al., 1977

Table V-11

Incidence of Mammary Adenocarcinomas in Female
Swiss Mice Receiving 1,1-DCE via Inhalation^a

	1,1-DCE Concentration, ppm			
	<u>0</u>	<u>10</u>	<u>0</u>	<u>25</u>
Age at start of test (weeks)	16	16	9	9
Number with tumors/ number at risk ^b	2/52	1/20	0/49	7/65
Incidence (%)	3.8	5.0	0	10.8
p-values ^c	—	0.63	—	0.017

a 4 hr/day, 4-5 days/week for 12 months

b Number at risk defined here as the number of animals that had died since the appearance of the first tumor (a kidney adenocarcinoma); or (survivors at time of the first tumor) - (survivors at the time these preliminary data were reported).

c Calculated using Fisher exact test and matched control incidence.

Based on Maltoni et al., 1977.

Table V-12

Incidence of Mammary Tumors in Sprague-Dawley
Rats Inhaling 1,1-DCE

	1,1-DCE Concentration, ppm					
	0	10	25	50	100	150
<u>Number with tumors</u> <u>Number initially</u>	32/100	15/30	12/30	15/30	18/30	35/60
Incidence (%)	32	50	40	50	60	58
p-values ^b	—	0.058	0.27	0.058	0.0058	0.001

^a 4 hr/day, 4-5 days/week for 12 months

^b Calculated using the Fisher exact test.

Based on Maltoni et al., 1977.

in the control group. The significance of these hepatomas was judged to be questionable because such tumors have been reported to occur spontaneously. However, two rats developed hemangiosarcomas in the mesenteric lymph node or subcutaneous tissue which were judged probably to be caused by 1,1-DCE. Although kidney pathology was observed, there was no report of adenocarcinoma.

An inhalation study using both Wistar rats and Sprague-Dawley rats has been reported (Viola and Caputo, 1977). Exposures were to 1,1-DCE concentrations from 75 to 200 ppm for 4 hr/day, 5 days/week for 12 months. Data from this study, summarized in Table V-13, were interpreted as showing no grossly observable correlation between tumor production and 1,1-DCE inhalation.

Additionally, male and female Sprague-Dawley rats were exposed to 1,1-DCE by inhalation (25 or 75 ppm for 6 hr/day, 5 days/week for 18 months). In the interim report of this study (Rampy et al., 1977), there was no evidence of increased tumor incidence in animals treated with 1,1-DCE. The data are summarized in Table V-14. The only adverse effects found were minimal microscopic changes in the liver with a higher incidence at 75 ppm than at 25 ppm. In all other respects there were no observed differences between control and treated groups.

•

Table V-13

Incidence of Tumors in Rats Inhaling 1,1-DCE^a

<u>1,1-DCE, ppm</u>	<u>Sex</u>	<u>Number of Rats</u>	<u>Number of Tumor- Bearing Animals</u>	<u>% of Total</u>	<u>Types of Tumors</u>
<u>Wistar Rats</u>					
0	M	30	5	17	Abdominal cavity (5)
0	F	30	10	33	Abdominal cavity (9) Lung (1)
b	M	51	8	16	Abdominal cavity (7) Liver (1)
b	F	23	9	39	Abdominal cavity (8) Lung (1)
<u>Sprague-Dawley Rats</u>					
0	M	30	0	0	
0	F	30	15	50	Subcutaneous fibromas (15)
75	M	16	1	6	Subcutaneous fibromas (1)
75	F	21	9	43	Subcutaneous fibromas (9)
100	M	30	3	10	Abdominal lymphomas (3)
100	F	30	17	57	Subcutaneous fibromas (16) Abdominal lymphoma (1)

^a 4 hr/day, 5 days/week for 12 months.

^b Exposure to 200 ppm for first 5 months, then reduced to 100 ppm.

Based on Viola and Caputo, 1977.

Table V-14
Grossly Observed Tumors in Sprague-Dawley Rats
Inhaling 1,1-DCE^a

Sex	Tumors	Exposure Level (ppm)	No. animals with tumor ^b	No. animals in group	Tumors, %
M	Subcutaneous tumor (mammary or midcervical region)	Control	8/6	86	7.0
		75	9/8	85	9.4
		25	8/7	86	8.1
M	Subcutaneous tumor (eye, ear or head region)	Control	2	86	2.3
		75	2	85	2.4
		25	5	86	5.8
M	Subcutaneous tumor (body or limb region)	Control	1	86	1.2
		75	4	85	4.7
		25	3	86	3.5
M	Liver nodule (tumor or mass)	Control	1	86	1.2
		75	2	85	2.4
		25	0	86	0
M	Kidney (primary site)	Control	3	86	3.5
		75	0	85	0
		25	0	86	0
F	Subcutaneous tumor (mammary or midcervical region)	Control	138/68	86	79.1
		75	159/74	84	88.1
		25	149/73	88	82.9
F	Subcutaneous tumor (eye, ear or head region)	Control	1	86	1.2
		75	1	84	1.2
		25	0	88	0
F	Subcutaneous tumor (body, limb region)	Control	2	86	2.3
		75	1	84	1.2
		25	2	88	2.3
F	Liver nodule (tumor or mass)	Control	2	86	2.3
		75	1	84	1.2
		25	0	88	0
F	Kidney (primary site)	Control	1	86	1.2
		75	1	84	1.2
		25	1	88	1.1

^a 6 hr/day, 5 days/week for 18 months.

^b Where two numbers appear, data represent number of tumors over number of animals with tumors. Percentage is based on number of animals with tumors.

Based on Rampy *et al.*, 1977.

The effect of weekly oral administration of 50 mg/kg of 1,1-DCE following in utero exposure (150 mg/kg on day 17 of gestation) was studied in BDIV rats (Ponomarkov and Tomatis, 1980). The oral administration was continued throughout the lifetime of the animals until the study was terminated after 120 weeks. The data are summarized in Table V-15. There was no statistically significant increase in the total number of tumor bearing animals. However, an increased incidence of tumors at certain sites was observed: liver tumors in females and meningiomas in males. Additionally, hyperplastic nodules of the liver were observed in both male and female rats; these were not seen in control animals. The authors concluded that the results provided limited evidence of carcinogenicity of 1,1-DCE.

Male and female Sprague-Dawley rats were exposed to 1,1-DCE in drinking water at 60, 100 or 200 ppm for two years, corresponding to average daily doses of 7, 10 or 20 mg/kg/day for males and 9, 14 or 30 mg/kg/day for females (Rampy, et al., 1977; Quast, et al., 1983). Details of the protocol are described in Section A of this chapter. Data from the interim report of this study (Rampy et al., 1977), summarized in Table V-16, showed no evidence of increased tumor incidence in animals treated with 1,1-DCE. No adverse effect was observed in any of the treated groups compared to controls with two exceptions. The 60 ppm female group had a statistically higher incidence of pituitary gland adenomas than control animals. However, this was considered not to be an effect of the treatment, since it was not dose-related and Sprague-Dawley rats have a high and variable spontaneous

Table V-15

Tumor Incidence in BDIV Rats Treated Weekly with 1,1-DCE

	Dose of 1,1-DCE, mg/kg			
	0		50	
	Male	Female	Male	Female
Effective number of rats ^a	49	47	81	80
Tumor-bearing rats				
Number	16	24	31	53
%	32.7	51.1	38.3	66.3
Number of tumors				
Total	16	29	35	64
Per Rat	0.3	0.6	0.4	0.8
Animals with more than one tumor				
Number	0	5	4	11
%	0	10.6	4.9	13.8
<u>Distribution of tumors</u>				
Meninges				
Number	1	0	6	0
%	2.0	0	7.4	0
Oral cavity				
Number	2	1	5	1
%	4.1	2.1	6.2	1.3
Stomach				
Number	0	1	1	2
%	0	2.1	1.2	2.5
Liver				
Number	0	0	1	3
%	0	0	1.2	3.8
Soft tissue				
Number	4	0	9	7
%	8.2	0	11.1	8.8
Mammary gland				
Number	0	22	1	39
%	0	46.8	1.2	48.8
Ovary				
Number	0	3	0	6
%	0	6.4	0	7.5
Other				
Number	9	2	12	6
%	18.4	4.3	14.8	7.5
Liver hyperplastic nodules				
Number	0	0	2	6
%	0	0	2.5	7.5

The percentage and the number of tumors are expressed in relation to the effective number of rats.

^a Survivors at the time the first tumors were observed.

Based on Ponomarev and Tomatis, 1980.

Table V-16

Grossly Observed Tumors in Sprague-Dawley Rats
Given 1,1-DCE in Drinking Water

Sex	Tumors	Dose (ppm)	No. animals with tumor ^a	No. animals in group	Tumors, %
M	Subcutaneous tumor (mammary or midcervical region)	Control	6/6	80	7.5
		200	6/4	47	8.5
		100	6/6	48	12.5
		60	6/6	48	12.5
M	Subcutaneous tumor (eye, ear or head region)	Control	4	80	5.0
		200	2	47	4.3
		100	0	48	0
		60	1	48	2.1
M	Subcutaneous tumor (body or limb region)	Control	2	80	2.5
		200	0	47	0
		100	0	48	0
		60	2	48	4.2
M	Nodular proliferation in liver (primary site)	Control	5	80	6.3
		200	0	47	0
		100	1	48	2.1
		60	1	48	2.1
M	Liver (metastatic foci)	Control	0	80	0
		200	0	47	0
		100	0	48	0
		60	1	48	2.1
M	Liver (diffuse tumor infiltrate and enlarged, associated with lymphoid)	Control	0	80	0
		200	0	47	0
		100	1	48	2.1
		60	2	48	4.2
M	Kidney (primary site)	Control	2	80	2.5
		200	0	47	0
		100	0	48	0
		60	1	48	2.1
F	Subcutaneous tumor (mammary and midcervical region)	Control	104/59	80	73.7
		200	64/36	48	75.0
		100	68/27	48	77.1
		60	71/40	48	83.3
F	Subcutaneous tumor (eye, ear and head region)	Control	1	80	1.3
		200	1	48	2.1
		100	2	48	4.2
		60	1	48	2.1

continued-

Table V-16 - continued

Sex	Tumors	Dose (ppm)	No. animals with tumor ^a	No. animals in group	Tumors, %
F	Subcutaneous tumor (body or limb region)	Control	0	80	0
		200	0	48	0
		100	1	48	2.1
		60	0	48	0
F	Nodular proliferation in liver (primary site)	Control	2	80	2.5
		200	3	48	6.3
		100	0	48	0
		60	2	48	4.2
F	Liver (metastatic foci)	Control	1	80	1.3
		200	0	48	0
		100	0	48	0
		60	0	48	0
F	Liver (diffuse tumor infiltrate and enlarged, associated with lymphoid)	Control	2	80	2.5
		200	0	48	0
		100	0	48	0
		60	0	48	0
F	Kidney (primary site)	Control	1	80	1.3
		200	0	48	0
		100	1	48	2.1
		60	0	48	0

^a Where two numbers appear, data represent number of tumors over number of animals with tumors. Percentage is based on number of animals with tumors.

Based on Rampy *et al.*, 1977.

incidence of this tumor. The other effect was a dose-related, statistically significant incidence of liver lesions, described as fatty degeneration which was more marked in females than in males. Accompanying this was atrophy of the centrilobular cells and hypertrophy of the periportal liver cells. Treatment-related necrosis of cells was not observed.

The carcinogenic effects of 1,1-DCE also were investigated in Ha:ICR Swiss mice by several routes of administration (Van Duuren et al., 1979). 1,1-DCE was inactive as a whole mouse skin carcinogen and inactive by subcutaneous injection. In the two stage carcinogenesis assay using phorbol myristate acetate as a promoter, 1,1-DCE administered as a single dose of 121 mg was shown to be active as a skin tumor initiator.

Table V-17 contains a summary of the results of the several carcinogenicity studies described in detail above.

There are no reported data to show if cis-1,2-DCE or trans-1,2-DCE is or is not a chemical carcinogen.

Table V-17

Summary of Results from Carcinogenicity Studies with 1,1-DCE

Route	Species	Dose	Study Duration	Carcinogenic Response	Reference
Inhalation	Swiss Mice	10 ppm 25 ppm for 12 months	98 weeks 98 weeks	negative positive	Maltoni, 1977; Maltoni et al., 1977
Inhalation	CD-1 Mice	55 ppm	52 weeks	negative	Lee et al., 1978
Not Reported	BALB/C Mice C56 BL Mice C3H Mice	Not Reported Not Reported Not Reported	Not Reported Not Reported Not Reported	negative negative negative	Fishbein, 1979 Report of Maltoni studies
Inhalation	Sprague-Dawley Rats	10 ppm 25 ppm 50 ppm 100 ppm 150 ppm for 12 months	98 weeks 98 weeks 98 weeks 98 weeks 98 weeks	negative negative negative positive positive	Maltoni, 1977; Maltoni et al., 1977
Inhalation	Sprague-Dawley Rats	75 ppm 200 ppm for 12 months	lifetime	negative negative	Viola and Caputo, 1977
Inhalation	Rats (Wistar)	75 ppm 200 ppm for 12 months	lifetime	negative	Viola and Caputo, 1977
Inhalation	Rats (CD)	55 ppm	52 weeks	negative	Lee et al., 1978

continued-

Table V-17 - Continued

Route	Species	Dose	Study Duration	Carcinogenic Response	Reference
Inhalation	Rats	25 ppm 75 ppm for 18 months	104 weeks	negative	Rampy et al., 1977
Inhalation	Chinese Hamsters	25 ppm	74 weeks	negative	Maltoni, 1977; Maltoni et al., 1977
Oral (gavage)	Rats (BDIV)	50 mg/kg/day	120 weeks	negative	Ponomarev and Tomatis, 1980
Oral (gavage)	Rats (Sprague-Dawley)	0.32 mg/kg·day 3.2 mg/kg·day 6.4 mg/kg·day 13 mg/kg·day	136 weeks	negative negative negative negative	Maltoni
Oral (drinking Water)	Rats (Sprague-Dawley)	7-9 mg/kg·day 10-14 mg/kg·day 20-30 mg/kg·day	104 weeks	negative negative negative	Rampy et al., 1977 Quast, et al., 1983
Oral (Gavage)	Rats (F344)	1 mg/kg/day 5 mg/kg/day	104 weeks	negative	NTP, 1982
	Mice (B6C3F1)	1 mg/kg/day 5 mg/kg/day	104 weeks	negative	NTP, 1982
Subcutaneous	Swiss mice	121 mg	single dose	inactive as whole mouse initiator active as initiator with phorbol myristate acetate	Van Duuren, et al., 1979

VI. HEALTH EFFECTS IN HUMANS

A. Acute and Chronic Effects

CNS. At high concentrations, the DCEs possess anesthetic properties, as do other members of the chlorinated ethylene series. Although considerable research has been done on those compounds which were used as general anesthetics, little is known concerning the short-term or long-term effects of DCEs on the CNS. The CNS depressant effect has been described from unpublished data (Irish, 1963). A concentration of 4000 ppm was estimated as sufficient to produce rapidly a state resembling drunkenness and was judged likely to result in unconsciousness if exposure were continued. A single report has been made associating sensory disturbance in the facial areas controlled by the trigeminal nerve with an accidental exposure to 1,1-DCE (Broser et al., 1970). Subsequent evaluation, however, suggested that the toxic agent was either mono- or dichloroacetylene which was a contaminant of 1,1-DCE (Henschler et al., 1970). No further information is available on the CNS effects of these compounds.

Teratogenicity/Mutagenicity. No studies addressing mutagenic or reproductive hazards among 1,1-DCE exposed populations have been reported (Bahlman et al., 1979).

Carcinogenicity. There are no published studies with adequate data to permit an evaluation of the carcinogenic risk of 1,1-dichloroethylene to humans (Bahlman et al., 1979). One study reported no excessive cancer risk among 138 workers occupationally exposed to 1,1-DCE, but methodological limitations of this study

(Ott et al., 1976) do not permit an adequate evaluation of the carcinogenic risk, since the number of individuals lost to follow-up in this study was high and the period of observation was relatively short. In a second study, mortality was examined among 629 workers occupationally exposed in a 1,1-dichloroethylene (1,1-DCE) production and polymerization plant where there was also exposure to vinyl chloride and acrylonitrile. It was reported that 7 of the 35 deaths that occurred were from malignant tumors. This was not greater than the expected number. Two bronchial carcinomas occurred in persons aged 35-39, whereas 0.08 were expected. However, no information was given on smoking habits (Theiss et al., 1977).

Immunological Response. A study was made of the effect of 1,1-DCE on the ability of murine and human lymphocytes to respond to mitogenic agents, allogenic lymphocytes or the antigenic nature of 1,1-DCE itself (Thurman et al., 1978). 1,1-DCE was found to cause no change in the response of lymphocytes to various stimuli and to have very low toxicity to lymphocytes.

Other Adverse Effects. Reports of effects on workers exposed to 1,1-dichloroethylene in combination with other vinyl compounds include liver function abnormalities, headache, vision problems, dizziness, weakness, fatigue and neurological sensory disturbances (NIOSH, 1979).

B. Epidemiology

There have been no adequate epidemiological studies of the dichloroethylenes that have not also involved exposure to other compounds e.g., vinyl chloride or acrylonitrile. The limited number of epidemiological investigations involving multiple compound exposures have been described above. These studies provide little evidence from which to define a human dose-response for the dichloroethylenes.

. VII-1

VII. MECHANISMS OF TOXICITY

The DCEs are readily absorbed and undergo rapid systemic distribution due to their lipid solubility and blood:gas partition coefficient. Therefore, there is fairly rapid equilibration throughout the body following exposure by any route of administration.

The DCEs, like other chlorinated hydrocarbons, have a depressant effect on the CNS which can lead to narcosis and, at high doses can ultimately cause death, probably due to respiratory depression. The exact neuronal mechanism of the CNS depression has not been determined.

Very little is known about the mechanism of toxicity of cis-and trans-1,2-DCE. However, there has been considerable work directed toward defining the mechanism of toxicity of 1,1-DCE. Aside from the CNS depressant effect mentioned above, which is probably due to 1,1-DCE itself, most of the acute and long-term toxic effects observed, e.g., hepatotoxicity, renal toxicity, mutagenicity and carcinogenicity, are due probably to the formation of toxic metabolites. It has been suggested that the acute toxicity of 1,1-DCE can be correlated to the amount of metabolite formed. For short-term inhalation exposures, mortality occurred in rats after the formation of 25-30 mg of metabolites/kg (Andersen et al., 1979b). Additionally, it has been shown that mice metabolize 1,1-DCE more rapidly than rats. There is a corresponding higher mortality resulting from a given dose with mice than with rats, presumably due to the formation of a greater amount of toxic metabolite (Short et al., 1977a; Maltoni, 1977; Jones and Hathway, 1978b).

The biotransformation of 1,1-DCE has been demonstrated to be a saturable process that follows Michaelis-Menten kinetics. At low doses, below the metabolic saturation point, the majority of an administered dose is biotransformed to water soluble products which are excreted via the kidney. However, when large doses of 1,1-DCE are administered by any route and metabolism is saturated, large amounts of unmetabolized 1,1-DCE are excreted via the lungs. Thus, although the single dose oral LD₅₀ value for 1,1-DCE in rats is 1500-1800 mg/kg, a large percentage of the administered dose is exhaled without biotransformation. There is also a difference in the toxic effects caused by continual exposure to 1,1-DCE compared to those caused by repeated intermittent exposures. Whereas adverse reactions including increased lethality were observed in several species following continual exposures to 1,1-DCE concentrations as low as 5 ppm, no toxic effects were observed following exposure for 8 hr/day, 5 days/week for six weeks to 100 ppm (Prendergast et al., 1967). With the intermittent exposure regimen, there was probably rapid elimination of unmetabolized 1,1-DCE between exposures, as well as opportunity for glutathione levels in organs to return to normal. Similarly, at high exposure concentrations, the acute inhalation toxicity was related to the duration of the exposure, i.e., the total amount of toxic metabolite formed when metabolism was proceeding at V_{max} , rather than to the ambient concentration (Andersen et al., 1979a). At low concentrations, it has been suggested that the rate of metabolism of 1,1-DCE is limited by the blood flow to the liver. Since the rate at which an inhaled chemical is presented to the liver is related to pulmonary uptake, it would be expected that

the smaller breathing volume (liters/kg/hr) in man relative to the rat would produce a corresponding slower rate of metabolism of 1,1-DCE in man (Andersen et al., 1980a) and the formation of smaller amounts of toxic metabolite(s).

The metabolism of 1,1-DCE is generally hypothesized to proceed via oxidation of the parent compound by microsomal enzymes of the mixed function oxidase system (MFOS) to produce 1,1-dichloroethylene oxide. This compound subsequently can follow one of several pathways: reaction with glutathione to produce a water soluble metabolite which undergoes renal excretion, presumably a detoxification mechanism reaction with macromolecules to produce covalently bound metabolites or rearrangement to form chloroacetyl chloride. This latter compound can either react with macromolecules or undergo hydrolysis to form chloroacetic acid, which reacts with glutathione to form a series of water soluble metabolites (see Figure IV-3). It is generally believed that reaction of these metabolites, i.e., 1,1-dichloroethylene oxide, chloroacetyl chloride and chloroacetic acid, with macromolecules leads to the observed toxic effects: hepatotoxicity, renal toxicity, mutagenicity and carcinogenicity.

The extent of hepatotoxicity of 1,1-DCE appears to be related to the rate of formation of toxic metabolites relative to the rate of metabolism of these materials. Glutathione conjugation is apparently a crucial mechanism since increased susceptibility to liver damage has been demonstrated when hepatic glutathione concentration is decreased by any of several methods: fasting, pretreatment with certain chemicals, e.g., diethyl maleate, pretreatment with thyroxine or normal diurnal variation. Conversely,

thyroidectomy, which increases hepatic glutathione concentration, decreases hepatotoxicity. It has been shown that there is an increase in 1,1-DCE metabolites covalently bound to liver macromolecules when the glutathione levels are decreased.

It has been demonstrated that a greater percentage of any orally administered dose is metabolized in mice than in rats. This has been attributed to greater activity of the cytochrome P-450 system in mice relative to rats which would lead to the formation of a larger amount of 1,1-dichloroethylene oxide and its rearrangement product, chloroacetyl chloride, in mice (Jones and Hathway, 1978b). This difference in metabolism is reflected in a change in the ratio of the metabolites formed. Additionally, the administration of 1,1-DCE has a much more toxic effect on mice (oral LD₅₀:200 mg/kg) than on rats (oral LD₅₀:1500 mg/kg). One possible explanation for this difference is that 1,1-DCE and its metabolites are equally toxic to mice and rats, but the difference in the LD₅₀ represents the relative ability of the two species to metabolize 1,1-DCE to the active metabolites. It has also been shown that there are much higher levels of covalently bound 1,1-DCE metabolites in both liver and kidney in mice than in rats.

The liver damage characteristically caused by exposure to other chlorinated hydrocarbons is injury to the endoplasmic reticulum. In contrast, 1,1-DCE causes nuclear changes, mitochondrial swelling and rupture of outer mitochondrial membranes. This indicates a basic difference in the mechanism of toxicity of 1,1-DCE. It has been suggested that chloroacetic acid may undergo further transformation to form a material, possibly monochlorocitric acid,

that inhibits mitochondrial performance and is the molecular basis for hepatic injury (Jaeger, 1977).

The renal damage caused by 1,1-DCE is characterized by vacuolization, tubular dilatation and necrosis. There is a considerable amount of covalent binding of 1,1-DCE metabolites in kidneys in both mice and rats. Mice have been shown to be more susceptible to kidney damage from 1,1-DCE than rats.

The mutagenic potential of the DCEs has been studied. Neither 1,1-DCE nor cis- or trans-1,2-DCE was mutagenic in bacterial systems without microsomal activation. However, in the presence of microsomal fractions from liver, kidney and lung from mice and rats, and from human liver, 1,1-DCE was shown to be mutagenic in Salmonella typhimurium and E. coli bacteria (Jones and Hathway, 1978c). Pretreatment of animals with modifiers of microsomal enzymes affected the bacteria mutagenicity of 1,1-DCE in the presence of microsomal preparations from these animals. These data have been interpreted as showing that the mutagenicity of 1,1-DCE is due to the formation of an unsymmetrical, highly reactive metabolite, 1,1-dichloroethylene oxide, which reacts with the DNA in the bacteria (Henschler et al., 1976; Henschler, 1977; Henschler and Bonse, 1977). In contrast, biotransformation of cis- and trans-1,2-DCE produces symmetrical epoxides which are more stable and do not undergo reaction with DNA to produce mutations. The finding of increased mutation rates with 1,1-DCE in bacterial systems has not been confirmed in mammalian systems. Both mice and rats exposed to 1,1-DCE failed to produce dominant lethal mutations.

Several studies have been conducted to investigate the carcinogenic potential of 1,1-DCE. Using several routes of administration to Ha:ICR Swiss mice, it was shown that 1,1-DCE was inactive as a whole mouse skin carcinogen and inactive by subcutaneous injection, but was active as a skin tumor initiator in a two stage carcinogenesis assay using phorbol myristate acetate as a promoter (Van Duuren, et al., 1979). In one carcinogenicity study, mice (Swiss, BALB/C, C56BL, and C₃H strains), rats (Sprague-Dawley) and hamsters were exposed to 1,1-DCE. At exposure to 10 ppm, there was no increased incidence of any tumor in any species. Exposure to 25 ppm of 1,1-DCE caused a statistically significant increase in kidney adenocarcinomas in Swiss mice, almost exclusively in the males (24/150 in males compared to 1/150 in females). Also, a statistically significant increase in mammary adenocarcinomas was found in Swiss mice at 25 ppm and in Sprague-Dawley rats at 100 and 150 ppm. No increase in kidney adenocarcinomas was found in Sprague-Dawley rats at exposures up to 200 ppm. Additionally, it has been reported that other studies by Maltoni found no statistically significant increased incidence of any tumor in BALB/C, C56BL or C₃H mice (Fishbein, 1979), or in hamsters (Maltoni, 1977; Maltoni et al., 1977). A second study using CD-1 mice and CD rats exposed to 55 ppm of 1,1-DCE found no statistically significant increase in incidence of kidney adenocarcinoma in mice or rats, while two rats developed hemangiosarcomas which were judged probably to be caused by 1,1-DCE (Lee et al., 1978). Three additional carcinogenicity studies conducted with rats (Sprague-Dawley, Wistar and BDIV strains) provided no unequivocal evidence for carcinogenicity

of 1,1-DCE in rats (Viola and Caputo, 1977; Rampy et al., 1977; Ponomarev and Tomatis, 1980). Further studies on the carcinogenic potential of 1,1-DCE in mice and rats sponsored by the National Cancer Institute have been completed and they suggest that 1,1-DCE is not carcinogenic by gavage, at least at the doses used.

In summary, the carcinogenic potential of 1,1-DCE has been shown to be quite different from that of vinyl chloride. Vinyl chloride has been shown to produce hepatic angiosarcomas, sebaceous carcinomas, cutaneous skin tumors and forestomach papillomas in rats, mice and hamsters as well as mammary carcinomas in both rats and mice. Additionally, vinyl chloride has been found to cause liver angiosarcoma in humans. For 1,1-DCE, aspects of the reported carcinogenicity appear conflicting and indicate sex, species and strain specificity. In mice, the most pronounced increases in tumor incidence caused by 1,1-DCE were kidney adenocarcinoma and mammary gland adenocarcinoma in Swiss mice. However, kidney adenocarcinomas were observed almost exclusively in male Swiss mice, and neither tumor type was observed in four other strains of mice. In rats, increase in mammary gland adenocarcinomas was found in Sprague-Dawley rats in one study, but was not found in a second study using this strain or in studies using two other strains. Additionally, 1,1-DCE was found to be inactive as a carcinogen in hamsters.

It has been suggested that development of kidney adenocarcinomas in mice is due to the increased rate of biotransformation of 1,1-DCE in mice, which produces a higher level of reactive intermediates that can subsequently react with macromolecules, e.g., DNA (Maltoni, 1977; Hathway, 1977; Henschler and Bonse, 1977). A

study has been made of the potential of 1,1-DCE to cause DNA alkylation, DNA repair and DNA replication in the liver and kidneys of mice and rats, and these results were compared with results obtained using the potent carcinogen dimethylnitrosamine (Reitz et al., 1980). Tumorigenic doses of dimethylnitrosamine produced relatively little tissue damage but caused a high degree of DNA alkylation and DNA repair synthesis. In contrast, tumorigenic doses of 1,1-DCE resulted in massive tissue damage but induced minimal DNA alkylation or DNA repair synthesis. These data were interpreted as suggesting that tumors observed in mice exposed to 1,1-DCE arise primarily through effects of the chemical on non-genetic components of cells.

Multiple Chemical Exposure: Potential for Interaction.

Jackson, et al. (1982) presented, in a poster session, the results of a study which investigated the interaction of 1,1-DCE with 1,2-dichloroethane (1,2-DCE). The compounds were administered via inhalation alone and together in several combinations. Their potential for acute hepatotoxicity and nephrotoxicity was assessed.

Male Sprague-Dawley rats were fasted overnight prior to exposure. Each was subjected in single 4-hour exposures to 200, 250 or 300 ppm 1,1-DCE alone, to 1400, 1600, 1800 or 2100 ppm 1,2-DCE alone or to combinations of 1,1-DCE and 1,2-DCE in the following ratios: 200/1200, 300/1800 or 400/2400 (see Table VII-1 for doses and animals/group). The dose combinations were chosen to reflect roughly equivalent potencies with respect to each compound's nephrotoxic effect.

VII-9
Table VII-1

Measure of Hepatotoxicity to Rats from Exposure to
1,1-DCE and 1,2-DCE

(Jackson, et al., 1982)

Treatment ^a	N ^b	serum SDH ^c	
Control	10	1.8 ±	1.0
1,1-DCE			
200 ppm	4	94.0 ±	9.1
250 ppm	4	832.0 ±	158.1
300 ppm	4	706.7 ±	133.8
1,2-DCE			
1400 ppm	4	1.4 ±	1.4
1600 ppm	6	9.5 ±	1.7
1800 ppm	4	---	
2100 ppm	6	17.0 ±	3.0
2400 ppm	6	33.2 ±	5.3
1,1-DCE/1,2-DCE			
200/1200	4	203.8 ±	110.1
300/1800	5	745.4 ±	116.2
400/2400	5	824.3 ±	151.4

^a Exposure concentration of 1,1-DCE and/or 1,2-DCE for 4 hours via inhalation

^b number of animals, pooled controls

^c serum sorbitol dehydrogenase ± S.E. measured at 30°C in mg/dl

Twenty hours after termination of exposure, the animals were sacrificed and blood collected. Serum sorbitol dehydrogenase (SDH) activity served as the indicator of hepatotoxicity. Nephrotoxicity was measured by kidney to body weight ratios, serum urea nitrogen and creatinine levels.

Changes in liver function as measured by serum SDH levels are shown in Table VII-1. As can be seen, 1,1-DCE, at all doses, caused very large increases in SDH levels, while changes after exposure to 1,2-DCE were less striking. The statistical significance of the effects, alone or in combination, were not reported. However, a cursory view of the data would suggest that effects seen after exposure to combinations of 1,1-DCE and 1,2-DCE were not significantly different from exposures to 1,1-DCE alone.

A less-than-additive or antagonistic effect on the kidney was demonstrated (see Table VII-2). When animals were exposed either to 300 ppm 1,1-DCE or 1800 ppm 1,2-DCE for four hours, significant increases occurred in the three parameters measuring nephrotoxicity. When animals were exposed to the same levels of each substance in combination, each parameter was decreased significantly from the levels noted for each chemical separately ($P < 0.05$). A similar antagonism also was reported after exposure to a mixture of 200 ppm 1,1-DCE and 1200 ppm 1,2-DCE, although this mixture had no nephrotoxic effect (data not shown). With simultaneous exposure to 400 ppm 1,1-DCE and 2400 ppm 1,2-DCE, fewer rats died than would be expected based upon the LD_{50} of 1,1-DCE alone. The mean values for nephrotoxicity of this mixture was equal to 2400 ppm 1,1-DCE alone (data not presented).

TABLE VII-2

Antagonistic Effect of a Combined 1,1-DCE and 1,2-DCE
Exposure on Nephrotoxicity

(Jackson, et al., 1982)

Treatment ^a	N ^b	Kidney/body weight ^c ($\bar{x} \pm \text{S.E.}$)	Serum SDH ^d ($\bar{x} \pm \text{S.E.}$)	Serum creatinine ^e ($\bar{x} \pm \text{S.E.}$)
Control	20	0.89 ± 0.07	8.25 ± 0.47	0.64 ± 0.01
300 ppm 1,1-DCE	4	1.66 ± 0.12	40.93 ± 11.30	1.79 ± 0.34
1800 ppm 1,2-DCE	4	1.57 ± 0.13	65.39 ± 4.87	4.51 ± 0.17
300 ppm 1,1-DCE + 1800 ppm 1,2-DCE	5	1.12 ± 0.10^f	22.64 ± 7.45^f	1.55 ± 0.55^f

^a Four-hour inhalation exposures, controls pooled from several experiments

^b number of animals in group

^c g kidney/ 100 g body weight

^d mg urea nitrogen/ 100 ml serum

^e mg creatinine/ 100 ml serum

^f values significantly less than values for 300 ppm 1,1-DCE or 1800 ppm 1,2-DCE alone ($P < 0.05$)

The authors proposed that a possible mechanism for this antagonism could come from competition for metabolic pathways, since each compound shares common routes of metabolism in the liver, and presumably, also, in the kidney. Thus, at these exposure levels, one or the other chemical could be inhibiting competitively the bioactivation or detoxification of the other. It would be important to establish whether or not this antagonistic interaction would occur at low levels of exposure, particularly in the range of occurrence in drinking water.

VIII. QUANTIFICATION OF TOXICOLOGICAL EFFECTS

The quantification of toxicological effects of a chemical consists of an assessment of the non-carcinogenic and carcinogenic effects. In the quantification of non-carcinogenic effects, an Adjusted Acceptable Daily Intake (AADI) for the chemical is determined. For ingestion data, this approach is illustrated as follows:

$$\text{Adjusted ADI} = \frac{(\text{NOAEL or MEL in mg/kg})(70 \text{ kg})}{(\text{Uncertainty factor})(2 \text{ liters/day})}$$

The 70 kg adult consuming 2 liters of water per day is used as the basis for the calculations. A "no-observed-adverse-effect-level" or a "minimal-effect-level" is determined from animal toxicity data or human effects data. This level is divided by an uncertainty factor because, for these numbers which are derived from animal studies, there is no universally acceptable quantitative method to extrapolate from animals to humans, and the possibility must be considered that humans are more sensitive to the toxic effects of chemicals than are animals. For human toxicity data, an uncertainty factor is used to account for the heterogeneity of the human population in which persons exhibit differing sensitivity to toxins. The guidelines set forth by the National Academy of Sciences (Drinking Water and Health, Vol. 1, 1977) are used in establishing uncertainty factors. These guidelines are as follows: an uncertainty factor of 10 is used if there exist valid experimental results on ingestion by humans, an uncertainty factor of 100 is used if there exist valid results on long-

term feeding studies on experimental animals, and an uncertainty factor of 1000 is used if only limited data are available.

In the quantification of carcinogenic effects, mathematical models are used to calculate the estimated excess cancer risks associated with the consumption of a chemical through the drinking water. EPA's Carcinogen Assessment Group has used the multistage model, which is linear at low doses and does not exhibit a threshold, to extrapolate from high dose animal studies to low doses of the chemical expected in the environment. This model estimates the upper bound (95% confidence limit) of the incremental excess cancer rate that would be projected at a specific exposure level for a 70 kg adult, consuming 2 liters of water per day, over a 70 year lifespan. Excess cancer risk rates also can be estimated using other models such as the one-hit model, the Weibull model, the logit model and the probit model. Current understanding of the biological mechanisms involved in cancer do not allow for choosing among the models. The estimates of incremental risks associated with exposure to low doses of potential carcinogens can differ by several orders of magnitude when these models are applied. The linear, non-threshold multi-stage model often gives one of the highest risk estimates per dose and thus would usually be the one most consistent with a regulatory philosophy which would avoid underestimating potential risk.

The scientific data base, which is used to support the estimating of risk rate levels as well as other scientific

endeavors, has an inherent uncertainty. In addition, in many areas, there exists only limited knowledge concerning the health effects of contaminants at levels found in drinking water. Thus, the dose-response data gathered at high levels of exposure are used for extrapolation to estimate responses at levels of exposure nearer to the range in which a standard might be set. In most cases, data exist only for animals; thus, uncertainty exists when the data are extrapolated to humans. When estimating risk rate levels, several other areas of uncertainty exist such as the effect of age, sex, species and target organ of the test animals used in the experiment, as well as the exposure mode and dosing rates. Additional uncertainty exists when there is exposure to more than one contaminant due to the lack of information about possible additive, synergistic or antagonistic interactions.

Non-Carcinogenic Effects

The principal toxic effects of the dichloroethylenes following acute and longer-term exposures are upon the liver and kidney. In addition, like other members of the chlorinated ethylene series, they also possess general anesthetic and narcotic properties. Available data suggest that the CNS effects occur at exposure levels near or above those at which the liver and kidney effects are seen, even with acute exposures.

Acute toxicity, as measured by the LD₅₀, has been reported in several studies (Jenkins, et al., 1972; Andersen and Jenkins, 1977b; Andersen, et al., 1979a; Freundt, et al., 1977; Jones and Hathway, 1978b; NIOSH, 1978; Ponomarev and Tomatis, 1980).

These data are summarized in Table VIII-1. The wide range in lethality observed for 1,1-dichloroethylene is dependent upon a number of factors: 1) nutritional status: fasted animals are more sensitive than fed animals; 2) age and size: younger, smaller animals are more sensitive than older, larger ones; 3) species: exposure to the same inhalation dose results in more severe effects in mice than in rats; and 4) sex: with repeated dosing, male mice are more sensitive than females.

A number of studies on 1,1-DCE have been reported which are of sufficient length (subchronic or chronic exposure) to be considered potentially useful in the development of an acceptable daily intake (ADI) and an adjusted acceptable daily intake (AADI). These studies describe good dose-response data which allow for the identification of no-observed-adverse-effect-levels (NOAELs) or minimal-effect levels (MELs). In several of these studies, the animals were exposed to the substance orally, either by gavage or in their drinking water. Equivalent studies for cis- and trans- 1,2-dichloroethylene are not available (the 1977 Freundt, et al., subchronic study with trans-1,2-DCE showed frank effects at all tested doses). However, the information that is available suggests that, although animals exposed to each of the three DCEs will have a greater amount of cis- and/or trans- isomer than 1,1-DCE present in their bodies at equilibrium, the non-carcinogenic toxicity induced by the 1,2- isomers appears to be somewhat less severe on an equivalent-dose basis (Jenkins, et al., 1972; Filser and Bolt, 1979). Since the end-points

Table VIII-1

Acute Toxic Effects of DCEs

Compound	Route	Species	Dose	Effect	Reference
1,1-DCE	oral	rat	200 mg/kg	LD ₅₀	NIOSH (1978)
1,1-DCE	oral	rat	>1500 mg/kg	LD ₅₀	Jenkins, <u>et al.</u> (1972)
		rat ^a	84 mg/kg	LD ₅₀	Jenkins, <u>et al.</u> (1972)
1,1-DCE	oral	rat (395 g) (fasted)	>1500 mg/kg	LD ₅₀	Andersen and Jenkins (1977b)
1,1-DCE	oral	rat (138 g) (fasted)	<50 mg/kg	LD ₅₀	Andersen and Jenkins (1977b)
1,1-DCE	oral	rat (Male)	1800 mg/kg		Ponomarev and Tomatis (1980)
		rat (Female)	1500 mg/kg		
1,1-DCE	oral	mouse (male)	217 mg/kg	LD ₅₀	Jones and Hathway (1978b)
		mouse (female)	194 mg/kg		Jones and Hathway (1978b)
1,1-DCE	oral	dog	5750 mg/kg	LD ₅₀	NIOSH (1978)
	iv	dog	225 mg/kg	LD ₅₀	NIOSH (1978)
1,1-DCE	inhal	rat (fed)	15,000 ppm/4 hr	LC ₅₀	Jaeger <u>et al.</u> (1974)
	inhal	rat (fasted)	600 ppm/4 hr	LC ₅₀	Jaeger <u>et al.</u> (1974)
	inhal	rat (fasted)	200 ppm/4.1 hr 400 ppm/3.6 hr 500 ppm/13.0 hr 1000 ppm/2.4 hr 2000 ppm/1.4 hr	LC ₅₀	Andersen <u>et al.</u> (1979a)
1,1-DCE	inhal	rat (fed)	6350 ppm/4 hr	LC ₅₀	Siegel <u>et al.</u> (1971)

Table VIII-1 (Continued)

Compound	Route	Species	Dose	Effect	Reference
1,2-DCE	oral	rat	770 mg/kg	LD ₅₀	NIOSH (1978)
	ip	mouse	2000 mg/kg	LD ₅₀	NIOSH (1978)
trans, 1-2-DCE	oral	rat (180-200 g)	1.0 ml/kg (1300 mg/kg)	LD ₅₀	Freundt <i>et al.</i> (1977)
	ip	rat (180-200 g)	6.0 ml/kg (7800 mg/kg)	LD ₅₀	Freundt <i>et al.</i> (1977)
	ip	mouse	3.2 ml/kg (4160 mg/kg)	LD ₅₀	Freundt <i>et al.</i> (1977)

^a Adrenalectomized

of non-carcinogenic toxicity to all three DCEs are essentially identical, it is defensible to suggest that the ADI(s) developed for 1,1-DCE be applied also to the 1,2-DCE isomers as well. It is understood that an added margin of safety would exist (perhaps 3-fold or so) based upon a comparison of shorter-term exposure data. This decision would be consistent with a regulatory philosophy which seeks to avoid underestimating the potential risk. In addition, it would provide a basis for the development of Acceptable Daily Intakes (ADIs) and Recommended Maximum Contaminant Levels (RMCLs, or health goals) for the 1,2-DCE isomers. While, of course, it is preferred that ADIs and RMCLs be based upon data generated in studies of the specific compounds under consideration, the appropriate data for the 1,2-DCE isomers do not exist at this time, while resolution of the problem of contamination of drinking water with these isomers of dichloroethylene is required in the short term. Therefore, it will be proposed that the ADI(s) and AADI developed for 1,1-dichloroethylene also be applied to each isomer of 1,2-dichloroethylene.

It has been reported that daily oral administration of 1,1-DCE to dogs for 97 successive days at dosages of 0, 6.25, 12.5 or 25 mg/kg bw caused no adverse effects (Norris, 1977; Quast, et al., 1983). The animals (4/sex/group) were given the compound as a 50% solution in peanut oil in a gelatin capsule. Each day, a control group of 4 animals/sex were given a capsule containing an amount of peanut oil equivalent to that given the dogs at the 25 mg/kg dose level.

No exposure-related changes were observed in appearance, demeanor, body weights or food consumption. The mean white cell counts of dogs receiving 6.25 or 25 mg/kg/day were significantly lower than control values on Day 84 ($P < 0.05$). However, these values were not significantly different from their own pre-exposure white cell counts. In addition, they were within the range of normal values observed in that laboratory. Therefore, the authors considered the differences to be unrelated to the ingestion of 1,1-DCE.

Female dogs receiving 6.25 mg/kg 1,1-DCE exhibited a significant decrease in BUN levels at Day -7 and a significant increase in SGOT at Day 85 ($P < 0.05$). Males in that dose group showed elevated SGOT and SGPT at sacrifice ($P < 0.005$). These comparisons were made with the concomitant controls. However, the investigators stated that the values were within the range of normal values observed historically in that laboratory. No alterations in the clinical chemistry parameters were noted at the 12.5 or 25 mg/kg/day doses except for one high dose male that had an elevated SGPT on Day 85 but not on Day 97. No changes were seen in the SH content of the liver or kidneys.

No compound-related changes were reported in any of the parameters measured on urinalysis, in organ weight or organ: body weight ratios or on gross or microscopic examination of tissues. One male receiving 12.5 mg/kg/day had grossly enlarged kidneys, but no accompanying histopathology. The investigators determined that this finding was not compound-related.

If one were to assume that the results of this study were appropriate for use in developing an ADI, it could be derived thusly:

$$\frac{25 \text{ mg/kg/day} \times 1.0 \times 70 \text{ kg}}{100 \times 10} = 1.75 \text{ mg/day (or 0.025 mg/kg/day for a 70 kg adult)}$$

Where: 25 mg/kg/day = NOAEL (highest observed NOAEL; since no minimal or frank effect level was identified, the actual NOAEL may be higher in the dog)

1.0 = ratio of administered dose absorbed

70 kg = weight of protected individual

100 = uncertainty factor, appropriate for use with NOAEL from animal studies with no comparable human data (longer-term exposure duration)

10 = uncertainty factor, appropriate for use of data from exposure duration significantly less than lifetime

Results were reported from a 90-day subchronic study in rats given nominal concentrations of 0, 50 100 or 200 ppm of 1,1-DCE in their drinking water (Rampy, et al., 1977). The highest dose given was close to the limits of solubility for the compound (DeLassus and Schmidt, 1981). Ten rats/sex/group were used, with 2 rats/sex/group sacrificed at Days 1, 3, 10 and 30 for the determination of non-protein sulfhydryl groups in the liver and kidney. The mean daily dosage levels in mg/kg based upon the amount of water consumed were 0, 7.5, 12.6 or 25.6 mg/kg for the females and 0, 5.9, 10 or 19 mg/kg for the males.

Except for a decreased kidney:body weight ratio in males at the low dose, there were no statistically significant differences in organ weights or organ:body weight ratios at the termination of the study. The only histopathology noted was an increased cytoplasmic vacuolization of hepatocytes in livers of both sexes exposed to the highest dose. The investigators considered this to be a minimal change which would be reversible if the animals were removed from exposure to the chemical.

If one were to assume that the results of this study were appropriate for use in developing an ADI, it could be derived thusly:

$$\frac{10 \text{ mg/kg/day} \times 1.0 \times 70 \text{ kg}}{100 \times 10} = 0.70 \text{ mg/day (or, 0.01 mg/kg/day for a 70 kg adult)}$$

Where: 10 mg/kg/day = NOAEL (100 ppm or 10-12.6 mg/kg mean daily dosage level)

1.0 = ratio of administered dose absorbed

70 kg = weight of protected individual

100 = uncertainty factor, appropriate for use with NOAEL from animal study, with no comparable human data (longer-term exposure duration)

10 = uncertainty factor, appropriate for use with data from exposure duration significantly less than lifetime

A two-year chronic toxicity/oncogenicity study was conducted in rats given nominal concentrations of 0, 50, 100 or 200 ppm of 1,1-DCE on their drinking water (Rampy, et al., 1977; Quast, et al., 1983). The time-weighted average mg/kg/day doses were 0, 7, 10 or 20 for the males and 0, 9, 14 or 20 for the females.

Groups of 48 animals/sex/group were used, except for the controls (80/sex). Further details of the protocol and parameters measured are described in Chapter V.

No consistent treatment-related changes were observed in any parameter measured. The only pathological finding considered by the investigators to be treatment-related was in the liver of animals of both sexes in the high dose group. These microscopic changes, when present, were usually characterized by a minimal amount of mid-zonal hepatocellular fatty change. The degree of increase in this pathology was statistically significant in the males. A trend toward this increase was seen in males at the intermediate dose. No exposure-related changes were seen in males at the low dose. Minimal hepatocellular swelling and fatty changes were detected in female rats at all dose levels. No significant treatment-related hepatocellular necrosis was evident in either sex at any dose.

If one were to assume that the results of this study were appropriate for use in developing an ADI, it would be derived thusly:

$$\frac{10 \text{ mg/kg/day} \times 1.0 \times 70 \text{ kg}}{100 \times 10} = 0.70 \text{ mg/day (or, 0.01 mg/kg/day for a 70 kg adult)}$$

Where: 10 mg/kg = MEL (100 ppm or 10 mg/kg/day mean daily dose in males; trend toward increase in focal fatty changes in liver)

1.0 = ratio of administered dose absorbed

70 kg = weight of protected individual

100 = uncertainty factor, appropriate for use with animal data, with no comparable human data (longer-term

10 = uncertainty factor, appropriate for use
in conversion of MEL to NOAEL

Ninety-day subchronic studies were performed to determine doses to be used in the chronic studies in the NTP carcinogenicity bioassay for 1,1-dichloroethylene (NTP, 1982). Groups of 10 rats and 10 mice of each sex were administered 1,1-DCE in corn oil by gavage 5 times/week at 0, 5, 15, 40, 100 or 250 mg/kg for 13 weeks. Vehicle control groups consisting of 10 males and 10 females of each species received corn oil alone. After 90 days, survivors were sacrificed and necropsied. Unfortunately, no serum enzyme activities were determined in clinical chemistry studies. Monitoring of SGOT, SGPT, alkaline phosphatase and other indicators of liver function would have been useful in identifying an NOAEL.

Representative tissues from rats and mice receiving 250 mg/kg, from mice receiving 100 mg/kg and from control animals were examined microscopically. Livers from all other dose groups also were examined. Original examination of the lesions in the rat livers placed more emphasis on the changes seen in the animals at the lower doses^o whereas a review interpreted these changes to be less important.

Severe centrilobular necrosis of the liver was observed in the 3 females receiving 250 mg/kg that died. Minimal to moderate hepatocytomegaly was seen in the rest of the rats that received 250 mg/kg. Lesser degrees (minimal to mild) of hepatocytomegaly were seen in 6/10 male rats and 3/10 female rats that received 100 mg/kg. Various combinations of portal and hepatocellular atrophy were seen in all male rats (mild to severe in 9/10

and minimal in the other) and in 7/10 female rats (mild to moderate in 6/10 and minimal in 1/10) receiving 250 mg/kg. The rats receiving 100 mg/kg were affected to a much lesser degree, both in numbers and severity. Foci of cytoplasmic changes, primarily clear cell foci, were seen in 3/10 males and 3/10 females receiving 250 mg/kg. Fatty metamorphosis or cytoplasmic vacuolization or both, usually in minimal or mild degrees of severity, occurred in animals of most groups but had no distinct dose relationship. Nonetheless, the number of animals affected in treatment group was significantly increased over control.

In the mice, centrolobular necrosis, hemorrhage and congestion of the liver were observed in males and females that died in the 250 mg/kg group. Cellular atypia of the liver (less severe than that seen in the rats) was observed in 7/10 males and 6/10 females receiving 100 mg/kg but not in animals receiving 250 mg/kg. At 40, 25 or 5 mg/kg, severity of hepatic lesions was dose-related. The incidence of hepatic lesions in males was dose-related and higher than in the females. The most frequently encountered change in mice exposed at 40 mg/kg or less was slight, sometimes moderate, fatty metamorphosis. Patchy foci of one or a few smaller cells with sparse cytoplasm were encountered much less frequently in mice than in rats.

Hepatic effects were considered to be minimal at 5 mg/kg.

If one were to assume that the results of this study were appropriate for use in developing an ADI, it would be derived thusly:

$$\frac{5 \text{ mg/kg} \times 1.0 \times 5 \times 70 \text{ kg}}{100 \times 10 \times 7} = 0.251 \text{ mg/day (or, 0.0036 mg/kg/day for a 70 kg adult)}$$

Where: 5 mg/kg = MEL (based upon increased incidence in fatty livers in both sexes of rats)

1.0 = ratio of administered dose absorbed

70 kg = weight of protected individual

100 = uncertainty factor, appropriate for use with animal data, with no comparable human data (longer-term exposure duration)

10 = uncertainty factor, appropriate for use in conversion of MEL to NOAEL

5/7 = conversion of 5 day/week dosing regimen to 7 day/week

In the chronic studies for the carcinogenicity bioassay, rats and mice were grouped 50/sex/group with controls receiving corn oil alone. Rats were dosed at 1 or 5 mg 1,1-DCE/kg, mice at 2 or 10 mg/kg. Doses were administered 5 times per week by gavage for 104 weeks.

Mean body weights of dosed and control rats of both sexes were comparable throughout the study. No compound-related signs of toxicity were observed. The number of accidental deaths may have influenced the incidence of late-appearing tumors in the control and low-dose males.

Several non-neoplastic lesions of possible significance were observed. The incidence of chronic inflammation of the kidney in both male and female rats was higher in the high dose groups than in the controls. Although the occurrence of chronic nephritis appears to be dose-related, this lesion is common in aging rats.

Among the mice, the mean body weights of dosed male mice were lower than those in the control group (see Chapter V). Mean body weights of high dose and control females were comparable. Mean body weights of low dose mice of either sex were lower than those of high dose or vehicle control mice. No compound-related clinical signs were observed.

No significant differences in survival were observed between the groups of male mice. A significant reduction in the survival of female mice was observed in the low dose group when compared with the high dose group.

Non-neoplastic lesions including necrosis of the liver (focal, multifocal and diffuse) were observed more frequently in dosed mice than in controls (males= 2%, 7% and 14%, respectively; females= 0%, 8% and 2%, respectively). The incidence of lung inflammation was slightly below that normally seen in 2-year old B6C3F1 mice.

If one were to assume that the results of this study were appropriate for use in developing an ADI, it could be derived thusly:

$$\frac{1 \text{ mg/kg} \times 1.0 \times 5 \times 70 \text{ kg}}{100 \times 7} = 0.5 \text{ mg/day (or, 0.07 mg/kg/day for a 70 kg adult)}$$

Where: 1 mg/kg/day = NOAEL (lack of significant increase in incidence of chronic kidney inflammation in rats of both sexes)

1.0 = ratio of administered dose absorbed

70 kg = weight of protected individual

100 = uncertainty factor, appropriate for use NOAEL from animal data, with no equivalent human data (longer-term exposure duration)

5/7 = conversion of 5 day/week dosing regimen to 7 day/week

Quantification of Non-carcinogenic Effects

Table VIII-2 summarizes the ADIs derived from the five oral studies which contain adequate dose-response data identifying NOAELs or MELs. It is apparent from the review of the available literature on the dichloroethylenes that the liver is usually the most sensitive target organ and that the rat is more sensitive to the toxicity of 1,1-DCE than is the dog or mouse. Since suitable data from lifetime studies in rats are available, these should be the data of choice in deriving an AADI. The 2-year drinking water study by Dow (Rampy, et al., 1977; Quast, et al., 1983) and the NTP gavage bioassay in rats (NTP, 1982) both describe lifetime studies. Of the two studies, the 2-year drinking water study is the more appropriate as it exactly parallels the route of exposure best suited for developing drinking water guidance and standards.

Table VIII-2

Possible ADIs for 1,1-Dichloroethylene

Experiment	Route of Exposure	Proposed ADI
90-day (dog)	gavage in oil	1.75 mg/day
90-day (rat)	drinking water	0.70 mg/day
2-year (rat)	drinking water	0.70 mg/day
90-day (rat)	gavage in oil	0.266 mg/day
2-year (rat)	gavage in oil	0.500 mg/day

If we were to assume that these studies were appropriate for use in developing an Adjusted Acceptable Daily Intake (AADI) for the three isomers of dichloroethylene, it would be derived thusly:

$$\text{Step 1: AADI} = \frac{\text{ADI}}{2 \text{ liters}}$$

$$\text{Step 2: ADI} = 0.70 \text{ mg/day}$$

$$\text{Step 3: } \frac{0.70 \text{ mg/day}}{2} = 0.350 \text{ mg/l/day}$$

The AADI reflects an allowable exposure for a 70 kg adult drinking 2 liters of water per day and whose sole source of exposure to the dichloroethylenes is via that drinking water.

It is further suggested that an AADI for total dichloroethylenes also be derived. This would address an instance in which more than one of the three isomers is present in a given analytical sample of finished drinking water. The AADI for total dichloroethylenes also should be 0.350 mg/l/day.

Carcinogenic Effects

1,1-Dichloroethylene. The carcinogenic potential of 1,1-DCE has been investigated in several species via various routes of exposure. The results of these studies are summarized in Table VIII-3. As can be seen, the results of most of the studies fail to support a significant, treatment-related increase in tumor incidence following exposure to 1,1-DCE. In no study in which the animals were exposed orally, either by gavage or in their drinking water, was there a significant tumor response.

Table VIII-3

Summary of Results from Carcinogenicity Studies with 1,1-DCE

Route	Species	Dose	Study Duration	Carcinogenic Response	Reference
Inhalation	Swiss Mice	10 ppm 25 ppm for 12 months	98 weeks 98 weeks	negative positive	Maltoni, 1977; Maltoni et al., 1977
Inhalation	CD-1 Mice	55 ppm	52 weeks	negative	Lee et al., 1978
Not Reported	BALB/C Mice C56 BL Mice C3H Mice	Not Reported Not Reported Not Reported	Not Reported Not Reported Not Reported	negative negative negative	Fishbein, 1979 Report of Maltoni studies
Inhalation	Sprague-Dawley Rats	10 ppm 25 ppm 50 ppm 100 ppm 150 ppm for 12 months	98 weeks 98 weeks 98 weeks 98 weeks 98 weeks	negative negative negative positive positive	Maltoni, 1977; Maltoni et al., 1977
Inhalation	Sprague-Dawley Rats	75 ppm 200 ppm for 12 months	lifetime	negative negative	Viola and Caputo, 1977
Inhalation	Rats (Wistar)	75 ppm 200 ppm for 12 months	lifetime	negative	Viola and Caputo, 1977
Inhalation	Rats (CD)	55 ppm	52 weeks	negative	Lee et al., 1978

continued-

Table VIII-3 - Continued

Route	Species	Dose	Study Duration	Carcinogenic Response	Reference
Inhalation	Rats	25 ppm 75 ppm for 18 months	104 weeks	negative	Rampy <u>et al.</u> , 1977
Inhalation	Chinese Hamsters	25 ppm	74 weeks	negative	Maltoni, 1977; Maltoni <u>et al.</u> , 1977
Oral (gavage)	Rats (BDIV)	50 mg/kg/day	120 weeks	negative	Ponomarev and Tomatis, 1980
Oral (gavage)	Rats (Sprague-Dawley)	0.32 mg/kg·day 3.2 mg/kg·day 6.4 mg/kg·day 13 mg/kg·day	136 weeks	negative negative negative negative	Maltoni
Oral (drinking Water)	Rats (Sprague-Dawley)	7-9 mg/kg·day 10-14 mg/kg·day 20-30 mg/kg·day	104 weeks	negative negative negative	Rampy <u>et al.</u> , 1977 Quast, <u>et al.</u> , 1983
Oral (Gavage)	Rats (F344)	1 mg/kg/day 5 mg/kg/day	104 weeks	negative	NTP, 1982
	Mice (B6C3F1)	1 mg/kg/day 5 mg/kg/day	104 weeks	negative	NTP, 1982
Subcutaneous	Swiss mice	121 mg	single dose	inactive as whole mouse initiator active as initiator with phorbol myristate acetate	Van Duuren, <u>et al.</u> , 1979

However, in some, but not all, of the inhalation studies, there were significant increases in tumor incidences. In addition, 1,1-DCE was active as an initiator by subcutaneous injection, when combined with phorbol myristate acetate as the promoter (Van Duuren, et al., 1979).

Assessment of the carcinogenic potential of 1,1-DCE is complicated further by the fact that the positive data developed by Maltoni, et al. are preliminary and have not been published or presented in a public forum for peer-review.

1,1-DCE has been tested in a number of short-term tests, some of which are considered to be useful in predicting mutagenic potential and also assisting in the evaluation of carcinogenic potential.

1,1-DCE was mutagenic to bacteria in the presence, but not the absence, of an exogenous metabolic activation system (Bartsch, et al., 1975; Griem, et al., 1975; Cerna and Kypenova, 1977; Simmon, et al., 1977; Simmon and Tardiff, 1978; Jones and Hathway, 1978c). It also induced point mutations and mitotic gene conversions in Saccharomyces cerevisiae, but only after metabolic activation, (Bronzetti, et al., 1981).

1,1-DCE was not mutagenic in the dominant lethal test in CD-1 mice exposed by inhalation to 40, 120 or 200 mg/m³ 1,1-DCE for 6 hours/day for five days (Anderson, et al., 1977). It also was not active in V79 Chinese hamster cells in the presence of 15,000 g liver supernatant from phenobarbital-treated rats and mice (Drevon and Kuroki, 1979), nor did it produce chromosomal aberrations in cytogenetic analyses of

bone marrow cells following intraperitoneal injections (Cerna and Kypenova, 1977).

Reitz, et al. (1980) showed that 1,1-DCE alkylated DNA in the liver and kidney of both rats and mice, but only to a slight degree after 10 or 50 ppm 6-hour inhalation exposures. The highest degree of alkylation occurred in the kidney of mice exposed at the higher dose. In measuring DNA repair, the only statistically significant increase caused by 1,1-DCE was that occurring in the kidney of mice exposed at 50 ppm.

On the basis of the data available to date, IARC (1983) concluded that there is sufficient evidence to state that 1,1-DCE is mutagenic. Earlier, IARC (1979) had stated that the available experimental evidence indicates that the compound produces malignant tumors in mice and rats and that some of the tumors are similar to those produced by vinyl chloride. The Agency said that this evidence is, however, limited by the fact that it is based partly on studies which were still in progress. A reevaluation will be made when IARC has the opportunity to review the data from completed study of Maltoni, et al. as well as the Dow study and the NTP gavage bioassay. IARC's assessment of the available human data stated that these data were not adequate to permit assessment of its carcinogenic potential in the human (IARC, 1983).

1,2-Dichloroethylenes. Neither of isomers of 1,2-DCE have been tested for carcinogenic potential in long-term studies. Therefore, it is not possible to make any judgment as to whether these compounds pose a human cancer risk.

Neither cis- nor trans- 1,2-DCE was mutagenic when assayed with E. coli at similar concentrations used for 1,1-DCE (Griem, et al., 1975). However, cis-1,2-DCE was found to be mutagenic in the host-mediated assay using Salmonella tester strains in mice, whereas trans-1,2-DCE was found to be non-mutagenic under the same conditions (Cerna and Kypenova, 1977). These authors also reported that only the cis- isomer, of all three tested, produced chromosomal aberrations in bone marrow cells following intraperitoneal injections. Clearly, more studies must be done before conclusions can be drawn concerning the mutagenic and carcinogenic potentials of the 1,2- isomers of dichloroethylene.

Quantification of Carcinogenic Effects

1,1-Dichloroethylene. Using methodology described in detail elsewhere (U.S. EPA, 1980), the EPA's Carcinogen Assessment Group calculated estimated incremental excess cancer risk associated with exposure to 1,1-dichloroethylene in ambient, extrapolating from the preliminary data obtained in Maltoni's study in Swiss mice (Maltoni, et al., 1977). CAG employed a linearized, non-threshold multistage model to estimate the upper bound 95% confidence limit of the excess cancer rate that would occur at a specific exposure level for a 70 kg adult ingesting two liters of water and 6.5 grams of fish and seafood ("fish factor") every day over a 70-year lifespan. The Office of Drinking Water Health Effects Branch modified the risks estimated for ambient water to reflect exposure to 1,1-dichloroethylene via drinking water alone

(U.S. EPA, 1981). Recently, CAG recalculated estimated risks for drinking water exposure using updated data from the Maltoni study (Maltoni, et al., 1980; CAG, 1983). This recalculation will be considered to be the appropriate one when estimating the potential carcinogenic risk following exposure to 1,1-DCE in drinking water.

A range of 1,1-dichloroethylene concentrations were computed that would be estimated to increase the risk by one excess cancer per million (10^6), per one hundred thousand (10^5) and per ten thousand (10^4) people over a 70-year lifetime. The ranges of concentrations developed by CAG and those modified by the Office of Drinking Water are summarized in Table VIII-4. As stated above, consumption of drinking water containing 24, 2.4 or 0.24 ug/l by a 70 kg adult over a 70-year lifespan at a rate of 2 liters/day is estimated to result in an excess cancer risk rate of 10^{-4} , 10^{-5} or 10^{-6} , respectively.

1,2-Dichloroethylenes. No data are available which indicate that these isomers have carcinogenic potential. Therefore, no estimation of risk has been made.

Table VIII-4

Drinking Water Concentrations and Estimated Excess Cancer Risk

Excess Lifetime Cancer Risk	Range of Concentrations (ug/l)		
	CAG ^a (1980)	ODW ^b (1981)	CAG ^{bc} (1983)
10 ⁻⁴	3.3	3.4	23.
10 ⁻⁵	0.33	0.34	2.3
10 ⁻⁶	0.033	0.034	0.23
0	0	0	0

^a Assumes daily consumption of 2 liters of water and 6.5 grams of fish/seafood by a 70 kg adult over a 70-year lifetime; number represents 95% upper bound confidence limit.

^b Assumes daily consumption of 2 liters of water by a 70 kg adult over a 70-year lifetime; number represents 95% upper bound confidence limit.

^c Considered to be the appropriate range of concentrations for estimation of risk following exposure via drinking water.

IX. REFERENCES

- ACGIH. 1982. American Council of Government Industrial Hygienists. TLVs. Threshold limit values for chemical substances and physical agents in the workroom environment. Cincinnati, OH.
- Andersen, M.E., J.E. French, M.L. Gargas, R.A. Jones and L.J. Jenkins, Jr. 1979a. Saturable metabolism of the acute toxicity of 1,1-dichloroethylene. Toxicol. Appl. Pharmacol. 47:385-393.
- Andersen, M.E., M.L. Gargas, R.A. Jones and L.J. Jenkins, Jr. 1979b. The use of inhalation techniques to assess the kinetic constants of 1,1-dichloroethylene metabolism. Toxicol. Appl. Pharmacol. 47:395-409.
- Andersen, M.E., M.L. Gargas, R.A. Jones and L.J. Jenkins, Jr. 1980a. Determination of the kinetic constants for metabolism of inhaled toxicants in vivo using gas uptake measurements. Toxicol. Appl. Pharmacol. 54:100-116.
- Andersen, M.E., and L.J. Jenkins, Jr. 1977a. Enhancement of 1,1-dichloroethylene hepatotoxicity by pretreatment with low molecular weight epoxides. Proc. Soc. Toxicol. 41.
- Andersen, M.E., and L.J. Jenkins, Jr. 1977b. Oral toxicity of 1,1-dichloroethylene in the rat: Effects of sex, age and fasting. Environ. Health Perspect. 21:157-163.
- Andersen, M.E., R.A. Jones and L.J. Jenkins, Jr. 1978. The acute toxicity of single, oral doses of 1,1-dichloroethylene in the fasted, male rat: Effect of induction and inhibition of microsomal enzyme activities on mortality. Toxicol. Appl. Pharmacol. 46:227-234.
- Andersen, M.E., O.E. Thomas, M.L. Gargas, R.A. Jones and L.J. Jenkins, Jr. 1980b. The significance of multiple detoxification pathways for reactive metabolites in the toxicity of 1,1-dichloroethylene. Toxicol. Appl. Pharmacol. 52:522-432.
- Anderson, D. 1977. Dominant lethal studies with the halogenated olefins vinyl chloride and vinylidene chloride in male CD-1 mice. Environ. Health Perspect. 21:71.
- Arthur D. Little, Inc. 1976. Vinylidene chloride monomer emissions from the monomer, polymer and polymer processing industries. U.S. Environmental Protection Agency, Research Triangle Park, North Carolina.

- Bahlman, L.J., V. Alexander, P.F. Infante, J.K. Wagoner, J.M. Lane and E. Bingham. 1979. Vinyl halides: Carcinogenicity, vinyl bromide, vinyl chloride and vinylidene chloride. Joint NIOSH/OSHA Current Intelligence Bulletin No. 28. Am. Ind. Hyg. Assoc. J. 40:A-30.
- Barr, R.F., and H. Watts. 1972. Diffusion of some organic and inorganic compounds in air. J. Chem. Eng. Data 17(1):45-46.
- Bartsch, H. 1976. Mutagenicity tests in chemical carcinogenesis. IARC Sci. Publ. 52:229-240.
- Bartsch, H., C. Malaveille, A. Barbin and C. Blanche. 1979. Mutagenic and alkylating metabolites of halo-ethylenes, chlorobutadienes and dichlorobutenes produced by rodent or human liver tissues. Arch. Toxicol. 41:249-277.
- Bartsch, H., C. Malaveille and R. Montesano. 1976. The predictive value of tissue-mediated mutagenicity assays to assess the carcinogenic risk of chemicals. IARC Sci. Publ. 12:467-491.
- Barstch, H., C. Malaveille, R. Montesano and L. Tomatis. 1975. Tissue mediated mutagenicity of vinylidene chloride and 2-chlorobutadiene in Salmonella typhimurium. Nature. 255:641-643.
- Bonse, G., T. Urban, R. Montessano and L. Tomatis. 1975. Chemical reactivity, metabolic oxirane formation and biological reactivity of chlorinated ethylenes in the isolated perfused rat liver preparation. Biochem. Pharmacol. 24:1829-1834.
- Bronzetti, G., C. Bauer, C. Corsi, C. Leporini, R. Nieri and R. del Carratore. 1981. Genetic activity of vinylidene chloride in yeast. Mutat. Res. 89:179-185.
- Broser, F., B. Henschler and H.C. Hopf. 1970. Chlorierte asetylene als ursache einer irreparablen trigeminusstorung dei zwei patienten. Dtsch. Z. Nervenheilk. 197:163-170.
- Carlson, G.P., and G.C. Fuller. 1972. Interaction of modifiers of hepatic microsomal drug metabolism and the inhalation toxicity of 1,1-dichloroethylene. Res. Commun. Chem. Pathol. Pharmacol. 4:553-560.
- Cerna, M., and H. Kypenova. 1977. Mutagenic activity of chloroethylenes analysed by screening system tests. Mutat. Res. 46:214(Abst).
- Chieco, P., M. Treinen Mosley and E.S. Reynolds. 1979. Histochemical evidence that mitochondria are foci of 1,1-dichloroethylene hepatotoxicity. Fed. Proc. 38:5882.
- CFR. 1981. Code of Federal Regulations. Title 21. Food and Drugs. Parts 175 and 177. Office of the Federal Register, National Archives and Record Service, Washington, D.C.

- DeLassus, P.T, and D.D. Schmidt. 1981. Solubilities of vinyl chloride and vinylidene chloride in water. J. Chem. Eng. Data. 26:274-276.
- Drevon, C. and T. Kuroki. 1979. Mutagenicity of vinyl chloride, vinylidene chloride and chloroprene in V79 Chinese hamster cells. Mutat. Res. 67:173-182.
- Filser, J.G., and H.M. Bolt. 1979. Pharmacokinetics of halogenated ethylenes in rats. Arch. Toxicol. 42:123-136.
- Filser, J.G., H.M. Bolt, K. Kimmich and F.A. Bencsath. 1978. Exhalation of acetone by rats on exposure to trans-1,2-dichloroethylene and related compounds. Toxicol. Letters. 2:247-252.
- Fishbein, L. 1979. Potential halogenated industrial carcinogenic and mutagenic chemicals. I. Halogenated unsaturated hydrocarbons. Sci. Total. Envir. 11:111-161.
- Freundt, K.J., G.P. Liebaltd and E. Lieberwirth. 1977. Toxicity studies on trans-1,2-dichloroethylene. Toxicology. 7:141-153.
- Freundt, J.J., and J. Macholz. 1978. Inhibition of mixed function oxidases in rat liver by trans-and cis-1,2-dichloroethylene. Toxicology. 10:131-139.
- Gage, J.C. 1970. Subacute inhalation toxicity of 109 industrial chemicals. British J. Ind. Med. 27:1.
- Greim, H. G. Bonse, Z. Radwan, D. Reichert and D. Henschler. 1975. Mutagenicity in vitro and potential carcinogenicity of chlorinated ethylenes as a function of metabolic oxirane formation. Biochem. Pharmacol. 24:2013-2017.
- Guyton, A.C. 1947. Measurement of the respiratory volumes of laboratory animals. Am. Jour. Physiol. 150:70.
- Hamada, N., and R.E. Peterson. 1977. Effect of chlorinated aliphatic hydrocarbons on excretion of protein and electrolytes by rat pancreas. Toxicol. Appl. Pharmacol. 39:185-194.
- Hardie, D.W.F. 1964. Dichloroethylene. In: Mark, H.F., J.J. McKetta, Jr., D.F. Othmer, eds. Kirk-Othmer encyclopedia of chemical technology, 2nd ed., Wiley-Interscience, New York, Vol. 5. pp. 178-183.
- Hathway, D.E. 1977. Comparative mammalian metabolism of vinyl chloride and vinylidene chloride in relation to oncogenic potential. Env. Health Perspect. 21:55-59.

- Henschler, D. 1977. Metabolism and mutagenicity of halogenated olefins -a comparison of structure and activity. Environ. Health Perspect. 21:61-64.
- Henschler, D., and G. Bonse. 1977. Metabolic activation of chlorinated ethylenes: Dependence of mutagenic effect on electrophilic reactivity of the metabolically formed epoxides. Arch. Toxicol. 39:8-12.
- Henschler, D., G. Bonse and H. Greim. 1976. Carcinogenic potential of chlorinated ethylenes tentative molecular rules. IARC Sci. Publ. 52:229-240.
- Henschler, D., F. Broser and H.C. Hopf. 1970. "Polyneuritis cranialis" durch vergiftung mit chloriertan acetylenen beim umgang mit vinyliden chloridcopylymeren. Arch. Toxicol. 26:62-65.
- Horsely, L.H. 1947. Table of azeotropes and nonazeotropes. Industrial and Engineering Chemistry, Analytical Chemistry. 19:508-600.
- Hushon, J., and M. Kornreich. 1976. Air pollution assessment of vinylidene chloride. U.S. Environmental Protection Agency. Contract No. 68-02-1495.
- IARC. 1979. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans. Some monomers, plastics and synthetic elastomers, and acrolein. Lyon. Volume 19. pp.439-459.
- IARC. 1982. International Agency for Reserach on Cancer. IARC monographs on the evaluation of carcinogenic risks of chemicals to humans. Chemicals, industrial processes and industries associated with cancer in humans. IARC monographs, Volumes 1 to 19. IARC monographs supplement 4. pp. 262-264.
- Irish, D.D. 1963. Vinylidene chloride. In: F.A. Patty (ed), Industrial Hygiene and Toxicology. 2nd ed. Vol. II. John Wiley and Sons, Inc., New York. P. 1305-1309.
- Jackson, N.M., W.J. Al-Hassan and R.B. Conolly. 1982. The nephrotoxicity of 1,2-dichloroethane and 1,1-dichloroethylene in male Sprague-Dawley rats. Toxicologist 2(1):127(Abst. 447).
- Jaeger, J., and W. Stringer. 1972. Vinylidine chloride monomer. Safe handling guide. Dow Chemical USA. No. 102-232-72.
- Jaeger, R.J. 1977. Effect of 1,1-dichloroethylene exposure on hepatic mitochondria. Res. Comm. Chem. Pathol. Pharmacol. 18:83.
- Jaeger, R.J., R.B. Conolly and S.D. Murphy. 1973a. Diurnal variation of hepatic glutathione concentration and its correlation with 1,1-dichloroethylene inhalation toxicity in rats. Res. Commun. Chem. Pathol. Pharmacol. 6:465-471.

- Jaeger, R.J., M.J. Trabelus and S.D. Murphy. 1973b. Biochemical effects of 1,1-dichloroethylene in rats: Dissociation of its hepatotoxicity from a lipoperoxidative mechanism. *Toxicol. Appl. Pharmacol.* 24:457-467.
- Jaeger, R.J., R.B. Conolly and S.D. Murphy. 1974. Effect of 18 hr fast and glutathione depletion of 1,1-dichloroethylene-induced hepatotoxicity and lethality in rats. *Exp. Mol. Pathol.* 20:187-198.
- Jaeger, R.J., R.B. Conolly and S. Murphy. 1975a. Short-term inhalation toxicity of halogenated hydrocarbons. *Arch. Environ. Health.* 30:26-31.
- Jaeger, R.J., R.B. Conolly, E.S. Reynolds and S.D. Murphy. 1975b. Biochemical toxicology of unsaturated halogenated monomers. *Environ. Health Perspect.* 11:121-128.
- Jaeger, R.J., L.G. Shoner and L.J. Coffman. 1977a. 1,1-Dichloroethylene hepatotoxicity: Proposed mechanism of action of distribution and binding of ^{14}C radioactivity following inhalation exposure in rats. *Environ. Health Perspect.* 21:113.
- Jaeger, R.J., S. Szabo and L.J. Coffman. 1977b. 1,1-dichloroethylene hepatotoxicity: Effect of altered thyroid function and evidence for the subcellular site of injury. *J. Toxicol. Environ. Health.* 3:545-555.
- Jenkins, L.J., Jr. and M.E. Andersen. 1978. 1,1-dichloroethylene nephrotoxicity in the rat. *Toxicol. Appl. Pharmacol.* 46: 131-141.
- Jenkins, L.J., Jr., M.J. Trabulus and S.D. Murphy. 1972. Biochemical effects of 1,1-dichloroethylene in rats: Comparison with carbon tetrachloride and 1,2-dichloroethylene. *Toxicol. Appl. Pharma.* 23:501-510.
- Jones, B.K., and D.E. Hathway. 1978a. The biological fate of vinylidene chloride in rats. *Chem. Biol. Interactions.* 20:27-41.
- Jones, B.K., and D.E. Hathway. 1978b. Differences in metabolism of vinylidene chloride between mice and rats. *Br. Jour. Cancer.* 37:411.
- Jones, B.K., and D.E. Hathway. 1978c. Tissue-mediated mutagenicity of vinylidene chloride in Salmonella typhimurium TA1535. *Cancer Lett.* 5:1-6.
- Lange, N.A., and G.M. Forker. 1961. Handbook of chemistry. McGraw-Hill, New York, pp. 37. 1484-1493.
- Lee, C.C., J.C. Bhandari, J.M. Winston and W.B. House. 1978. Carcinogenicity of vinyl chloride and vinylidene chloride. *J. Toxicol. Environ. Health.* 4:15-30.

- Leibman, K.C., and E. Ortiz. 1977. Metabolism of halogenated ethylenes. Environ. Health Perspect. 21:91-97.
- Ley, G.J.M., D.O. Hummel and C. Schneider. 1967.
- Adv. Chem. Ser. 66:191-
- Maltoni, C. 1977. Recent findings on the carcinogenicity of chlorinated olefins. Environ. Health Perspect. 21:1-5.
- Maltoni, C., G. Cotti, L. Morisi and P. Chieco. 1977. Carcinogenicity bioassays of vinylidene chloride. Research plan and early results. Med. Lav. 68:241.
- Maltoni, C., 1980.
- McKenna, M.J., P.G. Watanabe and P.J. Gehring. 1977. Pharmacokinetics of vinylidene chloride in the rat. Environ. Health Perspect. 21:99-105. For additional comments on this article see Dedrick, R.L. 1979. Environ. Health Perspect. 28:311 and McKenna, M.J. 1979. Environ. Health Perspect. 28:313.
- McKenna, M.J., J.A. Zempel, E.O. Madrid and P.J. Gehring. 1978a. The pharmacokinetics of (^{14}C) vinylidene chloride in rats following inhalation exposure. Toxicol. Appl. Pharmacol. 45:599-610.
- McKenna, M.J., J.A. Zempel, E.O. Madrid, W.H. Braun and P.J. Gehring. 1978b. Metabolism and pharmacokinetic profile of vinylidene chloride in rats following oral administration. Toxicol. Appl. Pharmacol. 45:821-835.
- Munson, A.E., V.M. Sanders, K.A. Douglas, L.E. Sain, B.M. Kauffman and K.L. White, Jr. 1982. In vivo assessment of immunotoxicity. Environ. Health Perspect. 43:41-52.
- Murray, F.J., K.D. Nitschke, L.W. Rumpy and B.A. Schwetz. 1979. Embryotoxicity and fetotoxicity of inhaled or ingested vinylidene chloride in rats and rabbits. Toxicol. Appl. Pharmacol. 49:189-202.
- Nakajima, T., and A. Sato. 1979. Enhanced activity of liver drug-metabolizing enzymes for aromatic and chlorinated hydrocarbons following food deprivation. Toxicol. Appl. Pharmacol. 50:549-556.
- NIOSH. 1978. 1,1-Dichloroethylene. Registry of toxic effects of chemical substances. p. 563.

NIOSH. 1979. (C.D. for Occupational Standard)

Norris, J.M. 1977. Toxicological and pharmacokinetic studies on inhaled and ingested vinylidene chloride in laboratory animals. Pap. Synth. Conf. 45-50.

NTP. 1982. National Toxicology Program. Carcinogenesis bioassay of vinylidene chloride (CAS No. 75-35-4) in F334 rats and B6C3F1 mice (gavage study). U.S. HHS. PHS. NIH NTP-80-2 NIH Publication No.82-1784.

Ott, M.G., W.A. Fishbeck, J.C. Townsend and E.J. Schneider. 1976. A health study of employees exposed to vinylidene chloride. J. Occup. Med. 18:735-738.

Pearson, C.R., and G. McConnell. 1975. Chlorinated C1 and C2 hydrocarbons in the marine environment. Proc. R. Soc. London B. 189:305.

Pellizzari, E.D. 1978. Quantification of chlorinated hydrocarbons in previously collected air samples. U.S. Environmental Protection Agency, Research Triangle Park, NC. EPA-450/3-78-112.

Perry, R.H., and C.H. Chilton. 1973. Chemical engineers' handbook, 5th ed. McGraw-Hill, New York, pp. 13-36 to 13-42.

Ponomarev, V., and I. Tomatis. 1980. Long-term testing of vinylidene chloride and chloroprene for carcinogenicity in rats. Oncology. 37:136-141.

Prendergast, J.A., R.A. Jones, L.J. Jenkins, Jr. and J. Siegel. 1967. Effects on experimental animals of long-term inhalation of trichloroethylene, carbon tetrachloride, 1,1,1-trichloroethane, dichlorodifluoromethane, and 1,1-dichloroethylene. Toxicol. Appl. Pharmacol. 10:270-289.

Quast, J.F., C.G. Humiston, C.E. Wade, J. Ballard, J.E. Beyer, R.W. Schwetz and J.M. Norris. 1983. A chronic toxicity and oncogenicity study in rats and subchronic toxicity study in dogs on ingested vinylidene chloride. Fund. Appl. Toxicol. 3:55-62.

Raddings, S., et al., 1977. Review of environmental fate of selected chemicals. U.S. Environmental Protection Agency. Contract No. 68-01-2681.

Rampy, L.W., J.F. Quast, C.G. Humiston, M.F. Blamer and B.A. Schwetz. 1977. Interim results of two-year toxicological studies in rats of vinylidene chloride incorporated in the drinking water or administered by repeated inhalation. Environ. Health Perspect. 21:33-43.

- Reichert, D., and D. Henschler. 1978. Uptake and hepatotoxicity of 1,1-dichloroethylene by the isolated blood-perfused rat liver. *Int. Arch. Occup. Env. Health.* 41:169-178.
- Reichert, D., H.W. Werner and D. Henschler. 1978. Role of liver glutathione in 1,1-dichloroethylene metabolism and hepatotoxicity in intact rats and isolated perfused rat liver. *Arch. Toxicol.* 41:169-178.
- Reichert, D., H.W. Werner, M. Metzler and D. Henschler. 1979. Molecular mechanism of 1,1-dichloroethylene toxicity: excreted metabolites reveal different pathways of reactive intermediates. *Arch. Toxicol.* 42:159-169.
- Reichert, D., and H.W. Werner. 1978. Disposition and metabolism of [^{14}C]1,1-dichloroethylene after single oral administration in rats (Abstract). *Naunyn-Schmiedeberg's Arch. Pharmacol.* 302(Suppl.), R-22.
- Reitz, R.H., P.G. Watanabe, M.J. McKenna, J.F. Quast and P.J. Gehring. 1980. Effects of vinylidene chloride on DNA synthesis and DNA repair in the rat and mouse: A comparative study with dimethylnitrosamine. *Toxicol. Appl. Pharmacol.* 52:357-370.
- Reynolds, E.S., and M.T. Moslen. 1977. Damage to hepatic cellular membranes by chlorinated olefins with emphasis on synergism and antagonism. *Environ. Health Perspect.* 21:137-147.
- Reynolds, E.S., M.T. Moslen, S. Szabo, R.J. Jaeger and S.D. Murphy. 1975. Hepatotoxicity of vinyl chloride and 1,1-dichloroethylene. *Am. Jour. Pathol.* 81:219.
- Sato, A., and T. Nakajima. 1979. A structure-activity relationship of some chlorinated hydrocarbons. *Arch. Environ. Health.* 34:6975.
- Short, R.D., J.L. Minor, W.B. House, W. Marcus and C.C. Lee. 1976. Continuous inhalation of 1,1-dichloroethylene (DCE) by rats and mice during gestation (Abstract). *Pharmacologist* 18:245.
- Short, R.D., J.M. Winston, J.L. Minor, J. Seifter and C.C. Lee. 1977a. Effect of various treatments on toxicity of inhaled vinylidene chloride. *Environ. Health Perspect.* 21:125-129.
- Short, R.D., J.M. Winston, J. L. Minor, C.B. Hung, J. Seifter and C. C. Lee. 1977b. Toxicity of vinylidene chloride in mice and rats and its alteration by various treatments. *J. Toxicol. Environ. Health.* 3:913-921.
- Short, R.D., J.L. Minor, J.M. Winston and C.C. Lee. 1977c. A dominant lethal study in male rats after repeated exposures to vinyl chloride or vinylidene chloride. *J. Toxicol. Environ. Health.* 3:965-968.

- Siegel, J., R.A. Jones, R.A. Coon and J.P. Lyon. 1971. Effects on experimental animals of acute, repeated and continuous inhalation exposures to dichloroacetylene mixtures. *Toxicol. Appl. Pharmacol.* 18:168-174.
- Siegers, C.P., M. Younes and G. Schmitt. 1979. Effects of dithiocarb and (+) cyanidanol-3 on the hepatotoxicity of metabolism of vinylidene chloride in rats. *Toxicology.* 15:55-64.
- Siletnik, L.M., and G.P. Carlson. 1974. Cardiac sensitizing effects of 1,1-dichloroethylene: Enhancement by phenobarbital pretreatment. *Arch. Int. Pharmacodyn.* 210:359-364.
- Simmon, V.F., K. Kauhanen and R.G. Tardiff. 1977. Mutagenic activity of chemicals identified in drinking water. *Dev. Toxicol. Environ. Sci.* 2:249-258.
- Simmon, V.F., and R.G. Tardiff. 1978. The mutagenic activity of halogenated compounds found in chlorinated drinking water. *Water Chlorination: Environ. Impact Health Eff. Proc. Conf.* 2:417.
- Szabo, S., R.J. Jaeger, M.T. Moslen and E.S. Reynolds. 1977. Modification of 1,1-dichloroethylene hepatotoxicity by hypothyroidism. *Toxicol. Appl. Pharmacol.* 42:367-376.
- Theiss, A.M., et al., 1977. Mortality study of vinylidene chloride exposed persons in BASF. *Proceedings of 5th Medichem. Congr. San Francisco, 1977.* Reported by Ponomarev and Tomatis. 1980. *Oncology* 37:136-141.
- Thurman, G.B., B.T. Simms, A.L. Goldstein and D.J. Kollan. 1978. The effects of organic compounds used in the manufacture of plastics on the responsivity of murine and human lymphocytes. *Toxicol. Appl. Pharmacol.* 44:617-641.
- U.S. Environmental Protection Agency. 1975. Preliminary assessment of suspected carcinogens in drinking water. Report to Congress. Office of Water Supply, Washington, D.C. pp. 9-11, I-13, I-16.
- U.S. Environmental Protection Agency. 1978. The Carcinogen Assessment Groups' preliminary risk assessment on vinylidene chloride. May 30, 1978.
- U.S. Environmental Protection Agency. 1980. Ambient water quality criteria for dichloroethylenes. Office of Water Regulations and Standards. Criteria and Standards Division, Washington, DC. EPA 440/5-80-041.
- U.S. Environmental Protection Agency. 1981. Draft advisory opinion for 1,1-dichloroethylene (vinylidene chloride). Office of Drinking Water. October 7, 1981 (amended June 15, 1982).

B95
10
U.S. Environmental Protection Agency. 1983. Memorandum from Dharm Singh to William Lappenbusch: "ODW September 15, 1983 Memorandum on Dichloroethylenes." September 20, 1983.

Van Duuren, B.L., B.M. Goldschmidt, G. Loewengart, A.C. Smith, S. Melchionne, I. Seldman and D. Roth, 1979. Carcinogenicity of halogenated olefinic and aliphatic hydrocarbons in mice. J. Natl. Cancer. Inst. 63:1433-1439.

Viola, P.L., and A. Caputo. 1977. Carcinogenicity studies on vinylidene chloride. Environ. Health Perspect. 21:45-47.

Warren, H.S., and B.E. Ricci. 1978. Vinylidene chloride. I. An overview. II. A literature collection. Oak Ridge National Laboratory, Oak Ridge, Tennessee. ORNL/TIRC-77/3.

Wessling, R., and F.G. Edwards. 1970. In: Mark, H.F., J.J. McKetta, Jr., D.F. Othmer, eds. Kirk-Othmer encyclopedia of chemical technology, 2nd ed., Wiley-Interscience, New York, Vol. 21, pp. 275, 297-301.

Wessling, R., and F.G. Edwards. 1971. In: Encyclopedia of Polymer Science and Technology. Wiley, New York. Volume 14. p. 542.

Windholz, M., S. Budvari, L.Y. Stroumtsos and M.N. Fertig (eds.). 1976. The Merck Index, 9th ed. Merck & Co., Inc., Rahway, N.J.

Younes, M., and C.P. Siegers. 1980. Lipid peroxidation as a consequence of glutathione depletion in rat and mouse liver. Res. Commun. Chem. Pathol. Pharmacol. 27:119-128.